list
oral
research
commun
esvc
european
societi
veterinari
cardiolog
alter
intestin
fecal
microbiota
dysbiosi
togeth
chang
fecal
bile
acid
ba
concentr
associ
type
diabet
mellitu
dm
peopl
dm
dog
resembl
human
type
dm
aim
studi
evalu
chang
fecal
microbiota
fecal
unconjug
ba
profil
dog
dm
insulin
therapi
compar
healthi
control
dog
hc
aim
fecal
sampl
left
serum
sampl
obtain
diagnost
propos
adult
dog
dm
collect
fecal
sampl
clinic
healthi
dog
use
control
popul
addit
serum
folat
cobalamin
ctli
assess
dm
group
exclud
presenc
caus
dysbiosi
dm
dog
fed
diet
known
use
antibiot
within
previou
month
exclud
dna
extract
fecal
sampl
prior
quantit
pcr
qpcr
analysi
data
bacteri
group
compil
calcul
microbiota
dysbiosi
index
di
concentr
proport
fecal
unconjug
primari
cholicchenodeoxychol
secondari
lithodeoxyursodeoxychol
ba
measur
use
ga
chromatographi
mass
spectrometri
platform
unpair
test
u
test
compar
median
valu
hc
dm
dog
signific
set
p
median
di
statist
differ
hc
dm
dog
hd
vs
dm
p
neg
dysbiosi
index
di
indic
normobiosi
present
dm
dog
four
dog
dm
dysbiot
di
index
tli
folat
cobalamin
concentr
normal
dog
dm
though
two
dog
cobalamin
level
ngl
signific
differ
group
total
ba
proport
secondari
ba
respect
p
p
result
preliminari
studi
confirm
associ
intestin
dysbiosi
fecal
bile
acid
dysmetabol
dm
dog
insulin
therapi
fecal
unconjug
ba
profil
dm
dog
mimick
seen
healthi
dog
studi
need
evalu
possibl
role
intestin
microbiota
pathogenesi
canin
dm
disclosur
report
human
antibiot
use
result
chang
bacteri
constitu
gastrointestin
gi
tract
microbi
shift
associ
predisposit
certain
diseas
chronic
gi
diseas
obes
allergi
studi
exist
kitten
investig
effect
antibiot
administr
gi
microbiota
durat
effect
studi
aim
determin
effect
antibiot
administr
kitten
certain
bacteri
group
potenti
associ
dysbiosi
natur
pass
fece
collect
healthi
kitten
receiv
antibiot
group
kitten
receiv
amoxicillinclavulan
acid
day
group
kitten
receiv
doxycyclin
day
group
part
standard
treatment
upper
respiratori
tract
infect
kitten
approxim
month
age
diet
antiparasit
treatment
prior
sampl
collect
fecal
sampl
collect
day
antibiot
treatment
group
group
respect
end
antibiot
administr
dna
extract
sampl
qpcr
perform
total
bacteria
turicibact
spp
faecalibacterium
spp
streptococcu
spp
escherichia
coli
e
coli
blautia
spp
fusobacterium
spp
clostridium
hiranoni
c
hiranoni
bifidobacterium
spp
data
test
normal
distribut
appropri
statist
analys
use
either
repeat
independ
measur
statist
signific
set
p
correct
multipl
comparison
use
appropri
day
signific
differ
identifi
among
group
day
signific
increas
e
coli
p
decreas
total
bacteria
p
blautia
p
c
hiranoni
p
faecalibacterium
p
group
compar
group
day
ecoli
p
significantli
increas
group
compar
group
group
e
coli
significantli
decreas
p
faecalibacterium
significantli
increas
p
time
group
total
bacteria
p
blautia
p
significantli
decreas
day
c
hiranoni
p
day
blautia
p
remain
decreas
day
ecoli
remain
unchang
day
p
decreas
day
p
faecalibacterium
remain
unchang
day
p
increas
day
p
group
statist
signific
differ
identifi
administr
amoxicillinclavulan
acid
doxycyclin
profound
effect
certain
bacteri
group
potenti
associ
dysbiosi
kitten
disclosur
report
sever
studi
report
intestin
microbi
dysbiosi
dog
chronic
enteropathi
limit
data
avail
microbiota
gene
function
patholog
dog
determin
function
attribut
microbiom
essenti
understand
role
host
metabol
diseas
aim
studi
compar
function
role
fecal
microbiota
healthi
dog
dog
ce
fecal
dna
shotgun
sequenc
fecal
sampl
collect
healthi
dog
dog
chronic
enteropathi
ce
fecal
dna
extract
use
commerci
kit
powersoil
qiagen
function
character
shotgun
sequenc
read
kegg
databas
perform
use
next
gener
sequenc
order
identifi
rel
abund
specif
metabol
pathway
wilcoxon
test
use
comparison
gene
abund
group
signific
set
q
phylum
level
low
abund
bacteroidet
observ
dog
ce
compar
healthi
control
dog
vs
q
fusobacteria
also
significantli
increas
healthi
control
vs
q
pathway
enrich
analysi
bacteri
metagenom
show
total
metabol
modul
differenti
abund
studi
group
gene
carbohydr
metabol
biosynthesi
amino
acid
lysin
threonin
histidin
isoleucin
tryptophan
leucin
serin
vitamin
ascorb
thiamin
riboflavin
decreas
dog
ce
gene
involv
transport
molecul
homeostasi
mainten
oxid
stress
glutathion
biosynthesi
increas
ce
data
present
previou
report
intestin
microbi
dysbiosi
dog
ce
new
find
result
show
alter
microbi
metabol
dog
ce
compar
healthi
dog
character
reduct
amino
acid
biosynthesi
carbohydr
metabol
studi
includ
transcriptom
analysi
warrant
defin
consequ
microbiota
dysfunct
dog
ce
disclosur
report
ple
syndrom
caus
variou
diseas
includ
idiopath
inflammatori
bowel
diseas
primari
lymphangiectasia
lymphoma
sever
acut
gastroenter
certain
breed
predisposit
wheaten
terrier
well
known
clinic
experi
suggest
pug
ple
respond
poorli
treatment
describ
literatur
aim
current
studi
assess
whether
pug
breed
demonstr
wors
respons
treatment
ple
breed
dog
retrospect
studi
compar
respons
treatment
pug
diagnos
ple
five
referr
centr
unit
kingdom
approv
studi
grant
univers
liverpool
research
ethic
committe
group
dog
also
diagnos
ple
within
period
select
comparison
ple
defin
gastrointestin
diseas
result
serum
albumin
laboratori
refer
interv
could
explain
anoth
caus
factor
associ
surviv
assess
use
simpl
statist
test
test
appropri
cox
proport
hazard
regress
initi
factor
test
individu
use
simpl
regress
multipl
regress
model
creat
subsequ
refin
backward
stepwis
elimin
best
model
found
total
pug
diagnos
ple
compar
dog
breed
simpl
regress
analysi
factor
associ
surviv
p
pug
breed
p
diet
use
treatment
p
receiv
immunosuppress
therapi
p
treatment
cobalamin
p
howev
factor
remain
final
model
pug
breed
diet
use
treatment
respect
dog
pug
breed
associ
greater
hazard
die
compar
hazard
ratio
hr
ci
p
whilst
fed
hydrolys
diet
associ
lesser
hazard
risk
death
fed
diet
compar
diet
hr
p
compar
diet
includ
diet
hr
p
conclus
studi
demonstr
associ
pug
breed
poorer
respons
treatment
ple
compar
breed
research
undertaken
underli
caus
disclosur
report
ajg
employe
univers
liverpool
post
financi
support
royal
canin
also
own
mar
petcar
ajg
also
receiv
financi
remuner
provid
educ
materi
speak
confer
consult
work
mar
petcar
remuner
project
unrel
work
report
manuscript
author
declar
conflict
interest
assess
serum
folat
sf
routin
perform
dog
chronic
enteropathi
ce
often
conjunct
serum
cobalamin
tradit
combin
use
differenti
intestin
malabsorpt
dysbiosi
despit
fact
diagnost
prognost
valu
serum
cobalamin
well
document
preval
hyperfolataemia
clinic
prognost
valu
assess
scrutinis
dog
ce
aim
studi
determin
preval
sf
abnorm
dog
ce
well
relationship
laboratori
paramet
outcom
file
dog
present
chronic
gastrointestin
gi
sign
week
durat
retrospect
evalu
exclus
criteria
lack
sf
assess
supplement
folat
cobalamin
beforehand
dog
fn
mn
fe
median
age
rang
includ
hypofolataemia
present
hyperfolataemia
remain
dog
normal
sf
valu
initi
dog
divid
group
accord
final
diagnosi
ce
n
gi
diseas
n
diseas
n
sf
valu
significantli
differ
across
group
p
divid
ce
dog
differ
subgroup
fre
sre
enteropathi
ple
differ
sf
valu
observ
anova
p
dog
group
sf
statu
low
normal
high
signific
differ
serum
cobalamin
p
alkalin
phosphatas
p
cholesterol
p
total
calcium
p
identifi
anova
dunn
post
hoc
test
multivari
analysi
confirm
correl
sf
cobalamin
p
well
cholesterol
p
total
calcium
p
howev
none
correl
linear
spearman
p
kaplan
maier
analysi
surviv
time
sf
statu
show
signific
differ
conclus
sf
associ
gi
diseas
subgroup
ce
improv
clinic
sign
surviv
associ
sf
statu
studi
diagnost
prognost
benefit
assess
sf
dog
chronic
gi
sign
could
detect
futur
prospect
studi
assess
folat
supplement
ce
dog
hypofolataemia
acceler
clinic
improv
influenc
outcom
prognosi
disclosur
report
acut
haemorrhag
diarrhoea
syndrom
ahd
dog
often
treat
antibiot
due
potenti
risk
bacteri
transloc
gastrointestin
tract
blood
stream
howev
recent
studi
indic
antibiot
alway
necessari
accord
danish
antibiot
use
guidelin
companion
anim
antibiot
recommend
routin
treatment
ahd
indic
hospit
dog
sever
affect
overal
condit
sign
system
inflamm
sir
sepsi
aim
studi
evalu
sever
diseas
outcom
hospit
dog
acut
haemorrhag
diarrhoea
receiv
antibiot
studi
perform
retrospect
observ
studi
base
inform
medic
record
dog
acut
haemorrhag
diarrhoea
unknown
aetiolog
hospit
univers
hospit
companion
anim
period
signal
concurr
diseas
clinic
diseas
time
hospit
consecut
day
treatment
prior
hospit
day
hospitalizationeuthanasia
laboratori
result
regist
patient
clinic
diseas
score
accord
system
number
sir
criteria
tachycardia
hr
tachypnea
rr
hyper
hypothermia
leucocytosi
wbc
leukopenia
wbc
band
neutrophilia
andor
hypoglycaemia
glucos
mmoll
record
dog
exclud
analysi
due
suspect
drug
induc
diseas
vaccin
n
anaesthet
n
corticosteroid
nsaid
n
alimentari
foreign
bodi
n
treatment
antibiot
hospit
n
dog
obviou
caus
diarrhoea
found
receiv
support
treatment
intraven
fluid
therapi
n
antiemet
n
gastroprotect
n
surviv
discharg
dog
two
dog
euthan
due
financi
constraint
reluct
owner
proceed
treatment
due
advanc
age
one
brachycephal
dog
suffer
respiratori
crisi
respiratori
arrest
resuscit
surviv
dog
hospit
averag
day
rang
day
mean
hospit
rang
mean
hour
hospit
rang
dog
met
sir
criteria
hospit
none
dog
degen
result
suggest
antimicrobi
therapi
dog
acut
haemorrhag
diarrhoea
may
alway
necessari
dog
even
met
disclosur
report
recent
studi
shown
alter
faecal
bile
acid
ba
profil
dog
chronic
enteropathi
potenti
contribut
clinic
sign
studi
aim
assess
faecal
ba
concentr
dog
acut
haemorrhag
diarrhoea
syndrom
time
compar
healthi
control
dog
enrol
faecal
ba
concentr
measur
ga
spectrometri
day
day
statist
analysi
perform
friedman
test
comparison
ba
time
unpair
comparison
p
day
concentr
lithochol
acid
significantli
lower
p
day
total
faecal
ba
significantli
increas
p
compar
precis
primari
ba
significantli
increas
day
p
significantli
higher
concentr
cholic
acid
p
secondari
ba
significantli
decreas
p
significantli
lower
concentr
deoxychol
acid
p
ursodeoxychol
acid
udca
p
dog
show
signific
decreas
total
primari
ba
concentr
p
significantli
lower
concentr
cholic
acid
p
deoxychol
acid
p
day
compar
day
conclus
show
alter
faecal
ba
profil
compar
howev
faecal
ba
profil
normal
rapidli
suggest
ba
dysmetabol
seem
play
major
role
pathophysiolog
ahd
disclosur
report
destruct
intestin
barrier
microbiota
dysbiosi
especi
around
time
wean
repres
import
mechan
allerg
sensit
consequ
young
dog
surviv
canin
parvoviru
cpv
infect
develop
chronic
gastrointestin
disord
later
live
unknown
adult
dog
sever
intestin
lesion
also
increas
risk
develop
chronic
gastrointestin
disord
aim
studi
evalu
whether
dog
acut
hemorrhag
diarrhea
syndrom
ahd
higher
preval
chronic
enteropathi
later
life
forti
dog
diagnos
ahd
least
month
avail
includ
studi
histor
control
group
dog
without
histori
gastroenter
includ
enabl
risk
assess
dog
owner
ask
complet
questionnair
percentag
dog
sign
chronic
enteropathi
group
compar
use
fisher
exact
test
signific
differ
ahd
control
dog
concern
develop
chronic
enteropathi
ahd
control
p
observ
time
ahd
median
year
rang
year
control
median
year
rang
year
result
studi
suggest
dog
experi
episod
ahd
increas
risk
develop
chronic
gastrointestin
diseas
later
life
differ
risk
young
dog
cpv
infect
thu
time
intestin
barrier
dysfunct
might
repres
one
main
risk
factor
conflict
interest
conflict
interest
report
disclosur
report
myxomat
mitral
valv
diseas
mmvd
associ
failur
mitral
valv
mv
apparatu
proport
affect
dog
mv
regurgit
sever
enough
caus
increas
left
atrial
la
volum
pressur
la
function
report
declin
increas
diseas
sever
pimobendan
phosphodiesteras
iii
inhibitor
exert
posit
inotrop
vasodilatori
effect
shown
decreas
la
pressur
although
effect
la
function
well
establish
studi
aim
prospect
evalu
acut
effect
pimobendan
la
function
mitral
regurgit
fraction
dog
stage
mmvd
sixteen
dog
stage
mmvd
includ
prospect
intervent
studi
echocardiogram
perform
present
hour
follow
pimobendan
doppler
imag
record
right
parastern
left
apic
standard
view
dog
left
atrial
volum
measur
use
biplan
method
three
immedi
mv
open
onset
mv
closur
reservoir
conduit
activ
pump
function
calcul
previous
describ
ten
dog
mv
regurgit
volum
calcul
subtract
forward
stroke
volum
aortic
outflow
veloc
time
integr
multipli
aortic
area
total
left
ventricular
lv
stroke
volum
lv
volum
subtract
lv
volum
measur
use
simpson
method
disc
mv
regurgit
fraction
calcul
percentag
regurgit
volum
total
stroke
volum
pair
student
wilcoxon
test
use
compar
result
compar
baselin
la
volum
significantli
lower
measur
immedi
mv
open
p
onset
p
mv
closur
p
howev
la
conduit
reservoir
activ
pump
function
chang
significantli
mv
regurgit
fraction
significantli
lower
p
compar
baselin
forward
stroke
volum
significantli
increas
p
total
stroke
volum
chang
significantli
studi
suggest
despit
acut
reduct
la
volum
pimobendan
may
exert
measur
effect
la
function
benefici
decreas
left
atrial
volum
appear
result
acut
reduct
mv
regurgit
fraction
mechan
pimobendan
reduc
regurgit
fraction
thought
associ
improv
forward
flow
secondari
inotrop
vasodilatori
effect
addit
reduc
lv
dimens
minimis
secondari
function
mitral
regurgit
disclosur
report
pimobendan
frequent
use
treatment
cat
congest
heart
failur
chf
secondari
hypertrophi
cardiomyopathi
hcm
concern
exist
regard
safeti
pimobendan
subset
cat
hcm
dynam
outflow
tract
obstruct
hocm
purpos
studi
evalu
safeti
toler
pimobendan
cat
chf
secondari
hocm
compar
nonobstruct
hcm
medic
record
cat
chf
hocm
nonobstruct
hcm
two
tertiari
referr
hospit
review
demograph
clinicopatholog
echocardiograph
treatment
data
collect
compar
group
includ
inform
regard
possibl
advers
effect
pimobendan
averag
age
cat
year
differ
hocm
hcm
p
compar
cat
hcm
cat
hocm
like
manifest
chf
pulmonari
edema
versu
p
less
like
pleural
effus
versu
p
higher
incid
heart
murmur
cat
hocm
p
clinic
variabl
differ
group
pimobendan
typic
initi
date
chf
diagnosi
median
time
diagnosi
chf
initi
pimobendan
day
initi
dose
pimobendan
mgkg
everi
hour
dose
frequenc
escal
point
chf
manag
case
differ
hocm
hcm
cat
clinic
sign
could
potenti
repres
advers
effect
pimobendan
vomit
diarrhea
anorexia
lethargi
arrhythmia
note
hcm
cat
hocm
cat
p
base
pattern
time
resolut
sign
gener
ascrib
recurr
chf
rather
pimobendan
administr
pimobendan
discontinu
due
advers
effect
cat
nonobstruct
hcm
experienc
lethargi
nausea
hour
follow
pimobendan
administr
resolv
pimobendan
discontinu
pimobendan
discontinu
addit
cat
either
owner
unabl
administ
medic
n
chf
resolv
n
case
chf
precipit
acut
extern
event
fluid
overload
inject
glucocorticoid
administr
cat
experienc
acut
advers
hemodynam
effect
hypotens
cardiovascular
collaps
follow
pimobendan
administr
result
studi
suggest
pimobendan
cat
cardiomyopathi
chf
regardless
presenc
dynam
outflow
tract
obstruct
disclosur
report
dr
defranceso
tou
keen
receiv
consult
fee
andor
honoraria
boehring
ingelheim
vetmedica
inc
ceva
anim
health
systol
heart
murmur
sm
commonli
diagnos
healthi
cat
aim
studi
determin
whether
angl
aosa
associ
sm
cat
hypothesis
sm
relat
presenc
septal
bulg
systol
anterior
motion
mitral
valv
sam
increas
aortic
flow
veloc
aov
novemb
februari
client
own
cat
refer
cardiolog
evalu
prospect
examin
regardless
presenc
systol
murmur
cat
normal
echocardiograph
exam
normal
blood
pressur
systol
pressur
mmhg
euthyroid
includ
studi
cat
normal
diastol
thick
left
ventricl
isol
basal
septal
hypertrophi
ibsh
mm
sam
also
includ
aosa
measur
right
parastern
five
chamber
view
base
publish
guidelin
dog
total
cat
examin
fulfil
inclus
criteria
left
parastern
sm
found
cat
cat
murmur
audibl
stress
auscult
sm
associ
narrow
aosa
p
higher
preval
ibsh
p
higher
aov
p
compar
cat
without
murmur
ibsh
increas
age
increas
mm
per
year
aosa
decreas
age
p
reduct
per
year
aosa
narrow
cat
ibsh
p
ibsh
alway
present
cat
aosa
aosa
differ
cat
without
sam
p
correl
aosa
aov
conclus
aosa
angl
remodel
interventricular
septum
may
correl
caus
systol
murmur
appar
healthi
cat
find
resembl
sigmoid
septum
found
human
consid
morpholog
variant
ventricular
septum
age
relat
associ
systol
murmur
disclosur
report
develop
pulmonari
hypertens
independ
predictor
poor
outcom
dog
affect
myxomat
valvular
degener
mmvd
pulmonari
arteri
pressur
routin
estim
appli
simplifi
bernoulli
equat
veloc
tricuspid
regurgit
paspd
accuraci
estim
unknown
dog
mmvd
experiment
studi
suggest
method
imperfect
prospect
enrol
dog
affect
acvim
stage
c
mmvd
treatment
unchang
least
one
month
thermodilut
monitor
cathet
percutan
place
right
jugular
vein
advanc
main
pulmonari
arteri
pulmonari
arteri
systol
pressur
record
paspc
second
oper
simultan
acquir
tricuspid
regurgit
veloc
spectra
calcul
paspd
oper
blind
result
techniqu
twenti
dog
enrol
technic
difficulti
prevent
catheter
dog
eighteen
measur
pair
therefor
use
comparison
paspc
paspd
analysi
linear
regress
statist
signific
bia
paspc
paspd
mean
differ
mmhg
confid
interv
mmhg
mmhg
detect
limit
agreement
techniqu
wide
mmhg
mmhg
regress
analysi
fail
identifi
signific
linear
associ
two
techniqu
r
p
conclus
paspd
estim
poorli
agre
paspc
measur
dog
affect
mmvd
acvim
stage
c
dog
paspd
could
paspc
mmhg
therefor
caution
use
interpret
paspd
disclosur
report
michel
borgarelli
receiv
financi
support
ceva
sant
animal
work
relat
abstract
left
atrial
tear
lat
acut
rare
complic
canin
myxomat
mitral
valv
diseas
mmvd
match
multicent
retrospect
studi
focuss
clinic
manifest
surviv
lat
dog
compar
control
dog
mmvd
without
lat
data
collect
veterinari
cardiolog
depart
databas
select
patient
advanc
mmvd
associ
lat
signal
clinic
present
echocardiographi
select
laboratori
find
caus
death
surviv
data
evalu
paramet
assess
upon
lat
diagnosi
time
resolut
pericardi
effus
time
control
dog
similarli
advanc
mmvd
select
base
quantit
echocardiograph
paramet
match
lat
dog
thirti
dog
includ
dog
mmvd
associ
lat
control
dog
without
lat
group
dog
acvim
congest
heart
failur
stage
c
mmvd
commonli
observ
clinic
sign
includ
dyspnoea
syncop
weak
signific
differ
found
age
group
year
p
bodi
weight
group
kg
p
gender
distribut
lat
group
femal
control
group
femal
p
serum
creatinin
concentr
lat
group
umol
control
group
umol
p
echocardiograph
variabl
group
mean
left
atrial
aortic
diamet
ratio
dog
lat
control
left
ventricular
intern
diamet
normal
bodi
weight
end
diastol
dog
lat
control
pericardiocentesi
perform
dog
studi
termin
dog
lat
control
group
die
cardiac
caus
five
dog
lat
die
first
week
post
admiss
compar
control
dog
mean
surviv
time
lat
dog
day
exclud
anim
die
first
week
surviv
time
dog
lat
day
control
dog
p
conclus
dog
mmvd
associ
lat
bear
high
mortal
risk
especi
first
week
post
event
howev
surviv
critic
time
lat
seem
significantli
impact
surviv
disclosur
report
one
hundr
twenti
dog
enrol
valu
effect
load
condit
chang
left
ventricular
volum
patent
ductu
arteriosu
pda
occlus
acdo
use
standard
echocardiographi
anim
divid
pure
breed
n
mix
breed
n
subsequ
pure
breed
dog
divid
basi
size
breed
belong
group
small
size
n
medium
size
n
larg
size
n
moreov
anim
divid
three
class
base
age
month
month
month
signific
reduct
examin
paramet
lvidd
lvid
edv
esv
edvi
esvi
fs
observ
ductal
closur
evalu
rel
percentag
differ
rdp
echocardiograph
paramet
show
closur
signific
reduct
higher
small
size
breed
larg
size
breed
dog
signific
differ
relat
breed
size
observ
rpdf
variabl
signific
interact
effect
breed
size
age
class
observ
rpdedvi
f
p
six
month
age
signific
differ
rpdedvi
reduct
month
signific
reduct
small
size
larg
size
breed
dog
occlus
observ
conclus
data
seem
indic
small
breed
dog
show
greater
toler
congenit
volum
overload
reason
could
possibl
delay
pda
closur
month
allow
weight
gain
make
easier
intervent
procedur
hand
larg
breed
dog
submit
ductal
closur
soon
possibl
order
avoid
excess
lv
wall
stress
disclosur
report
intraven
furosemid
mainstay
treatment
acut
congest
heart
failur
dog
howev
potenti
delay
effect
hydrat
electrolyt
renal
function
studi
studi
sought
evalu
paramet
normal
dog
receiv
furosemid
continu
rate
infus
cri
without
system
inhibitor
ten
healthi
dog
studi
random
design
dog
oral
receiv
either
placebo
benazepril
benazeprilspironolacton
day
prior
furosemid
cri
mgkghr
bodi
weight
bw
renal
valu
serum
electrolyt
pack
cell
volum
total
protein
measur
oral
medic
hour
furosemid
cri
hour
variabl
compar
treatment
loss
bw
cri
exceed
recoveri
hour
hemoconcentr
occur
incomplet
return
baselin
hour
blood
urea
nitrogen
creatinin
unchang
cri
increas
hour
serum
sodium
chang
cri
decreas
hour
serum
chlorid
decreas
hour
return
baselin
hour
hypochlorem
metabol
alkalosi
increas
anion
gap
present
hour
normal
hour
differ
treatment
found
furosemid
biochem
chang
delay
hour
other
evid
hour
partial
improv
hour
normal
dog
find
implic
clinic
patient
renal
dysfunct
receiv
higher
dose
longer
furosemid
infus
disclosur
report
studi
fund
ceva
sant
animal
dr
adin
receiv
fund
american
kennel
club
canin
health
foundat
unrel
studi
pathway
disrupt
axi
dog
incomplet
defin
renal
endothelin
system
may
play
key
role
regul
blood
pressur
sodium
homeostasi
kidney
also
mediat
vascular
dysfunct
chang
increas
cardiovascular
risk
peopl
urinari
marker
renal
vascular
tubular
activ
could
provid
insight
chang
renal
signal
contribut
interact
dog
hypothesis
renal
activ
increas
advanc
canin
chronic
cardiac
renal
diseas
pilot
studi
compar
cystatin
c
marker
renal
injurydysfunct
concentr
surplu
urin
four
group
dog
present
r
sv
healthi
n
chronic
kidney
diseas
ckd
iri
stage
serum
creatinin
n
cardiac
diseas
acvim
classif
n
chronic
diseas
n
urin
morn
appoint
sampl
exclud
contain
activ
sediment
store
batch
analysi
cystatin
c
measur
commerci
elisa
index
urinari
creatinin
concentr
enzymat
method
comparison
anova
yield
residu
dunn
post
hoc
test
use
signific
p
mark
increas
excret
dog
stage
c
heart
diseas
iqr
pgmg
n
compar
healthi
dog
pgmg
iqr
p
excret
also
increas
stage
heart
diseas
pgmg
iqr
p
n
although
lesser
degre
predominantli
due
increas
dog
mmvd
pgmg
iqr
p
n
rather
cardiac
diseas
pgmg
iqr
al
increas
ckd
chronic
diseas
group
statist
signific
contrast
ckd
markedli
increas
urinari
cystatin
c
excret
limit
detect
ngmg
iqr
p
modest
increas
p
observ
dog
chronic
diseas
ngmg
iqr
none
heart
diseas
stage
renal
activ
increas
congest
heart
failur
surprisingli
also
increas
mmvd
congest
develop
neither
increas
associ
renal
injuri
consequ
chronic
diseas
state
renal
may
mediat
pathophysiolog
interact
mmvd
differ
isol
ckd
develop
congest
heart
failur
disclosur
report
third
degre
atrioventricular
block
avb
characteris
complet
atrioventricular
av
dissoci
caus
independ
atrial
ventricular
rhythm
persist
third
degre
avb
pavb
commonli
describ
anoth
form
avb
av
dissoci
intermitt
iavb
also
recognis
cat
avb
associ
underli
cardiac
system
diseas
present
clinic
sign
associ
form
avb
includ
weak
lethargi
syncop
clinic
sign
particular
syncop
present
epicardi
pacemak
implant
repres
effect
treatment
aim
studi
retrospect
assess
present
echocardiograph
data
comorbid
outcom
cat
diagnos
avb
pavb
iavb
singl
referr
hospit
includ
underw
pacemak
implant
non
parametr
test
kaplan
meier
curv
log
rank
test
perform
cat
includ
period
cat
pavb
iavb
median
age
present
year
differ
avb
type
p
cat
male
femal
cat
refer
cardiac
complaint
syncop
arrhythmia
dyspnoea
cat
sign
lethargi
cat
avb
incident
find
cat
iavb
like
present
syncop
event
p
median
durat
clinic
sign
prior
present
day
cat
echocardiograph
chang
left
ventricular
hypertrophi
chamber
dilat
cat
present
congest
heart
failur
chf
cat
one
comorbid
common
hyperthyroid
diabet
mellitu
azotaemia
fifteen
cat
underw
epicardi
pacemak
implant
mainli
cat
iavb
five
cat
minor
complic
lead
dislodg
pacemak
undersens
exit
block
cat
show
clinic
sign
sinc
implant
cat
die
mortal
median
surviv
time
day
differ
surviv
observ
cat
present
chf
p
iavb
p
comorbid
p
pacemak
placement
p
death
due
cardiac
caus
occur
fewer
cat
shorter
surviv
mortal
day
p
chf
present
associ
cardiac
death
p
result
studi
show
variabl
outcom
cat
avb
cardiac
death
occur
minor
cat
associ
chf
present
cat
comorbid
affect
mortal
pacemak
implant
control
clinic
sign
major
cat
disclosur
report
complet
balanc
diet
one
test
one
control
evalu
prospect
random
multicent
studi
effect
clinic
biochem
echocardiograph
paramet
cat
asymptomat
hypertroph
cardiomyopathi
ahcm
cat
diastol
interventricular
septum
ivsd
andor
left
ventricular
wall
lvwd
thick
mm
includ
inform
examin
fast
cat
month
test
control
diet
includ
auscult
bodyweight
bw
bodi
condit
score
bc
echocardiographi
wall
thick
measur
basal
mid
lvwd
ivsd
apic
ivsd
level
record
maximum
number
area
mm
blood
analysi
includ
serum
amyloid
saa
insulin
glucos
linear
gener
mix
model
analyz
diet
time
interact
signific
level
signific
interact
p
p
test
control
diet
show
signific
decreas
time
p
p
p
p
p
p
p
p
ivsd
lvwd
p
p
ctni
p
signific
chang
bw
bc
effect
cardiac
medic
observ
cat
left
atrium
remodel
separ
significantli
decreas
p
p
p
revers
effect
primari
echocardiograph
paramet
ahcm
decreas
observ
test
diet
research
need
evalu
effect
clinic
outcom
disclosur
report
ingrid
van
hoek
jeremi
laxald
employe
royal
canin
sa
studi
describ
financi
support
royal
canin
sa
cardiomyopathi
frequent
cat
diagnosi
reli
combin
physic
examin
thorac
radiographi
electrocardiographi
echocardiographi
addit
last
decad
assay
measur
circul
biomark
heart
diseas
cardiac
troponin
natriuret
peptid
becom
avail
cat
assay
proven
use
diagnosi
felin
cardiomyopathi
although
certain
case
may
less
reliabl
therefor
aim
studi
detect
new
circul
protein
may
improv
identif
cat
affect
cardiomyopathi
use
biomark
discoveri
cat
prospect
enrol
evalu
compris
complet
blood
count
biochem
profil
determin
blood
pressur
measur
thorac
radiographi
echocardiographi
base
diagnosi
cat
alloc
group
name
symptomat
cardiomyopathi
sign
congest
heart
failur
group
asymptomat
cardiomyopathi
group
respiratori
diseas
group
system
diseas
without
system
hypertens
group
healthi
control
group
healthi
plasma
sampl
process
untreat
follow
enrich
protein
submit
mass
spectrometri
protein
profil
compar
statist
softwar
put
biomark
evalu
western
immunoblot
experi
cat
includ
healthi
cat
hypertroph
cardiomyopathi
restrict
cardiomyopathi
lung
edema
identifi
pleural
effus
aortic
thromboembol
cat
hypertroph
cardiomyopathi
mass
spectrometri
sever
differenti
protein
identifi
among
group
put
biomark
test
western
immunoblot
protein
protein
differenti
detect
compar
other
particular
protein
identifi
cat
plasma
sampl
cat
healthi
visibl
band
respect
p
protein
detect
plasma
cat
band
detect
healthi
p
data
suggest
novel
put
biomark
differenti
cat
symptomat
cardiomyopathi
studi
higher
number
cardiomyopath
cat
differ
symptomat
statu
mandatori
optim
test
evalu
sensit
specif
candid
biomark
disclosur
report
grant
sardegna
ricerch
incent
polari
research
clinic
environ
stress
cat
therebi
affect
blood
pressur
bp
record
aim
investig
differ
clinic
set
order
sequenc
set
perform
affect
bp
record
healthi
cat
healthi
cat
prospect
includ
health
examin
includ
physic
examin
echocardiographi
hematolog
biochemistri
blood
pressur
measur
oscillometr
hdo
devic
cuff
tail
three
clinic
set
cat
taken
carrier
place
examin
tabl
veterinarian
present
cat
carrier
veterinarian
present
cat
carrier
without
veterinarian
present
owner
present
set
sequenc
clinic
set
random
record
made
set
combin
effect
set
sequenc
associ
lower
systol
sbp
mean
arteri
map
diastol
bp
dbp
bp
measur
owner
cat
carrier
last
sequenc
p
heart
rate
higher
bp
measur
cat
examin
tabl
first
sequenc
p
measur
made
cat
examin
tabl
higher
coeffici
variat
cv
found
sbp
map
dbp
hr
p
conclus
measur
bp
cat
carrier
gave
lower
bp
hr
cv
compar
measur
examin
tabl
sequenc
affect
bp
lower
valu
record
made
last
owner
time
might
influenc
result
disclosur
report
aortic
thromboembol
ate
cardiac
complic
cat
left
atrial
la
enlarg
consid
risk
factor
dog
activ
coagul
follow
fibrinolysi
occur
type
pleural
effus
dog
pleural
effus
type
ascit
secondari
congest
heart
failur
chf
show
enhanc
system
fibrinolysi
may
decreas
clot
format
therefor
aim
studi
determin
whether
cardiopath
cat
pleural
effus
less
like
develop
aortic
thromboembol
ate
cat
without
pleural
effus
studi
retrospect
evalu
cat
heart
diseas
present
cat
includ
underw
full
echocardiographi
evalu
thorac
radiograph
cat
divid
group
without
chf
group
cardiogen
pulmonari
edema
group
pleural
effus
group
frequenc
ate
among
group
compar
test
la
diamet
laaorta
ratio
la
ao
also
compar
cat
without
ate
also
among
group
anova
follow
tamhan
analysi
studi
includ
cat
group
group
group
cat
time
present
ate
overal
preval
la
cat
ate
mm
significantli
p
bigger
cat
without
ate
la
ao
cat
ate
significantli
p
higher
cat
without
ate
frequenc
ate
statist
p
differ
among
group
group
group
group
la
significantli
f
p
increas
cat
group
mm
group
mm
compar
group
mm
signific
differ
present
group
la
ao
significantli
f
p
increas
cat
group
group
compar
group
signific
differ
present
group
expect
cat
chf
edema
pleural
effus
bigger
la
compar
cat
without
chf
moreov
also
cat
ate
present
larger
la
atrium
compar
cat
without
ate
nevertheless
pleural
effus
present
frequenc
ate
remain
low
despit
enlarg
la
disclosur
report
heart
murmur
commonli
detect
appar
healthi
cat
doppler
echocardiograph
evalu
ultim
requir
identifi
caus
blood
flow
turbul
respons
clinic
find
howev
even
doppler
echocardiographi
occasion
fail
demonstr
origin
murmur
cat
nevertheless
year
observ
appli
gentl
pressur
right
side
chest
wall
cat
ultrasound
probe
provoc
test
induc
temporari
narrow
right
ventricular
infundibulum
dynam
right
ventricular
outflow
obstruct
subsequ
caus
blood
flow
turbul
also
observ
similar
phenomenon
reproduc
gentli
press
stethoscop
head
right
wall
chest
induc
audibl
murmur
auscult
aim
studi
evalu
effect
increas
pressur
ultrasound
probe
chest
wall
cat
undergo
echocardiograph
examin
increas
right
ventricular
outflow
veloc
evok
blood
flow
turbul
anatom
area
clinic
record
appar
healthi
cat
dynam
systol
heart
murmur
underw
echocardiographi
retrospect
review
cat
blood
flow
turbul
infundibular
tract
induc
provoc
test
imag
acquisit
right
parastern
short
axi
view
level
heart
base
function
structur
abnorm
echocardiograph
examin
includ
studi
n
median
age
year
mean
bodi
weight
kg
median
murmur
grade
cat
includ
studi
present
laminar
blood
flow
colour
doppler
assess
right
infundibular
tract
howev
turbul
could
subsequ
visualis
follow
provoc
test
similarli
provoc
test
caus
increas
peak
systol
veloc
profil
characterist
dynam
obstruct
outflow
peak
systol
veloc
normal
distribut
ms
ms
differ
ms
statist
signific
pair
sampl
test
p
result
studi
confirm
murmur
cat
iatrogen
origin
caus
pressur
ultrasound
probe
chest
wall
postul
similar
phenomenon
evok
press
stethoscop
head
chest
wall
disclosur
report
human
medicin
caudal
vena
cava
cvc
diamet
cvcd
collaps
index
cvcci
evalu
via
point
care
ultrasound
pocu
accept
marker
intravascular
volum
statu
human
chronic
heart
failur
cvc
pocu
help
identifi
patient
requir
hospit
risk
decompens
degen
mitral
valv
diseas
dmvd
common
acquir
canin
cardiac
diseas
typic
associ
subsequ
hypervolem
state
advanc
stage
intravascular
volum
statu
impact
treatment
like
correl
prognosi
dog
cvc
paramet
obtain
via
pocu
describ
marker
intravascular
volum
statu
goal
studi
investig
cvc
paramet
evalu
via
pocu
differ
acvim
stage
degen
mitral
valv
diseas
dog
echocardiograph
cvc
pocu
find
dog
dmvd
present
januari
januari
retrospect
review
acvim
stage
recent
administr
diuret
record
dog
signific
right
side
heart
diseas
pericardi
effus
exclud
pocu
cvc
cineloop
obtain
echocardiograph
evalu
use
longitudin
subxyphoid
view
dog
place
right
later
recumb
cvc
maxim
minim
diamet
measur
index
aortic
diamet
cvcci
calcul
one
singl
observ
unawar
diseas
sever
acvim
stage
perform
measur
subject
assess
cvc
fat
flat
normal
cvc
paramet
compar
acvim
stage
use
fisher
exact
test
ancova
use
assess
effect
acvim
stage
diuret
treatment
cvc
paramet
data
express
median
rang
dog
dmvd
includ
acvim
stage
c
recent
receiv
diuret
cvc
paramet
associ
acvim
stage
significantli
larger
wherea
cvcci
significantli
reduc
dog
acvim
stage
c
compar
acvim
stage
differ
dog
acvim
stage
compar
stage
signific
associ
subject
fat
cvc
advanc
dmvd
stage
acvim
c
ancova
reveal
cvc
paramet
influenc
acvim
stage
diuret
administr
cvc
pocu
paramet
cvcci
correl
diseas
sever
patient
dmvd
could
use
identifi
dog
need
hospit
increas
risk
decompens
disclosur
report
echocardiograph
left
ventricular
lv
volum
estim
help
clinician
identifi
quantifi
cardiomegali
cardiac
function
dog
cardiologist
obtain
estim
differ
view
index
bodi
size
normal
comparison
individu
classifi
rang
diseas
sever
howev
studi
compar
estim
obtain
differ
view
perform
one
group
investig
examin
specif
breed
therefor
examin
agreement
two
method
obtain
lv
volum
estim
dog
rang
diseas
diseas
state
also
gener
refer
interv
lv
volum
indic
five
investig
contribut
echocardiograph
data
dog
one
dog
exclud
analys
lv
dog
measur
triplic
use
simpson
singl
plane
method
either
right
parastern
long
axi
view
left
apic
view
systol
diastol
measur
averag
two
method
compar
use
analys
volum
index
bodyweight
bodi
surfac
area
refer
interv
creat
measur
obtain
healthi
dog
index
lv
dimens
regress
la
ao
dog
mitral
valv
diseas
systol
diastol
lv
volum
estim
obtain
two
method
agre
show
fix
proport
bias
dog
show
markedli
differ
lv
volum
two
method
limit
agreement
approxim
mlkg
diastol
lv
volum
index
mlkg
systol
lv
volum
index
healthi
dog
upper
limit
mlkg
mlkg
left
apic
view
mlkg
mlkg
right
parastern
view
diastol
systol
respect
confid
interv
limit
includ
point
estim
complementari
method
diastol
systol
lv
volum
index
increas
increas
la
ao
dog
mitral
valv
diseas
r
data
provid
investig
appear
similar
investig
show
obviou
bia
studi
suggest
littl
differ
exist
estim
lv
volum
two
echocardiograph
view
estim
interchang
dog
rang
cardiac
diseas
diseas
sever
addit
data
provid
refer
limit
volum
index
weight
mathemat
physiolog
appropri
index
surfac
area
disclosur
report
causal
mechan
predispos
factor
natur
cours
supraventricular
tachycardia
svt
atrial
fibril
af
well
describ
peopl
lesser
extent
dog
svt
cat
report
af
limit
aim
studi
describ
signal
clinic
find
outcom
cat
svt
versu
cat
af
cat
includ
retrospect
studi
cat
svt
af
cat
examin
novemb
april
inclus
criteria
avail
mm
ecg
concurr
echocardiograph
studi
continu
variabl
compar
group
use
u
test
categor
variabl
summaris
use
fisher
exact
test
surviv
curv
gener
assess
impact
rhythm
diagnosi
presenc
ventricular
arrhythmia
left
atrial
diamet
heart
rate
congest
heart
failur
statu
cardiac
death
differ
surviv
group
compar
use
logrank
comparison
surviv
curv
overal
common
present
respiratori
distress
cat
follow
lethargi
n
collaps
n
cat
af
slower
median
heart
rate
rang
bpm
compar
cat
svt
rang
bpm
p
cat
af
cardiac
chamber
remodel
wherea
cat
svt
structur
abnorm
left
atrial
diamet
significantli
larger
af
cat
mm
compar
mm
svt
cat
p
median
surviv
day
cat
af
compar
day
cat
svt
p
cat
present
sign
chf
wors
overal
surviv
p
rhythm
diagnosi
ventricular
arrhythmia
left
atrial
size
heart
rate
impact
surviv
statu
cat
af
svt
advanc
cardiac
remodel
median
left
atrial
size
greater
cat
af
svt
cat
svt
evid
cardiac
remodel
suggest
svt
cat
alway
consequ
atrial
enlarg
disclosur
report
ventricular
vpe
describ
activ
portion
ventricular
myocardium
along
accessori
pathway
ap
occur
sooner
electr
impuls
conduct
along
normal
system
ventricular
document
dog
ap
aim
studi
explor
electrocardiograph
ecg
featur
vpe
identifi
ecg
criteria
determin
ap
locat
speci
record
dog
document
ap
retrospect
review
dog
ecg
detail
electrophysiolog
map
analyz
dog
classifi
three
group
accord
posit
ap
antero
right
posterior
right
later
right
ecg
measur
differ
beat
perform
follow
paramet
wave
interv
segment
durat
durat
morpholog
axi
ms
durat
morpholog
axi
descript
statist
perform
quantit
variabl
normal
distribut
valu
assess
mean
median
quartil
standard
deviat
calcul
test
use
evalu
differ
posit
delta
wave
measur
lead
dog
vpe
manifest
intermitt
common
complex
morpholog
lead
ii
multipl
peak
qr
rr
rr
found
dog
right
posterior
right
later
ap
taller
respect
lead
p
ii
p
antero
ap
taller
lead
iii
p
taller
lead
p
result
studi
suggest
local
ap
use
surfac
ecg
criteria
possibl
addit
studi
need
test
use
dr
amplitud
guid
subsequ
radiofrequ
cathet
ablat
procedur
disclosur
report
subvalvular
pulmon
stenosi
sp
classifi
two
subtyp
infundibular
isp
sisp
isp
primari
due
fix
obstruct
right
ventricular
rv
outflow
tract
secondari
right
ventricular
concentr
hypertrophi
caus
pulmon
stenosi
furthermor
sisp
also
defin
doubl
chamber
right
ventricl
dcrv
superior
chamber
inferior
chamber
aim
studi
describ
treatment
isp
dcrv
dog
cat
cut
balloon
cb
techniqu
retrospect
studi
includ
patient
dog
cat
diagnos
isp
dcrv
case
underw
dilat
mm
diamet
length
cm
cb
follow
dilat
high
patient
maximum
outflow
veloc
vmax
maximum
pressur
gradient
pgmax
tricuspid
regurgit
maximum
veloc
trvmax
right
atrial
ra
area
rv
systol
function
estim
measur
procedur
hr
month
procedur
right
atrial
ventricular
pressur
procedur
mean
diamet
stenosi
mm
dog
mm
cat
mean
vmax
ms
mean
pgmax
mmhg
mean
trv
max
ms
mean
ra
area
mean
taps
mm
mean
tdi
ms
mean
fac
mean
pressur
valu
measur
catheteris
procedur
ra
pressur
mmhg
rv
superior
chamber
mmhg
rv
inferior
chamber
mmhg
cb
dilat
could
complet
dog
cat
dilat
mean
rv
superior
chamber
pressur
mmhg
avail
treat
dog
avail
treat
dog
follow
cb
dilat
mean
rv
superior
chamber
pressur
reduc
whilst
mean
pgmax
reduc
present
studi
describ
success
treatment
isp
dcrv
dog
cb
dilat
pgmax
reduct
revers
right
atrioventricular
remodel
procedur
could
complet
dog
cat
probabl
small
bodi
size
andor
sever
ra
remodel
imped
us
advac
stiff
cb
softer
guid
preliminari
result
indic
possibl
applic
cb
dilat
treatment
isip
dcrv
disclosur
report
aim
studi
describ
preval
morpholog
size
right
appendag
aneurysm
raa
dog
studi
ct
report
dog
underw
thorac
ct
examin
variou
reason
review
patient
characterist
assess
like
associ
raa
radiograph
echocardiograph
studi
also
evalu
avail
continu
data
assess
normal
distribut
test
dog
raa
compar
dog
without
raa
variabl
gender
sexual
statu
use
test
test
use
analys
age
bodi
weight
group
bodi
condit
score
five
point
score
system
analyz
use
fischer
exact
test
distribut
data
report
median
interquartil
rang
iqr
rang
statist
analys
signific
level
set
ct
data
dog
raa
retriev
archiv
analyz
use
variou
techniqu
raa
locat
shape
record
obliqu
multiplanar
view
use
area
measur
orthogon
long
axi
raa
raa
measur
includ
neck
maximum
height
width
addit
ct
featur
cardiac
extracardiac
structur
also
record
raa
detect
dog
thorac
ct
select
period
time
preval
radiograph
echocardiograph
studi
avail
dog
mediastin
mass
visibl
radiograph
echocardiograph
examin
disclos
raa
dog
pulmonari
hypertens
bodyweight
dog
raa
significantli
lower
remain
dog
without
raa
median
kg
iqr
rang
median
kg
iqr
rang
respect
p
femal
sex
also
significantli
associ
raa
p
dog
also
right
atrial
dilat
three
differ
raa
phenotyp
detect
dog
focal
dog
fusiform
dog
result
ct
measur
mean
neck
cm
iqr
rang
mean
height
cm
iqr
rang
mean
width
cm
iqr
rang
raa
infrequ
often
incident
condit
differ
phenotyp
studi
femal
sex
smaller
size
show
associ
raa
studi
necessari
assess
possibl
relationship
raa
pulmonari
hypertens
disclosur
report
aim
studi
identifi
predictor
reoccurr
congest
sign
cs
dog
mmvd
clinic
stabl
heart
failur
hf
congest
sign
defin
tachypnea
dyspnea
cough
resolv
medic
treatment
hf
medic
record
dog
enrol
registri
novemb
juli
review
identifi
dog
stabl
c
mmvd
defin
dog
cs
unchang
medic
treatment
least
four
week
sinc
first
identif
hf
studi
popul
compos
dog
subsequ
divid
two
group
reoccurr
group
rg
n
reoccurr
group
nrg
n
reoccurr
cs
defin
rest
respiratori
rate
breathminut
andor
dyspnea
within
studi
period
resolv
furosemid
increas
baselin
bodi
weight
bw
presenc
cough
left
ratio
laao
left
ventricular
intern
diamet
index
bodi
size
mitral
valv
peak
e
wave
veloc
furosemid
daili
dosag
associ
reoccurr
cs
univari
analysi
bw
p
laao
p
remain
signific
multivari
analysi
increment
laao
kg
bodi
weight
associ
increas
odd
reoccurr
studi
suggest
bw
laao
independ
predictor
reoccurr
cs
dog
stabl
c
mmvd
disclosur
report
dr
michel
borgarelli
receiv
financi
support
ceva
sant
animal
studi
unrel
abstract
dr
alessandra
franchini
receiv
finic
support
form
ceva
sant
animal
phd
object
studi
test
efficaci
two
diet
supplement
either
diet
u
plu
lemon
balm
melissa
officinali
l
fish
peptid
diet
us
reduct
urinari
cortisol
stress
marker
cat
ten
coloni
cat
firstli
receiv
control
adult
cat
diet
diet
c
five
week
randomli
assign
two
group
test
diet
u
us
five
week
cross
design
two
week
period
natur
void
urin
obtain
end
period
routin
condit
follow
applic
test
overnight
fast
blood
sampl
urinari
cortisol
serum
serotonin
concentr
measur
behaviour
test
perform
test
reaction
presenc
contact
unfamiliar
person
mix
model
repeat
measur
spss
use
analys
data
compar
control
diet
supplement
diet
effect
reduc
urinari
cortisol
almost
test
situat
p
compar
diet
u
diet
us
result
lower
urinari
cortisol
concentr
averag
overnight
fast
p
differ
routin
margin
p
diet
us
result
also
margin
increas
serum
serotonin
p
compar
two
diet
c
u
diet
u
result
higher
averag
score
unfamiliar
person
test
diet
us
mainli
increas
toler
presenc
unfamiliar
person
compar
c
conclus
supplement
diet
effect
reduc
stress
marker
cat
enhanc
effect
lemon
balm
fish
peptid
supplement
compar
alon
supplement
diet
may
also
help
improv
interact
unfamiliar
person
new
trial
conduct
cat
suffer
disord
confirm
clinic
benefit
dietari
supplement
disclosur
report
studi
fund
affin
petcar
sa
jeusett
fernandez
c
torr
employe
affin
petcar
sa
use
probiot
believ
health
promot
effect
stabilis
gut
microbiom
increas
fatti
acid
scfa
product
lower
circul
cholesterol
level
howev
probiot
supplement
may
also
affect
vitamin
b
metabol
indic
circul
cobalamin
may
deplet
level
refer
level
dog
yet
probiot
effect
highli
strain
specif
aim
studi
investig
effect
commerci
complet
diet
contain
enterococcu
faecium
ncimb
faecal
qualiti
faecal
scfa
acet
butyr
propion
concentr
well
serum
folic
acid
cobalamin
cholesterol
triglycerid
ten
healthi
client
own
dog
includ
random
prospect
crossov
studi
dog
went
day
acclimatis
period
gradual
transit
regular
diet
control
diet
acclimatis
period
follow
two
studi
period
day
studi
period
dog
randomli
assign
start
fed
control
diet
cd
probiot
diet
pd
control
diet
supplement
e
faecium
ncimb
cfukg
blood
sampl
rectal
faecal
sampl
collect
inclus
day
end
feed
period
day
faecal
qualiti
score
daili
owner
result
present
mean
sd
differ
p
consid
signific
signific
reduct
serum
cholesterol
vs
pd
mmoll
increas
faecal
content
butyr
found
pd
rel
pd
cd
serum
cobalamin
significantli
reduc
vs
cd
pd
ngl
within
refer
interv
ngl
faecal
concentr
acet
significantli
increas
compar
chang
found
serum
concentr
triglycerid
folic
acid
faecal
concentr
propion
faecal
qualiti
base
studi
e
faecium
incorpor
commerci
diet
potenti
health
promot
effect
dog
reduc
serum
concentr
cholesterol
increas
faecal
concentr
butyr
circul
cobalamin
decreas
follow
intervent
irrespect
whether
e
faecium
ncimb
includ
could
indic
dietari
factor
may
significantli
impact
cobalamin
level
disclosur
report
studi
fond
studi
diet
provid
bacterfield
gmbh
hamburg
germani
employ
one
author
theres
g
hosbjerg
iatrogen
hypothyroid
cat
associ
reduc
glomerular
filtrat
rate
increas
occurr
azotemia
shorten
long
term
surviv
previou
studi
support
conclus
limit
small
sampl
size
symmetr
dimethylarginin
sdma
shown
earlier
sensit
reliabl
renal
biomark
decreas
glomerular
filtrat
rate
creatinin
found
influenc
fluctuat
lean
muscl
mass
purpos
studi
util
big
data
character
relationship
sdma
creatinin
cr
subnorm
total
post
hyperthyroid
treatment
use
us
idexx
refer
laboratori
databas
cat
identifi
sampl
test
sdma
cr
dataset
hyperthyroid
treat
group
identifi
treat
popul
total
subnorm
cat
identifi
defin
post
hyperthyroid
treatment
remain
cat
euthyroid
treatment
compar
control
group
post
treatment
euthyroid
cat
subnorm
cat
use
evalu
sdma
cr
mcnemar
pair
test
test
use
appropri
signific
increas
number
subnorm
cat
sdma
concentr
refer
interv
found
compar
euthyroid
control
vs
p
cr
concentr
also
increas
refer
interv
significantli
greater
number
subnorm
cat
compar
control
vs
p
subnorm
group
increas
sdma
concentr
identifi
cat
potenti
decreas
gfr
reduct
renal
function
cr
studi
confirm
signific
percentag
cat
subnorm
attribut
overtreat
hyperthyroid
abnorm
renal
biomark
compar
euthyroid
follow
therapi
big
data
use
studi
support
import
avoid
iatrogen
hypothyroid
identifi
associ
reduc
renal
function
iatrogen
hypothyroid
emphas
import
avoid
overtreat
comprehens
renal
monitor
includ
measur
sdma
part
routin
manag
hyperthyroid
cat
disclosur
report
author
list
employ
idexx
laboratori
diagnosi
atyp
addison
diseas
typic
made
patient
diagnos
hypoadrenocortic
na
k
ratio
present
percentag
patient
hypoadrenocortic
atyp
diseas
remain
unknown
primari
aim
studi
determin
percentag
dog
diagnos
atyp
diseas
within
gener
popul
dog
diagnos
hypoadrenocortic
determin
percentag
differ
popul
diagnos
first
opinion
practic
popul
diagnos
referr
practic
databas
commerci
laboratori
unit
kingdom
search
find
dog
diagnos
hypoadrenocortic
four
year
period
dog
includ
acth
stimul
test
perform
post
acth
cortisol
concentr
mmoll
result
serum
plasma
sodium
potassium
concentr
time
initi
present
also
requir
inclus
dog
exclud
receiv
trilostan
medic
known
expect
interfer
adren
function
test
dog
diagnos
atyp
hypoadrenocortic
na
k
ratio
time
present
dog
newli
diagnos
hypoadrenocortic
identifi
includ
case
includ
case
diagnos
atyp
hypoadrenocortic
case
diagnos
referr
practic
diagnos
atyp
hypoadrenocortic
case
diagnos
first
opinion
practic
diagnos
atyp
hypoadrenocortic
overal
percentag
case
diagnos
atyp
hypoadrenocortic
may
higher
previou
estim
percentag
newli
diagnos
case
hypoadrenocortic
referr
practic
atyp
diseas
appear
higher
percentag
atyp
case
diagnos
first
opinion
practic
absenc
electrolyt
abnorm
classic
associ
typic
case
hypoadrenocortic
particularli
na
k
ratio
index
suspicion
diseas
may
low
find
higher
percentag
patient
atyp
diseas
consid
popul
diagnos
referr
practic
rais
concern
case
may
go
undiagnos
first
opinion
practic
disclosur
report
one
author
employ
commerci
laboratori
allow
databas
search
order
identifi
case
commerci
laboratori
perform
measur
serum
cortisol
concentr
includ
case
addison
diseas
character
defici
cortisol
aldosteron
lack
aldosteron
result
renal
sodium
wast
potassium
retent
lead
hyponatriemia
hyperkalemia
bodi
volum
deplet
effect
aldosteron
serum
potassium
excret
evalu
compar
urin
serum
potassium
concentr
correct
urin
potassium
concentr
reabsorpt
water
kidney
estim
call
ttkg
thu
aim
studi
evalu
abil
ttkg
identif
dog
affect
addison
diseas
among
popul
hyperkalem
dog
studi
retrospect
search
data
base
dog
serum
potassium
concentr
mmoll
refer
interv
present
decemb
februari
inclus
criteria
urin
ttkg
calcul
hospit
admiss
routin
done
laboratori
final
diagnosi
avail
base
final
diagnosi
dog
divid
newli
diagnos
addison
diseas
diagnos
acth
stimul
test
diseas
dog
exclud
studi
histori
corticosteroid
administr
andor
drug
affect
potassium
excret
eg
blocker
diuret
fludrocortison
iv
fluid
moreov
hyperkalem
dog
also
exclud
urin
osmol
mosmkg
urin
sodium
mmoll
preclud
valu
correct
ttkg
calcul
ttkg
compar
dog
addison
diseas
sick
hyperkalem
control
dog
final
roc
curv
analysi
use
identifi
best
cutoff
valu
youden
index
discrimin
dog
addison
diseas
sick
hyperkalem
control
dog
without
addison
diseas
analys
signific
set
eighti
hyperkalem
dog
includ
studi
addison
diseas
without
ttkg
dog
addison
diseas
significantli
p
lower
ttkg
control
dog
youden
index
identifi
roc
curv
analysi
ttkg
sensit
specif
auc
ci
p
present
studi
show
ttkg
hyperkalem
patient
use
diagnost
tool
initi
discrimin
dog
addison
diseas
hyperkalem
dog
without
addison
diseas
subset
hyperkalem
dog
ttkg
may
help
patient
manag
confirmatori
diagnosi
acth
stimul
test
avail
disclosur
report
monitor
trilostan
treatment
drug
choic
medic
therapi
canin
hypercortisol
hc
current
base
evalu
clinic
sign
result
acth
stimul
test
howev
method
mani
limit
recent
data
shown
lack
correl
acth
stimul
test
result
clinic
sign
dog
hc
treat
trilostan
last
year
mani
differ
studi
investig
possibl
altern
method
conflict
result
singl
studi
compar
method
canin
popul
lack
aim
studi
evalu
previou
investig
monitor
method
better
correl
standard
publish
clinic
score
cs
obtain
owner
questionnair
could
repres
best
method
monitor
trilostan
therapi
conduct
prospect
multicentr
studi
dog
hc
treatment
trilostan
twice
daili
least
two
week
blood
sampl
categor
unwel
sick
dog
well
control
dose
dose
increas
requir
dog
respect
base
cs
result
cs
compar
serum
cortisol
concentr
administr
plasma
acth
concentr
administr
plasma
acthcortisol
ratio
serum
haptoglobin
concentr
hp
chemistri
variabl
alp
alt
ggt
urinari
cortisolcreatinin
ratio
urin
specif
graviti
urin
evalu
day
morn
day
plasma
acth
serum
urinari
cortisol
measur
chemilumesc
assay
immulit
dog
includ
unwel
dog
exclud
analysi
haptoglobin
paramet
better
correl
cs
r
follow
alt
r
r
uccr
averag
urinari
sampl
r
roc
curv
analysi
identifi
concentr
hp
mgdl
concentr
use
valu
discrimin
well
control
dog
specif
respect
hp
seem
best
paramet
monitor
trilostan
therapi
howev
hp
like
limit
capabl
identifi
dog
concurr
evalu
cortisol
may
use
detect
overdos
trilostan
combin
evalu
hp
correctli
categor
case
use
altern
monitor
method
dog
hc
trilostan
therapi
disclosur
report
federico
fracassi
financi
support
dechra
msd
speak
consult
boehring
ingelheim
dechra
msd
royal
canin
hill
purina
la
vallonea
stefania
golinelli
consult
dechra
viviani
de
marco
speak
royal
canin
hill
purina
dechra
pharmaceut
support
studi
provid
vetoryl
free
natur
occur
hypercortisol
hc
hypoadrenocortic
rare
condit
cat
diagnosi
challeng
actual
lack
valid
studi
measur
felin
plasmat
adrenocorticotrop
hormon
acth
aim
studi
valid
commerci
avail
chemiluminesc
assay
measur
felin
acth
concentr
determin
normal
refer
interv
ri
assess
plasma
endogen
acth
concentr
cat
primari
hypoadrenocortic
ph
hc
cat
diseas
od
healthi
cat
cat
od
cat
diabet
mellitu
hyperthyroid
chronic
kidney
diseas
gastrointestin
diseas
acut
kidney
injuri
hypovolem
shock
septic
shock
hyperaldosteron
includ
prospect
studi
data
cat
ph
hc
hypercortisol
pdh
hypercortisol
adh
retriev
medic
record
three
referr
center
univers
bologna
zurich
utrecht
use
method
measur
immulit
left
sampl
collect
diagnost
purpos
use
coeffici
varianc
cv
rang
interassay
cv
sampl
high
low
concentr
acth
respect
dilut
studi
perform
two
sampl
high
concentr
acth
use
diluent
provid
manufactur
show
excel
accuraci
ri
plasma
endogen
acth
healthi
cat
establish
use
robust
method
pgml
median
pgml
plasma
acth
concentr
rang
pgml
pgml
pgml
healthi
od
pdh
cat
respect
cat
adh
show
acth
valu
pgml
detect
limit
assay
cat
ph
concentr
acth
pgml
acth
concentr
show
signific
differ
healthi
od
group
cat
pdh
ph
significantli
higher
acth
valu
group
pdh
cat
result
rang
healthi
od
cat
immulit
chemiluminesc
assay
valid
techniqu
measur
acth
felin
plasma
ri
quit
wide
due
low
overlap
healthi
od
cat
ph
hc
measur
endogen
acth
seem
use
includ
diagnost
workup
ph
hc
suspect
disclosur
report
ce
reusch
financi
support
purina
hill
provet
antlia
sa
glycemicon
novarti
anim
health
clinic
studi
fund
societi
compar
endocrinolog
speak
consult
boehring
ingelheim
dechra
novarti
anim
health
waltham
royal
canin
sara
galac
financi
support
morri
anim
foundat
sticht
dog
akc
canin
health
foundat
maria
gorkum
fond
speak
dechra
federico
fracassi
financi
support
dechra
msd
speak
consult
boehring
ingelheim
dechra
msd
royal
canin
hill
purina
la
vallonea
canin
diabet
mellitu
dm
classifi
insulin
resist
insulin
defici
diabet
case
requir
daili
insulin
inject
control
hyperglycaemia
number
patholog
mechan
thought
lead
develop
diseas
includ
destruct
beta
cell
diseas
risk
differ
consider
breed
suggest
genet
factor
involv
environment
trigger
also
thought
play
role
human
type
dm
region
genom
contain
human
leucocyt
antigen
hla
mhc
class
ii
gene
confer
approxim
genet
risk
associ
dog
leucocyt
antigen
dla
class
ii
haplotyp
also
identifi
diabet
dog
investig
date
consid
breed
togeth
studi
aim
identifi
dla
haplotyp
expand
data
set
take
highli
repres
breed
previou
studi
increas
data
diabet
dog
control
enabl
statist
analysi
dog
genotyp
use
type
dna
extract
blood
surplu
diagnost
requir
studi
popul
includ
dog
uk
femal
entir
case
expect
dioestru
diabet
exclud
breed
least
ten
case
number
control
equal
greater
number
case
genotyp
three
loci
combin
identifi
dla
class
ii
haplotyp
affect
risk
dm
across
breed
individu
breed
togeth
p
use
fisher
exact
test
odd
ratio
confid
interv
entir
five
breed
identifi
one
dla
haplotyp
significantli
differ
dm
case
control
breed
bichon
frise
one
risk
haplotyp
labrador
retriev
one
risk
haplotyp
cavali
king
charl
spaniel
one
risk
haplotyp
cocker
spaniel
one
risk
haplotyp
one
protect
haplotyp
border
terrier
one
protect
haplotyp
combin
analysi
sampl
identifi
four
haplotyp
one
risk
three
protect
includ
one
protect
haplotyp
identifi
previou
studi
new
dla
associ
provid
evid
role
adapt
immun
system
canin
dm
highlight
potenti
differ
aetiolog
breed
disclosur
report
denyer
al
dechra
ltd
partial
sponsorship
phd
kennel
club
charit
trust
prize
grant
support
research
career
develop
catchpol
b
dechra
ltd
msd
anim
health
financi
support
research
davison
lj
dechra
ltd
financi
support
research
serum
thyroxin
concentr
commonli
measur
assess
canin
thyroid
function
monitor
therapi
sever
refer
laboratori
immunoassay
commonli
use
pathogenesi
hypothyroid
may
result
endogen
antibodi
sera
proport
case
may
interfer
analysi
aim
studi
compar
result
seven
two
method
investig
effect
five
serum
pool
predict
equidist
concentr
cover
refer
interv
creat
use
sequenti
mix
initi
pool
low
high
concentr
surplu
canin
serum
analys
radioimmunoassay
ria
immulit
total
immulit
canin
total
total
idexx
catalyst
idexx
snapshot
tosoh
aia
two
free
method
antech
free
dialysi
immulit
veterinari
free
mix
pool
approach
allow
assess
intern
agreement
within
method
linear
well
comparison
method
determin
impact
pool
addit
analys
mix
posit
canin
surplu
serum
pool
total
method
agre
one
anoth
eg
highest
pool
vari
nmoll
two
method
ria
demonstr
good
linear
point
agre
predict
concentr
method
demonstr
less
good
intern
agreement
three
linear
result
match
predict
across
rang
two
linear
although
one
data
point
predict
effect
seen
method
includ
caus
fals
low
result
fals
high
ria
gener
nmoll
result
across
concentr
presenc
choic
analyt
method
canin
serum
like
impact
patient
manag
decis
commonli
avail
method
agre
one
anoth
sever
agre
within
effect
vari
method
combin
fals
high
fals
low
method
within
thyroid
test
panel
could
help
detect
like
presenc
interf
measur
directli
disclosur
report
graham
nationwid
laboratori
consult
dechra
veterinari
product
consult
diabet
mellitu
dm
cat
resembl
human
type
dm
complex
diseas
involv
combin
genet
environment
factor
previou
associ
studi
gwa
singl
nucleotid
polymorph
snp
found
associ
dm
lean
domest
shorthair
dsh
cat
polymorph
gene
associ
dm
overweight
dsh
cat
candid
gene
studi
suscept
gene
burmes
cat
breed
predispos
dm
identifi
initi
gwa
studi
attempt
overcom
limit
present
burmes
breed
due
inbreed
data
previou
gwa
dm
dsh
burmes
cat
combin
analysi
genotyp
perform
use
illumina
infinium
k
iselect
dna
array
qualiti
filter
diabet
control
dsh
cat
well
diabet
control
burmes
cat
includ
analysi
control
significantli
older
diabet
cat
p
bodi
condit
score
bc
known
cat
lean
obes
stratifi
analysi
use
cmh
test
within
strata
defin
multidimension
scale
md
logist
regress
md
coordin
use
bc
breed
covari
conduct
case
control
associ
test
cmh
test
adjust
genom
inflat
felin
standard
signific
set
p
max
permut
use
gener
correct
empir
follow
logist
regress
signific
set
p
singl
signific
snp
praw
adjust
genom
inflat
identifi
stratifi
analysi
singl
signific
snp
pgenom
permut
identifi
logist
regress
snp
chromosom
associ
dm
previous
report
gwa
dm
lean
dsh
associ
snp
chromosom
breed
new
snp
locat
within
close
gene
respect
relat
enzym
involv
degrad
incretin
analysi
reveal
new
potenti
candid
gene
breed
highlight
use
altern
approach
gwa
analysi
implic
metabol
immun
function
suggest
investig
gene
pathogenesi
felin
dm
warrant
disclosur
report
snp
chip
gwa
provid
morri
anim
foundat
katarina
hazuchova
phd
studentship
support
boehring
ingelheim
beryl
evett
robert
luff
welfar
trust
glycem
variabl
gv
refer
glycem
excurs
episod
hypoglycemia
hyperglycemia
throughout
day
differ
day
appar
causal
link
consid
indic
glycem
control
human
diabet
mellitu
dm
ad
analogu
convent
therapi
result
signific
reduct
gv
cat
knowledg
gv
scarc
influenc
differ
treatment
modal
studi
object
studi
evalu
gv
cat
receiv
analogu
exenatid
eer
addit
insulin
therapi
blood
glucos
curv
recent
prospect
clinic
trial
evalu
gv
week
start
therapi
cat
treat
eer
salin
administ
subcutan
weekli
group
receiv
insulin
glargin
twice
daili
diet
assess
gv
mean
glucos
concentr
standard
deviat
sd
calcul
compar
treatment
group
eer
group
cat
achiev
achiev
remiss
depend
variabl
mean
sd
analyz
use
repeat
mix
linear
model
includ
fix
effect
treatment
week
interact
repeat
anim
effect
data
report
mean
se
thirti
cat
newli
diagnos
dm
includ
receiv
eer
receiv
placebo
six
cat
achiev
remiss
eer
placebo
group
respect
p
mean
whole
studi
period
lower
eer
group
compar
placebo
vs
mmoll
p
consid
singl
time
point
mean
lower
week
vs
mmoll
p
whole
studi
period
lower
eer
group
compar
placebo
vs
mmoll
p
eer
group
cat
achiev
remiss
lower
mean
vs
mmoll
p
lower
vs
mmoll
p
achiev
remiss
conclus
analogu
eer
lead
reduct
gv
better
glycem
control
cat
dm
furthermor
lower
gv
associ
higher
remiss
rate
cat
treat
eer
result
studi
therefor
suggest
ad
analogu
convent
therapi
may
advantag
treatment
cat
dm
disclosur
report
federico
fracassi
financi
support
dechra
msd
speak
consult
boehring
ingelheim
dechra
msd
royal
canin
hill
purina
la
vallonea
claudia
reusch
financi
support
purina
hill
provet
antlia
sa
glycemicon
novarti
anim
health
clinic
studi
fund
societi
compar
endocrinolog
speak
consult
boehring
ingelheim
dechra
novarti
anim
health
waltham
royal
canin
nadja
member
vetoryl
novel
monitor
meet
organ
dechra
veterinari
product
ltd
flash
glucos
monitor
system
fgm
freestyl
recent
valid
use
diabet
dog
dd
continu
measur
interstiti
glucos
concentr
day
aim
studi
evalu
clinic
use
fgm
monitor
dd
twenti
dd
insulin
treatment
prospect
enrol
studi
fgm
place
neck
day
duringth
blood
glucos
curv
bgc
perform
simultan
hospit
fgm
valid
portabl
blood
glucos
meter
pbgm
optiumxce
owner
perform
bgc
use
fgm
home
bgc
perform
pbgm
fgm
hospit
perform
fgm
home
hospit
compar
bgc
evalu
optim
consid
valu
mgdl
glucos
nadir
mgdl
glucos
nadir
obtain
data
download
softwar
dd
fgm
scan
pbgm
compar
moreov
glucos
gdtn
nadir
gntn
compar
evalu
bgc
perform
hospit
fgm
pbgm
led
decis
insulin
adjust
case
consid
percentag
valu
rang
mgdl
glucos
nadir
respect
evalu
bgc
perform
home
follow
day
hospit
fgm
led
decis
insulin
adjust
case
consid
percentag
valu
rang
mgdl
glucos
nadir
respect
glucos
nadir
identifi
case
dd
case
use
fgm
scan
pbgm
respect
median
gntn
significantli
higher
gdtn
hypoglycem
episod
obtain
dd
immedi
show
display
fgm
conclus
adjust
insulin
dose
base
bgc
obtain
fgm
pbgm
similar
fgm
detect
nadir
hypoglycem
episod
frequent
pbgm
allow
assess
glucos
variat
also
differ
consecut
day
therefor
fgm
potenti
valuabl
tool
monitor
canin
diabet
mellitu
disclosur
report
federico
fracassi
financi
support
dechra
msd
speak
consult
boehring
ingelheim
dechra
msd
royal
canin
hill
purina
la
vallonea
stefania
golinelli
consult
dechra
canin
diabet
mellitu
dm
preval
certain
breed
suggest
underli
genet
basi
although
environment
factor
may
also
involv
notabl
dog
breed
low
dm
risk
studi
neoplast
transform
pancreat
insulinoma
suggest
surviv
may
import
contribut
factor
canin
dm
similar
gene
may
involv
canin
dm
insulinoma
previou
genet
work
canin
diabet
mellitu
dm
focus
candid
gene
associ
studi
employ
design
within
individu
breed
howev
design
account
fact
within
high
risk
breed
fix
genet
risk
dm
may
exist
result
minim
genet
differ
case
control
aim
studi
develop
new
model
identif
genet
risk
variant
complex
diseas
order
identifi
new
canin
dm
gene
achiev
explor
genet
differ
dog
breed
high
risk
dm
samoy
odd
ratio
except
low
risk
dm
boxer
odd
ratio
part
canin
diabet
genet
partnership
initi
whole
genom
sequenc
wg
coverag
undertaken
diabet
samoy
boxer
insulinoma
use
illumina
hiseqx
technolog
six
samoy
boxer
without
dm
insulinoma
underw
wg
control
dna
extract
blood
sampl
surplu
requir
clinic
purpos
custom
bioinformat
pipelin
develop
annot
prioritis
variant
base
genom
analysi
toolkit
variant
annot
accord
minor
allel
frequenc
breed
statu
predict
impact
gene
function
locat
near
region
plausibl
role
function
diabet
risk
samoy
high
moder
impact
variant
identifi
present
one
samoy
found
exclus
diabet
group
boxer
high
moder
impact
variant
identifi
present
one
boxer
found
exclus
insulinoma
group
replic
function
studi
progress
valid
candid
investig
underli
mechan
studi
demonstr
wg
offer
promis
rout
investig
complex
diseas
genet
risk
may
fix
high
low
level
within
breed
disclosur
report
author
member
canin
diabet
genet
partnership
support
dechra
veterinari
product
provid
financi
support
member
travel
cdgp
meet
three
time
year
act
industri
partner
phd
studentship
alic
denyer
cdgp
fund
petplan
charit
trust
fund
paid
whole
genom
sequenc
well
salari
author
attend
congress
bioinformatician
marsha
wallac
brian
catchpol
also
receiv
fund
phd
student
unrel
project
msd
anim
health
luci
davison
senior
author
present
fund
uk
medic
research
council
also
fund
bsava
petsav
work
unrel
abstract
also
alreadi
entitl
free
registr
meet
chair
ecvim
exam
committe
want
disclos
esv
involv
abstract
review
would
happi
provid
detail
request
author
cdgp
member
involv
wide
varieti
research
project
respect
institut
across
larg
number
field
numer
fund
sourc
none
fund
sourc
access
potenti
gain
data
present
cdgp
member
receiv
salari
consult
fee
role
cdgp
none
stand
make
direct
financi
gain
data
abstract
author
seen
inform
present
abstract
given
opportun
comment
interest
full
disclosur
pleas
note
preliminari
find
abstract
whole
genom
sequenc
canin
diabet
submit
canin
diabet
genet
partnership
accept
poster
present
canin
felin
genet
genom
meet
bern
howev
ecvim
abstract
submit
base
screen
variant
larger
data
set
use
data
addit
dog
breed
also
includ
bioinformat
improv
allow
better
quantif
annot
candid
genet
variant
canin
lipas
scpl
consid
sensit
specif
test
diagnosi
pancreat
dog
howev
rel
high
cost
long
turnaround
time
limit
everyday
clinic
use
access
serum
assay
avail
daili
usag
like
lipas
assay
total
lipas
tl
glutar
ester
dggr
lipas
assay
dggrl
recent
studi
compar
scpl
dggrl
obtain
high
agreement
reason
dggrl
actual
wide
use
recent
studi
observ
dog
hypercortisol
scpl
concentr
elev
result
fals
posit
result
pancreat
aim
present
studi
evalu
serum
dggrl
tl
activ
dog
affect
natur
occur
hypercortisol
dog
acut
pancreat
ap
healthi
dog
hd
use
control
left
sampl
use
diagnost
propos
store
select
retrospect
follow
stabil
period
recommend
analyz
dog
hypercortisol
ap
hd
respect
serum
ddgrl
tl
measur
use
autom
analyz
diagnosi
hypercortisol
perform
combin
typic
clinic
sign
posit
specif
endocrin
test
acth
stimul
test
andor
ldd
test
dog
hypercortisol
includ
absenc
clinic
ultrasonograph
sign
suggest
ap
diagnosi
ap
base
presenc
suggest
clinic
clinicopatholog
exclud
studi
variabl
ultrasonograph
find
data
express
median
rang
compar
use
nonparametr
statist
p
consid
signific
median
dggrl
concentr
ul
dog
hypercortisol
ap
hd
respect
median
tl
concentr
ul
dog
hypercortisol
ap
hd
respect
dggrl
tl
concentr
significantli
differ
among
hd
two
group
result
differ
dog
hypercortisol
ap
p
p
dggrl
concentr
refer
interv
ul
dog
hypercortisol
ap
hd
respect
tl
concentr
refer
interv
ul
dog
hypercortisol
ap
hd
respect
high
rate
fals
posit
result
dggrl
concentr
evalu
caution
ap
suspect
dog
hypercortisol
disclosur
report
federico
fracassi
financi
support
dechra
msd
speak
consult
boehring
ingelheim
dechra
msd
royal
canin
hill
purina
la
vallonea
francesco
dondi
financi
support
zoeti
speak
consult
boehring
ingelheim
la
vallonea
measur
free
thyroxin
concentr
equilibrium
dialysi
technic
demand
expens
autom
free
analogu
immunoassay
immulit
veterinari
free
siemen
recent
gain
popular
howev
concern
regard
abil
differenti
hypothyroid
ill
nti
aim
studi
evalu
chang
concentr
dog
nti
comparison
simultan
total
concentr
hypothes
would
provid
good
poor
agreement
total
concentr
respect
initi
concentr
measur
surplu
serum
sampl
dog
variou
nti
hypothyroid
suspect
total
concentr
immulit
canin
total
siemen
free
equilibrium
dialysi
antech
laboratori
subsequ
measur
subpopul
dog
select
rang
concentr
refer
interv
pmoll
pmoll
nmoll
total
respect
kruskal
walli
test
use
statist
analysi
appropri
dog
nti
significantli
p
p
respect
lower
dog
sever
compar
mild
moder
nti
proport
dog
valu
refer
interv
significantli
p
respect
less
n
compar
n
total
proport
differ
significantli
p
total
among
dog
low
total
concentr
normal
dog
significantli
p
differ
among
dog
low
dog
normal
valu
differ
plot
reveal
underestim
overestim
free
concentr
measur
low
high
concentr
respect
consid
lack
agreement
observ
use
interchang
oppos
provid
diagnost
inform
gain
measur
total
dog
nti
base
result
recommend
differenti
nti
hypothyroid
dog
low
total
concentr
repres
popul
measur
free
concentr
commonli
recommend
disclosur
report
carmel
mooney
provid
consult
servic
dechra
veterinari
product
helen
evan
veterinari
servic
oper
manag
nationwid
specialist
laboratori
grow
tissu
cell
cultur
system
organoid
revolution
vitro
cancer
research
contrast
cell
line
organoid
grown
effici
conserv
import
featur
origin
tumor
tissu
architectur
cellular
heterogen
human
medicin
organoid
cultur
provid
uniqu
platform
person
cancer
therapi
studi
aim
cultur
character
organoid
deriv
thyroid
carcinoma
ftc
dog
tissu
sampl
follicular
type
n
compact
type
n
ftc
deriv
two
euthyroid
dog
frozen
freez
medium
within
h
thyroidectomi
store
process
thaw
tissu
digest
collagenas
iv
dissoci
mechan
cell
subsequ
seed
basement
membran
extract
cultur
organoid
advanc
dmem
supplement
supplement
egf
noggin
organoid
split
passag
everi
day
day
organoid
pellet
agaros
process
stain
immunohistochemistri
ihc
thyroid
transcript
thyroglobulin
tg
calcitonin
vimentin
perform
section
primari
tumor
organoid
organoid
ftc
cultur
effici
use
protocol
organoid
tumor
form
structur
compos
singl
epitheli
cell
layer
epitheli
cell
round
cuboid
variabl
distinct
cell
border
abund
eosinophil
foami
cytoplasm
anisocytosi
anisokaryosi
observ
either
organoid
line
present
ftc
compact
type
nuclear
express
organoid
line
confirm
thyroid
origin
organoid
deriv
compact
ftc
approxim
cell
posit
tg
show
tg
express
organoid
deriv
follicular
ftc
tg
express
cell
show
tg
express
organoid
vimentin
express
observ
organoid
line
cell
higher
primari
tumor
tumor
cell
posit
ihc
calcitonin
neg
organoid
line
organoid
deriv
natur
occur
canin
ftc
abl
conserv
histolog
immunohistochem
featur
primari
tumor
provid
interest
vitro
model
better
understand
pathogenesi
optim
treatment
thyroid
cancer
dog
cultur
protocol
like
requir
optim
disclosur
report
author
contribut
equal
work
human
airway
narrow
due
asthma
copd
commonli
result
heterogen
deposit
aerosol
within
lung
consequ
uneven
distribut
inhal
medic
may
lead
variabl
inadequ
drug
level
certain
lung
area
current
known
effect
occur
dog
lower
airway
diseas
purpos
studi
evalu
effect
pharmacolog
induc
airway
narrow
pulmonari
deposit
nebul
radiopharmaceut
ie
amount
distribut
healthi
dog
prospect
studi
conduct
ten
healthi
beagl
radiopharmaceut
inhal
perform
occas
wash
period
least
week
experi
ie
without
immedi
induct
airway
narrow
narrow
airway
achiev
nebul
increas
concentr
carbachol
barometr
whole
bodi
plethysmographi
chamber
harbor
anim
airway
narrow
detect
system
buxco
endpoint
increas
penh
baselin
occas
dog
inhal
dose
nebul
acid
medium
attach
custom
mask
minut
immedi
afterward
dog
scan
planar
scintigraphi
right
later
left
later
sternal
recumb
deposit
head
region
lung
stomach
well
whole
bodi
distribut
record
quantifi
manual
isocontour
region
interest
roi
analysi
deposit
calcul
percentag
deliv
dose
roi
compar
distribut
deposit
within
lung
score
independ
blind
observ
degre
asymmetri
right
left
lung
patchi
individu
imag
well
possibl
differ
scan
imag
pair
ie
airway
narrow
random
order
analysi
individu
score
averag
mean
percentag
uptak
deliv
dose
lung
significantli
differ
airway
narrow
airway
narrow
averag
asymmetri
score
wherea
none
dog
patchi
distribut
score
airway
narrow
score
asymmetri
patchi
significantli
increas
respect
comparison
scan
imag
pair
airway
narrow
reveal
signific
differ
score
studi
indic
airway
narrow
dog
result
heterogen
aerosol
deposit
within
lung
although
overal
amount
drug
deposit
affect
disclosur
report
lectur
improv
hirt
lung
recogn
host
divers
low
biomass
bacteri
popul
identifi
lung
microbiota
lm
human
chronic
lung
diseas
cld
lm
alter
compar
healthi
patient
howev
whether
alter
caus
consequ
diseas
still
unclear
dog
lm
describ
mostli
healthi
experiment
beagl
howev
previou
work
team
impact
live
condit
andor
breed
suspect
healthi
beagl
west
highland
white
terrier
whwt
recent
studi
mice
hors
show
modif
lm
accord
live
condit
modif
lm
could
predispos
individu
certain
cld
aim
assess
breed
impact
influenc
live
condit
either
experiment
domest
lm
healthi
dog
healthi
dog
sampl
total
dog
categor
group
experiment
beagl
eb
shepherd
terrier
brachycephal
br
whwt
dog
breed
high
suscept
canin
idiopath
pulmonari
fibrosi
cipf
bronchoalveolar
lavag
fluid
balf
obtain
anaesthesia
dog
dna
extract
balf
pcr
target
region
rdna
perform
amplicon
sequenc
miseq
illumina
sequenc
taxonom
assign
microbiota
commun
analysi
done
mothur
otu
cluster
distanc
result
show
bacteri
load
higher
eb
dog
p
amova
result
indic
differ
eb
group
compar
group
p
signific
differ
rel
abund
famili
genu
level
found
genu
hydrogenophilu
higher
eb
genera
brochothrix
limnohabitan
parabacteroid
curvibact
higher
whwt
compar
group
p
group
specif
genera
found
indic
discrimin
p
bacteri
rich
higher
whwt
eb
group
p
signific
differ
even
group
studi
demonstr
effect
live
condit
lm
breed
differ
also
shown
lm
modif
might
relat
breed
suscept
lower
respiratori
diseas
cipf
whwt
need
consid
futur
analys
role
lm
disturb
diseas
disclosur
report
reflux
aspir
peopl
caus
exacerb
respiratori
diseas
protein
biomark
human
detect
reflux
eer
absenc
overt
dysphagia
regurgit
vomit
dog
reflux
like
contribut
respiratori
diseas
pathogenesi
progress
studi
object
follow
perform
comprehens
analysi
canin
gastric
fluid
gf
proteom
compar
oropharyng
op
proteom
normal
vomitingregurgit
cough
dog
identifi
potenti
biomark
eer
aspir
compar
biolog
function
protein
site
dog
prospect
enrol
canin
gf
sampl
n
op
swab
normal
n
vomitingregurgit
n
cough
n
dog
evalu
protein
digest
analyz
liquid
chromatographi
mass
spectrometri
lcm
data
search
ncbimu
databas
differenti
abund
da
protein
function
group
evalu
fisher
exact
test
anosim
respect
p
p
respect
consid
signific
correct
multipl
comparison
across
site
individu
protein
identifi
normal
spectral
abund
demonstr
pancreat
protein
increas
compar
pepsin
gf
signific
differ
da
group
note
p
gf
vs
normal
n
cough
vs
normal
n
refluxvomit
vs
normal
n
mark
variat
observ
protein
da
function
proteom
dissimilar
group
p
conclus
proteom
composit
op
swab
vari
health
diseas
variabl
abund
may
impact
util
individu
gastric
protein
diseas
biomark
investig
biomark
panel
warrant
disclosur
report
though
unrel
project
portion
salari
provid
boehring
ingelheim
fellow
program
vitamin
import
role
innat
adapt
immun
respons
hypovitaminosi
peopl
associ
increas
suscept
sever
ill
varieti
inhal
respiratori
pathogen
sinonas
aspergillosi
sna
common
caus
chronic
nasal
diseas
remain
challeng
treat
associ
substanti
morbid
dog
lack
biomark
predict
develop
sna
treatment
outcom
dog
therefor
object
studi
compar
serum
oh
concentr
dog
sna
healthi
control
dog
determin
serum
oh
concentr
predict
first
time
treatment
outcom
nine
dog
sna
healthi
control
dog
includ
retrospect
arm
studi
serum
sampl
obtain
dog
store
c
analysi
diagnosi
sna
base
presenc
compat
clinic
sign
identif
fungal
plaqu
turbin
destruct
fungal
cultur
treatment
deem
success
resolut
clinic
sign
absenc
fungal
plaqu
rhinoscopi
serum
oh
measur
use
hplc
percent
dog
sna
complet
fungal
debrid
seven
dog
avail
first
time
treatment
success
dog
sna
significantli
decreas
serum
oh
concentr
mean
sd
ngml
ngml
compar
healthi
control
dog
ngml
p
serum
oh
concentr
associ
first
time
treatment
outcom
p
logist
regress
result
suggest
serum
oh
significantli
decreas
dog
sna
well
potenti
immunolog
contributori
role
diseas
addit
result
support
pursuit
prospect
arm
studi
investig
potenti
mechan
decreas
serum
oh
dog
sna
role
treatment
outcom
disclosur
report
cathelicidin
antimicrobi
peptid
essenti
innat
immun
system
whose
circul
concentr
well
document
posit
associ
oh
peopl
decreas
oh
concentr
predict
surviv
peopl
dog
critic
ill
decreas
product
cathelicidin
propos
import
mechan
link
decreas
oh
concentr
surviv
critic
ill
peopl
therefor
aim
evalu
associ
plasma
cathelicidin
mrna
express
serum
oh
concentr
surviv
critic
ill
dog
nineteen
dog
sepsi
n
critic
ill
without
sepsi
n
healthi
control
n
cohort
n
previous
measur
oh
concentr
randomli
select
plasma
mrna
extract
revers
transcrib
result
cdna
use
templat
pcr
use
specif
primer
canin
cathelicidin
signific
differ
cathelicidin
concentr
dog
sepsi
mean
sd
critic
ill
without
sepsi
healthi
control
p
anova
signific
correl
oh
cathelicidin
express
rs
p
spearman
correl
percent
critic
ill
dog
surviv
discharg
cathelicidin
concentr
predict
surviv
discharg
p
logist
regress
dog
sepsi
mean
sd
ngml
p
critic
ill
dog
without
sepsi
ngml
p
significantli
decreas
serum
oh
compar
healthi
control
ngml
anova
sever
ill
defin
applefast
score
p
serum
oh
concentr
p
presenc
sepsi
p
logist
regress
predict
surviv
base
small
cohort
associ
plasma
cathelicidin
mrna
express
serum
oh
concentr
outcom
critic
ill
dog
neg
result
preliminari
investig
interpret
caution
number
dog
enrol
small
type
ii
error
might
contribut
factor
lack
associ
disclosur
report
methemoglobin
form
hemoglobin
iron
oxid
ferrou
iron
ferric
iron
incap
bind
hereditari
methemoglobinemia
dog
commonli
caus
cytochrom
reductas
defici
recent
report
variant
dog
scatter
case
report
show
vari
clinic
consequ
hereditari
methemoglobinemia
dog
therefor
object
studi
determin
metabol
molecular
base
character
clinicopatholog
featur
canin
defici
dog
variou
breed
investig
unexplain
mild
sever
cyanosi
edta
blood
use
determin
methemoglobin
concentr
methb
enzym
activ
analyz
gene
mutat
previous
document
nonsynonym
variant
homozyg
dog
heterozyg
dog
previous
identifi
variant
found
dog
whole
genom
sequenc
analysi
identifi
novel
nonsynonym
variant
homozyg
dog
homozyg
dog
mean
methb
sd
median
activ
dog
homozyg
variant
significantli
greater
methb
clinic
sign
homozyg
variant
p
besid
cyanosi
dog
exhibit
clinic
sign
conclus
studi
reveal
clinic
metabol
molecular
genet
variat
seen
defici
dog
variant
appear
caus
sever
phenotyp
variant
dna
variant
identifi
readili
use
genet
screen
test
disclosur
report
canin
primari
haemolyt
anaemia
imha
common
haematolog
emerg
incid
differ
among
breed
unknown
whether
dog
predispos
breed
present
differ
degre
diseas
sever
differ
clinic
sign
differ
clinicopatholog
find
inform
could
use
clinic
guid
treatment
provid
prognost
advic
owner
primari
aim
retrospect
studi
identifi
differ
find
outcom
breed
hypothesis
spaniel
breed
would
find
associ
sever
diseas
poorer
outcom
compar
breed
electron
record
canin
patient
tertiari
referr
centr
search
year
period
keyword
algorithm
use
assess
confid
diagnosi
imha
case
suffici
featur
imha
analys
exclud
investig
reveal
possibl
underli
diseas
incomplet
case
also
exclud
receiv
immunosuppress
blood
transfus
therapi
hour
prior
present
case
fulfil
inclus
criteria
frequent
five
breed
select
analysi
well
cross
breed
serv
control
group
data
collect
histor
clinic
sign
clinicopatholog
find
outcom
continu
variabl
anova
dunnett
multipl
comparison
test
perform
compar
breed
control
group
categor
variabl
use
compar
proport
record
identifi
contain
imha
keyword
fulfil
inclus
criteria
cocker
spaniel
n
springer
spaniel
n
labrador
n
jack
russel
terrier
n
n
select
final
analysi
alongsid
crossbre
n
control
group
labrador
significantli
older
compar
control
group
mean
v
year
p
surviv
cocker
spaniel
significantli
shorter
hospitalis
period
compar
control
group
mean
v
day
p
compar
cross
breed
greater
proport
jack
russel
terrier
surviv
discharg
v
p
spaniel
breed
appear
affect
sever
surviv
cocker
spaniel
requir
shorter
hospitalis
period
jack
russel
terrier
may
favour
outcom
find
could
confound
effect
treatment
requir
confirm
disclosur
report
diagnost
imag
dog
diagnos
haemolyt
anaemia
imha
indic
rule
system
diseas
mimick
trigger
imha
howev
studi
provid
descript
thorac
abdomin
abnorm
support
clinic
decis
make
dog
imha
lack
aim
studi
describ
chang
document
thorac
abdomin
imag
dog
confirm
imha
medic
record
referr
hospit
search
dog
diagnos
imha
underw
thorac
abdomin
imag
radiographi
ultrasound
comput
tomographi
ct
includ
complet
histori
clinic
routin
laboratori
examin
find
avail
well
total
client
own
dog
fulfil
inclus
criteria
includ
retrospect
studi
median
age
dog
year
rang
month
year
sexual
intact
femal
spay
femal
sexual
intact
neuter
male
respect
ct
thorax
abdomen
perform
radiograph
thorax
abdomin
ultrasound
dog
fine
needl
aspir
fna
collect
dog
ct
radiograph
thorax
reveal
abnorm
dog
sternal
lymphadenopathi
cardiomegali
document
dog
respect
pleural
effus
dog
ct
ultrasound
abdomen
reveal
abnorm
dog
hepatomegali
periton
effus
present
dog
respect
gallbladd
wall
thicken
gallbladd
sludg
splenic
nodul
diffus
steatiti
enlarg
pancrea
abdomin
lymphadenopathi
splenomegali
dog
hepatomegali
splenomegali
investig
via
fna
dog
reveal
extramedullari
haematopoiesi
hepat
splenic
sampl
cholestasi
vacuolar
hepatopathi
reactiv
lymphoid
hyperplasia
document
less
sampl
collect
organ
round
cell
neoplasia
document
via
fna
liver
spleen
abdomin
lymph
node
one
dog
cholecystocentesi
perform
dog
gallbladd
wall
thicken
reveal
posit
bile
cultur
dog
popul
dog
imha
thorac
imag
abnorm
uncommon
hepatomegali
gallbladd
wall
thicken
periton
effus
common
abdomin
imag
find
bactibilia
confirm
one
third
collect
bile
sampl
hepatosplenomegali
abdomin
lymphadenopathi
uncommonli
associ
neoplasia
disclosur
report
dog
blood
group
system
littl
known
frequenc
europ
report
extens
type
survey
avail
reagent
establish
new
clinic
kit
purebr
dog
leftov
edta
blood
sampl
examin
use
immunochromatograph
strip
method
dea
gel
column
techniqu
dal
kai
new
agglutin
card
test
dea
dea
partial
compar
gel
column
monoclon
antibodi
use
dea
kai
type
polyclon
type
among
examin
dog
dea
dea
card
gel
dea
kai
kai
blood
dea
dog
bound
strongli
posit
strip
agglutin
reaction
card
gel
test
concord
dea
sampl
contrast
reaction
dea
gener
less
agglutin
test
gel
column
test
discord
reaction
none
dog
kai
one
kai
dog
found
cane
corso
dalmatian
doberman
maltes
mastiff
shih
tzu
pug
dog
variou
blood
group
pattern
observ
breed
first
extens
blood
type
survey
purebr
dog
europ
proport
posit
neg
blood
type
similar
us
newer
type
techniqu
seem
work
well
dea
card
improv
use
detect
prevent
specif
blood
type
incompat
clinic
disclosur
report
studi
part
ebelt
doctor
thesi
support
laboklin
author
associ
either
laboklin
ebelt
fuch
weber
penngen
giger
diagnost
laboratori
offer
blood
type
reagent
kit
gener
suppli
survey
alvedia
franc
dm
laboratori
flemington
us
system
protein
misfold
diseas
human
anim
aris
format
amyloid
fibril
acut
phase
protein
serum
amyloid
anim
common
chicken
cheetah
kept
captiv
latest
studi
show
transmiss
system
occur
cheetah
involv
fecal
shed
amyloid
fibril
domest
shorthair
cat
rare
affect
system
whether
system
common
domest
shorthair
cat
live
shelter
shed
amyloid
fibril
occur
unknown
thu
aim
studi
determin
frequenc
system
differ
cat
shelter
investig
excret
amyloid
fibril
cat
shelter
includ
necropsi
perform
within
hour
death
liver
kidney
spleen
bile
obtain
necropsi
clinic
laboratori
result
retriev
avail
medic
archiv
identifi
tissu
stain
confirm
immunoblot
shed
amyloid
fibril
investig
immunoblot
bile
sampl
descript
statist
test
use
deposit
observ
liver
kidney
spleen
cat
die
shelter
particular
preval
cat
cat
cat
respect
cat
organ
involv
cat
organ
cat
organ
cat
organ
sensit
specif
identif
bile
respect
liver
involv
note
semiquantit
analysi
bile
show
none
cat
without
organ
deposit
score
score
identifi
cat
organ
involv
p
cat
organ
medic
record
show
kidney
liver
involv
azotemia
proteinuria
hemoabdomen
due
spontan
hepat
ruptur
conclus
preval
system
appear
elev
shelter
cat
shed
amyloid
fibril
occur
bile
cat
system
like
shed
higher
amount
whether
bile
excret
indic
horizont
transmiss
relev
diseas
shelter
cat
remain
undefin
disclosur
report
use
sodium
solut
treat
metabol
acidosi
current
debat
alkal
effect
solut
elev
strong
ion
differ
sid
recent
describ
primari
aim
studi
evalu
safeti
efficaci
solut
elev
sid
compar
ringer
lactat
use
treatment
metabol
acidosi
solut
prepar
ad
meql
sodium
meql
lactat
meql
potassium
meql
aspart
steril
water
inject
calcul
sid
meql
prospect
multicent
random
studi
evalu
efficaci
safeti
author
ethic
committe
hospit
dog
excess
base
meql
enrol
studi
baselin
lactat
level
greater
meql
patient
classifi
ultrasonograph
method
hypovolem
normovolem
random
random
number
gener
type
fluid
receiv
ringer
lactat
rl
group
group
normovolem
hypovolem
dog
receiv
hour
infus
rate
ml
respect
blood
ga
analysi
fluid
infus
hour
compar
follow
paramet
ph
sodium
potassium
chlorid
lactat
normal
distribut
analysi
variabl
describ
evalu
use
statist
signific
level
set
forti
dog
includ
analysi
median
age
month
median
weight
kg
dog
classifi
hypovolem
rl
group
group
dog
classifi
normovolem
rl
group
group
basal
differ
treatment
group
p
normovolem
patient
median
increas
rl
group
meql
meql
p
respect
wherea
hypovolem
patient
respect
meql
meql
p
lactat
valu
greater
meql
document
patient
studi
solut
prove
effect
superior
rl
solut
treatment
metabol
acidosi
hospit
dog
sampl
subject
belong
group
side
effect
rais
lactatemia
report
infus
period
disclosur
report
serum
symmetr
dimethylarginin
sdma
concentr
shown
marker
renal
dysfunct
dog
cat
human
dialysi
lower
sdma
less
effici
urea
former
larger
distribut
volum
inform
concern
sdma
anim
undergo
extracorpor
renal
replac
therapi
yet
lack
aim
studi
describ
dynam
sdma
concentr
dog
cat
acut
kidney
injuri
treat
intermitt
hemofiltr
ihf
report
ihf
perform
octob
collect
medic
record
review
case
biochem
profil
includ
ihf
perform
accord
standard
method
urea
creatinin
sdma
urr
crearr
sdmarr
calcul
ihf
dog
cat
separ
first
session
ihf
includ
group
second
session
group
b
third
session
group
c
urr
crearr
sdmarr
compar
within
group
test
overal
ihf
session
perform
dog
cat
specif
dog
cat
group
dog
cat
group
b
dog
cat
group
c
five
dog
cat
surviv
median
sdma
concentr
dog
rang
cat
rang
dog
median
valu
urr
crearr
sdmarr
rang
rang
rang
respect
cat
median
valu
rang
rang
rang
ihf
session
dog
sdmarr
either
neg
n
n
session
perform
dog
leptospirosi
poison
grape
ethylen
glycol
die
median
sdmarr
lower
urr
group
b
dog
p
p
differ
cat
group
dog
sdmarr
also
lower
crearr
p
differ
observ
speci
conclus
sdmarr
repres
accur
marker
assess
effici
ihf
dog
partial
inabl
ihf
clear
sdma
larg
distribut
volum
sdma
unknown
condit
affect
sdma
concentr
might
contribut
result
differ
sdmarr
may
reliabl
evalu
ihf
effici
cat
disclosur
report
cat
chronic
kidney
diseas
ckd
often
present
superimpos
acut
urem
crisi
happen
prognost
indic
would
relev
felin
practition
aim
studi
determin
variabl
commonli
assess
azotem
cat
particular
context
could
accur
predictor
surviv
medic
record
year
azotem
cat
hospit
least
two
day
acut
sign
confirm
ckd
base
ultrasonograph
find
andor
previous
document
azotemia
retrospect
review
cat
potenti
toxic
neoplast
obstruct
caus
azotemia
includ
signal
clinic
sign
combin
clinic
sever
score
css
select
laboratori
diagnost
imag
result
outcom
regist
machin
classif
regress
tree
method
use
assess
predictor
surviv
day
cat
includ
studi
overal
median
surviv
time
day
rang
day
plasma
creatinin
concentr
day
hospit
best
predictor
surviv
less
mgl
best
predict
surviv
se
sp
day
less
mgl
best
predict
surviv
day
censor
analysi
lower
css
younger
age
also
predict
surviv
day
studi
confirm
good
predictor
short
surviv
cat
ckd
present
urem
crisi
disclosur
report
mfaucher
webconfer
boehring
ingelheim
acomb
speaker
veterinariu
blood
pressur
bp
measur
wide
use
diagnos
hypertens
yet
mani
factor
affect
measur
accuraci
acvim
guidelin
propos
standard
protocol
suggest
bp
perform
owner
present
studi
perform
evalu
dog
evalu
whether
sbp
vari
differ
hospit
locat
aim
determin
whether
sbp
differ
dog
measur
consult
room
owner
quiet
room
away
owner
determin
whether
sbp
measur
dog
differ
measur
kennel
quiet
room
away
dog
dog
bp
measur
use
high
definit
oscillometri
locat
consecut
consult
room
owner
quiet
room
kennel
quiet
room
measur
locat
order
random
blood
pressur
measur
method
standard
base
acvim
consensu
statement
instrument
manufactur
recommend
bp
cuff
place
tail
measur
taken
singl
veterinari
surgeon
use
cuff
bodi
posit
dog
locat
puls
waveform
visual
measur
valid
read
collect
averag
locat
descript
statist
perform
number
dog
differ
locat
calcul
addit
sbp
classifi
use
acvim
consensu
statement
hypertens
categori
sbp
mean
mmhg
sd
higher
quiet
room
dog
sbp
mmhg
differ
locat
higher
consult
room
fourteen
chang
hypertens
categori
locat
chang
higher
away
client
mean
differ
sbp
locat
mmhg
sd
howev
mmhg
differ
sbp
dog
higher
kennel
eleven
chang
hypertens
categori
locat
chang
higher
kennel
although
mean
differ
sbp
locat
small
approxim
quarter
dog
group
differ
locat
approxim
half
chang
hypertens
categori
suggest
measur
chang
trend
individu
anim
locat
measur
kept
constant
disclosur
report
hdo
devic
bought
money
univers
glasgow
veterinari
fund
small
grant
scheme
chronic
kidney
diseas
ckd
typic
mediat
origin
cat
glomerulonephr
icgn
scarc
describ
date
descript
icgn
publish
cat
membran
glomerulonephropathi
mgn
commonli
report
therefor
aim
studi
character
morpholog
diagnos
icgn
light
electron
microscopi
larg
cohort
cat
identifi
associ
clinic
laboratori
find
addit
comparison
perform
cat
affect
non
glomerulonephr
renal
biopsi
cat
icgn
examin
consid
light
electron
microscopi
avail
data
collect
analysi
includ
breed
sex
age
felin
immunodefici
viru
fiv
felin
leukemia
viru
felv
statu
serum
creatinin
concentr
urin
upc
ratio
systol
blood
pressur
sbp
differ
morpholog
diagnos
icgn
includ
tubulointerstiti
damag
score
investig
test
likelihood
diagnos
icgn
versu
explor
logist
regress
cat
includ
icgn
cat
affect
icgn
mgn
membranoprolif
glomerulonephr
mpgn
mesangioprolif
glomerulonephr
breed
sex
age
fiv
felv
statu
creatinin
upc
ratio
sbp
differ
among
morpholog
diagnos
cat
ckd
focal
segment
glomerulosclerosi
global
mesangiosclerosi
glomerular
atrophi
renal
dysplasia
amyloidosi
eight
cat
grade
tubulointerstiti
damag
grade
grade
creatinin
upc
ratio
posit
associ
grade
p
p
cat
icgn
like
fiv
felv
infect
vs
p
higher
mean
upc
ratio
vs
p
mean
age
cat
icgn
lower
vs
year
p
conclus
mgn
mpgn
two
common
morpholog
diagnos
icgn
cat
clinic
laboratori
find
allow
differenti
cat
serum
creatinin
concentr
upc
ratio
associ
degre
tubulointerstiti
damag
confirm
previou
literatur
cat
retroviru
infect
higher
upc
ratio
younger
age
like
affect
icgn
disclosur
report
glucocorticoid
influenc
renal
function
frequent
prescrib
dog
extent
durat
effect
scarc
describ
object
assess
prednisolon
effect
renal
electrolyt
hydrat
statu
healthi
dog
urin
collect
total
bodi
water
content
tbwc
use
pharmacokinet
equat
glomerular
filtrat
rate
gfr
use
plasma
exogen
creatinin
clearanc
serum
symmetr
dimethylarginin
sdma
complet
plasma
biochemistri
urinalysi
includ
urin
ratio
obtain
beagl
dog
blind
placebo
design
one
group
receiv
cours
prednisolon
second
receiv
placebo
period
group
switch
blood
urin
collect
treatment
period
gener
linear
model
use
test
period
sequenc
treatment
dog
weight
effect
dunnett
test
use
evalu
effect
steroid
day
serv
control
correl
assess
use
pearson
coeffici
prednisolon
significantli
affect
bodi
weight
p
mean
differ
kg
gfr
p
mlkgmin
sdma
p
creatinin
p
urea
p
mmoll
chlorid
p
mmoll
bicarbon
p
mmoll
magnesium
p
mmoll
total
protein
p
gl
albumin
p
gl
tbwc
p
mlkg
urin
specif
graviti
p
void
urin
p
ml
sdma
r
creatinin
r
correl
significantli
p
gfr
variat
becam
prednisolon
dosag
rapidli
decreas
tbwc
bodi
weight
induc
relev
revers
renal
hyperfiltr
clinic
signific
variat
sever
analyt
disclosur
report
sdma
dosag
provid
idexx
laboratori
inc
westbrook
main
unit
state
america
rise
antibiot
resist
amongst
urinari
tract
infect
uti
cat
dog
underscor
need
approach
uti
probiot
escherichia
coli
ecn
mani
benefit
includ
antimicrobi
activ
mani
human
pathogen
includ
uropathogen
e
coli
upec
aim
studi
phylogenet
character
upec
felin
uti
case
investig
vitro
suscept
isol
ecn
cat
posit
e
coli
urin
cultur
includ
studi
sampl
use
studi
obtain
surplu
urin
collect
routin
evalu
possibl
urinari
tract
infect
character
upec
isol
perform
clade
analysi
serotyp
virul
factor
analysi
multiplex
pcr
test
ecn
effect
upec
isol
test
vitro
use
microcidin
plate
analysi
clinic
sign
consist
lower
urinari
tract
infect
cat
serogroup
virul
factor
correl
clade
analysi
report
human
upec
studi
percent
upec
isol
suscept
ecn
probiot
vitro
averag
zone
growth
inhibit
ecn
probiot
mm
rang
mm
upec
isol
felin
patient
similar
isol
human
patient
pathogen
suscept
genet
background
vitro
suscept
felin
upec
isol
frequent
suscept
ecn
probiot
growth
rate
characterist
andor
microcin
product
find
suggest
potenti
use
nissl
novel
therapeut
treat
felin
urinari
tract
infect
disclosur
report
fund
studi
provid
acvim
resid
research
grant
author
declar
conflict
interest
littl
known
impact
increas
urin
protein
creatinin
ratio
upc
surviv
dog
differ
underli
diseas
associ
risk
factor
death
establish
therefor
aim
studi
assess
dog
sever
proteinuria
upc
least
diseas
measur
surviv
time
underli
diseas
possibl
prognost
factor
like
upc
time
diagnosi
creatinin
urin
specif
graviti
albumin
haematocrit
dog
sever
proteinuria
retrospect
analys
among
dog
diagnos
glomerulopathi
median
upc
rang
dog
cush
diseas
median
upc
rang
dog
leishmaniosi
median
upc
rang
dog
variou
diseas
median
upc
rang
dog
increas
upc
identifi
risk
factor
death
p
median
time
surviv
day
upc
time
surviv
differ
significantli
group
among
dog
glomerulopathi
identifi
signific
risk
factor
death
includ
increas
upc
p
increas
creatinin
p
low
haematocrit
p
low
urin
specif
graviti
p
dog
cush
diseas
urin
specif
graviti
signific
risk
factor
death
p
dog
leishmaniosi
increas
upc
creatinin
signific
risk
factor
death
p
p
increas
upc
risk
factor
death
dog
glomerulopathi
leishmaniosi
cush
diseas
explain
differ
pathogenesi
lead
proteinuria
disclosur
report
b
gerber
speaker
boehring
ingelheim
calcium
oxal
caox
recurr
challeng
manag
dog
rel
supersatur
rss
measur
crystal
risk
lower
urinari
concentr
caox
precursor
decreas
caox
rss
urinari
dilut
primari
strategi
decreas
caox
rss
achiev
increas
sodium
content
pet
food
drive
water
intak
howev
human
caox
renolith
advis
decreas
sodium
intak
potenti
increas
renal
calcium
excret
could
increas
risk
diseas
aim
studi
compar
effect
two
dri
pet
food
differ
sodium
chlorid
content
urinari
volum
urinari
calcium
excret
concentr
caox
rss
studi
use
healthi
coloni
dog
base
diet
produc
sodium
content
fed
lsd
formula
supplement
nacl
achiev
diet
hsd
sodium
fed
compar
commerci
avail
urinari
diet
dog
fed
diet
day
follow
day
urin
collect
urinari
miner
measur
pool
sampl
use
ionic
chromatographi
caox
rss
calcul
use
supersat
softwar
impact
diet
urinari
volum
calcium
excret
concentr
oxal
concentr
caox
rss
evalu
use
wilcoxon
test
signific
set
p
data
present
median
percentil
hsd
led
increas
urin
volum
lsd
vs
hsd
mlkg
bwday
p
urinari
calcium
excret
significantli
differ
diet
lsd
vs
hsd
bwday
p
urinari
calcium
concentr
lower
hsd
lsd
vs
hsd
mmoll
p
urinari
oxal
concentr
lower
hsd
lsd
vs
hsd
mmoll
p
caox
rss
significantli
lower
hsd
lsd
vs
hsd
p
result
studi
support
increas
urinari
calcium
excret
increas
dietari
sodium
commerci
relev
level
increas
urin
volum
seen
high
salt
diet
decreas
urinari
calcium
oxal
concentr
could
explain
decreas
caox
rss
increas
dietari
sodium
therefor
decreas
risk
caox
urolithiasi
feed
trial
studi
requir
assess
effect
increas
dietari
sodium
diet
fed
longer
period
time
disclosur
report
author
current
employe
royal
canin
mar
petcar
prolif
urethr
pu
uncommon
inflammatori
diseas
unknown
etiolog
data
prognosi
affect
dog
current
lack
aim
studi
describ
clinic
endoscop
histopatholog
find
investig
influenc
outcom
dog
pu
medic
record
dog
underw
cystoscopi
diagnos
pu
histopatholog
retrospect
review
dog
document
follow
period
least
month
diagnosi
includ
result
regard
signal
clinic
cystoscop
microbiolog
histopatholog
find
collect
endoscop
score
es
grade
urethr
lesion
use
mild
local
lesion
es
complet
involv
without
stenosi
es
urethr
stenosi
es
urethr
obstruct
uo
es
treatment
complic
month
surviv
time
diagnosi
variabl
associ
surviv
month
investig
data
analyz
use
descript
statist
report
median
rang
surviv
analysi
perform
use
cox
proport
hazard
regress
analysi
p
valu
consid
signific
thirteen
femal
dog
spay
met
inclus
criteria
median
age
month
median
bodi
weight
kg
main
clinic
sign
dysuria
stranguria
urethr
obstruct
detect
dog
dog
result
avail
urin
microbi
cultur
posit
dog
endoscop
evid
irregular
tissu
project
urethr
lumen
extend
along
entir
urethra
dog
es
urethr
strictur
note
case
es
dog
uo
es
histopatholog
lymphoplasmacyt
lymphoplasmacyt
neutrophil
granulomat
inflamm
detect
medic
treatment
start
dog
diagnosi
includ
antimicrobi
glucocorticoid
nonsteroid
medic
median
surviv
time
month
complic
includ
relaps
clinic
sign
recurr
uti
dog
requir
addit
intervent
surgic
treatment
restor
urethr
patenc
variabl
associ
surviv
age
hr
ci
p
bodi
weight
hr
ci
p
develop
uo
within
month
diagnosi
hr
ci
p
sever
es
time
diagnosi
affect
outcom
dog
pu
howev
small
size
older
dog
develop
uo
diagnosi
like
worst
prognosi
disclosur
report
canin
parvoviru
cpv
felin
parvoviru
fpv
caus
sever
often
fatal
enter
host
uk
studi
report
faecal
shed
cpv
fpv
asymptomat
shelter
cat
contrast
australian
studi
util
similar
convent
pcr
cpcr
assay
report
cpv
shed
fpv
shed
asymptomat
shelter
cat
aim
longitudin
studi
determin
whether
parvovir
shed
undetect
cpcr
occur
australian
shelter
cat
residu
faecal
sampl
previou
australian
studi
n
collect
asymptomat
shelter
cat
three
sampl
day
n
n
n
month
test
occur
fpv
outbreak
parvovir
dna
detect
use
quantit
pcr
qpcr
minor
groov
binder
pcr
assay
differenti
fpv
parvovir
dna
detect
faecal
sampl
posit
sampl
fpv
respect
viral
load
x
median
x
templat
dna
lower
fpv
x
x
median
x
templat
dna
quantit
pcr
sensit
cpcr
detect
parvovir
shed
fpv
shed
asymptomat
cat
fpv
outbreak
low
preval
cpv
shed
detect
potenti
role
cat
reservoir
cpv
infect
dog
vari
popul
test
disclosur
report
author
receiv
fund
support
unrel
research
project
australian
research
council
vb
boehring
ingelheim
vb
morri
anim
foundat
vb
jb
winn
felin
foundat
vb
jb
partnership
collabor
award
univers
sydney
vb
jb
univers
glasgow
vb
univers
california
davi
jb
senior
author
vb
member
australian
infecti
diseas
advisori
panel
aidap
fund
zoeti
felin
parvoviru
fpv
common
infecti
agent
lethal
aim
studi
assess
prognost
valu
sir
presenc
serum
concentr
serum
amyloid
saa
haptoglobin
cholesterol
total
thyroxin
felin
panleukopenia
retrospect
cohort
studi
enrol
cat
felin
panleukopenia
present
januari
januari
definit
diagnosi
felin
panleukopenia
requir
posit
direct
elisa
assay
fece
andor
posit
pcr
fece
andor
blood
accord
surviv
statu
present
cat
divid
survivor
nonsurvivor
prognost
import
present
variabl
age
sex
reproduct
statu
presenc
sir
serum
concentr
saa
haptoglobin
cholesterol
measur
left
serum
sampl
investig
univari
multivariabil
cox
regress
model
final
roc
curv
analysi
use
identifi
best
cutoff
valu
youden
index
discrimin
survivor
nonsurvivor
prognost
variabl
result
statist
signific
multivari
analysi
analys
signific
set
seventi
cat
elig
studi
survivor
nonsurvivor
present
nonsurvivor
significantli
u
p
younger
survivor
differ
reproduct
statu
found
signific
differ
p
number
cat
fulfil
sir
criteria
survivor
nonsurvivor
saa
concentr
significantli
lower
u
p
survivor
median
rang
compar
nonsurvivor
median
rang
serum
haptoglobin
concentr
significantli
lower
p
survivor
mean
mgdl
compar
nonsurvivor
mean
mgdl
differ
serum
cholesterol
concentr
found
final
serum
concentr
significantli
higher
p
survivor
mean
compar
nonsurvivor
cox
regress
model
serum
concentr
significantli
associ
surviv
hr
p
youden
index
identifi
roc
curv
analysi
serum
concentr
sensit
specif
auc
ci
p
present
studi
show
serum
present
cat
fpv
could
use
prognost
factor
predict
diseas
outcom
disclosur
report
felin
calicivirus
fcv
common
felin
pathogen
caus
flu
sign
rare
fcv
caus
virul
system
diseas
characteris
jaundic
faciallimb
oedema
skin
ulcer
death
pathogenesi
poorli
understood
aim
studi
characteris
clinic
virolog
featur
two
nosocomi
outbreak
australia
assess
efficaci
three
antivir
repres
outbreak
strain
vitro
cat
present
sign
consist
outbreak
includ
viral
isol
whole
genom
sequenc
perform
residu
diagnost
oropharyng
swab
andor
necropsi
tissu
one
viru
outbreak
test
plaqu
reduct
assay
nitazoxanid
ntz
antivir
determin
therapeut
index
ti
deriv
half
maxim
cytotox
concentr
crfk
cell
twenti
case
nsw
n
qld
n
identifi
age
month
median
onset
sign
day
hospit
admiss
surgeri
case
fcv
vaccin
statu
known
current
case
overal
mortal
phylogenet
analysi
full
fcv
genom
reveal
two
fcv
lineag
nsw
separ
lineag
qld
inhibit
strain
obtain
antivir
ntz
ti
ti
ti
outbreak
continu
occur
vaccin
cat
associ
high
mortal
three
antivir
potent
inhibitor
outbreak
strain
test
disclosur
report
statement
disclosur
studi
support
financi
australian
companion
anim
health
foundat
philanthrop
donat
sydney
school
veterinari
scienc
univers
sydney
research
donat
virbac
australia
pti
ltd
virbac
involv
studi
design
includ
select
antivir
drug
test
analysi
author
receiv
fund
support
unrel
research
project
australian
research
council
vb
ech
ms
boehring
ingelheim
vb
morri
anim
foundat
vb
jb
winn
felin
foundat
vb
jb
partnership
collabor
award
univers
sydney
vb
jb
mb
univers
glasgow
vb
mb
univers
california
davi
jb
senior
author
vb
member
australian
infecti
diseas
advisori
panel
aidap
fund
zoeti
unknown
cat
field
react
felin
caliciviru
fcv
vaccin
studi
evalu
preval
fcv
antibodi
healthi
adult
cat
antibodi
respons
fcv
vaccin
cat
year
n
receiv
vaccin
within
month
receiv
vaccin
contain
inactiv
fcv
antigen
strain
day
fcv
antibodi
determin
leftov
sampl
viru
neutral
vn
use
isol
antigen
elisa
factor
associ
presenc
antibodi
respons
vaccin
determin
multivari
statist
analysi
antibodi
detect
cat
ci
vn
ci
elisa
titr
increas
vaccin
observ
ci
vn
ci
elisa
cat
year
like
vn
antibodi
cat
year
p
presenc
vn
antibodi
also
correl
cat
vaccin
statu
p
presenc
elisa
antibodi
associ
time
sinc
last
vaccin
p
outdoor
cat
like
titr
increas
elisa
p
mani
cat
fcv
antibodi
even
vaccin
perform
year
ago
preval
antibodi
depend
previou
vaccin
seem
increas
age
titr
increas
vaccin
rare
observ
influenc
cat
lifestyl
disclosur
report
poulet
global
head
companion
anim
equin
biolog
r
boehring
ingelheim
provid
antibodi
test
elisa
boehring
ingelheim
play
role
collect
interpret
data
decis
submit
manuscript
public
katrin
hartmann
given
talk
msd
merial
boehring
ingelheim
idexx
particip
research
fund
use
product
msd
merial
boehring
zoeti
megacor
biogal
scil
bergmann
given
talk
merial
particip
research
fund
use
product
msd
merial
boehring
zoeti
megacor
biogal
scil
commerci
conflict
interest
inform
gener
sole
scientif
dissemin
author
declar
compet
interest
felin
coronaviru
fcov
infect
common
household
propos
cat
higher
antibodi
titr
like
shed
fcov
faec
aim
studi
determin
possibl
correl
fcov
serum
antibodi
titr
faecal
fcov
shed
four
faecal
sampl
cat
origin
german
catteri
examin
fcov
quantit
revers
transcriptas
polymeras
chain
reaction
serum
antibodi
titr
determin
immunofluoresc
assay
weak
posit
correl
height
antibodi
titr
mean
faecal
viru
load
spearman
r
p
antibodi
titr
significantli
higher
cat
shed
fcov
frequent
kruskal
walli
test
p
cat
four
faecal
sampl
cat
significantli
lower
antibodi
titr
cat
shed
continu
four
sampl
dunn
test
p
analys
cat
shed
least
cat
fcov
continu
four
sampl
significantli
higher
antibodi
titr
u
test
p
significantli
higher
mean
faecal
viru
load
u
test
p
cat
fcov
one
two
three
sampl
eight
cat
detect
antibodi
shed
fcov
height
antibodi
titr
correl
faecal
viru
load
chronic
fcov
shedder
higher
antibodi
titr
shed
viru
knowledg
import
manag
fcov
infect
environ
howev
measur
serum
antibodi
replac
faecal
disclosur
report
dr
christian
leutenegg
head
molecular
diagnost
idexx
laboratori
inc
dr
nikola
pantchev
employ
idexx
laboratori
ludwigsburg
laboratori
offer
fcov
commerci
basi
perform
studi
dissemin
aspergillosi
da
dog
guard
prognosi
aim
studi
describ
da
treatment
regimen
associ
post
diagnosi
surviv
time
retrospect
studi
evalu
dog
diagnos
da
veterinari
referr
centr
privat
univers
around
australia
period
januari
june
inclus
criteria
includ
consist
diagnost
find
posit
cultur
aspergillu
steril
site
posit
serum
galactomannan
assay
data
analys
use
surviv
analysi
outcom
interest
length
time
day
date
diagnosi
date
death
euthanasia
due
da
factor
influenc
surviv
time
post
diagnosi
quantifi
use
cox
proport
hazard
regress
model
data
organis
count
process
format
allow
us
quantifi
effect
antifung
agent
surviv
time
total
dog
includ
studi
common
breed
german
shepherd
dog
n
common
organ
cultur
terreu
n
posit
cultur
treatment
start
dog
wherea
dog
receiv
specif
treatment
dog
lost
follow
dog
treat
itraconazol
treatment
singl
agent
dog
total
nine
dog
treat
concurr
terbinafin
median
surviv
time
post
diagnosi
day
age
diagnosi
signific
effect
surviv
time
daili
hazard
death
da
dog
elev
serum
creatinin
concentr
diagnosi
ci
time
dog
normal
serum
creatinin
concentr
daili
hazard
death
da
dog
treat
itraconazol
ci
time
dog
treat
treatment
daili
hazard
death
da
dog
treat
terbinafin
ci
time
dog
treat
terbinafin
consist
previou
studi
found
da
case
german
shepherd
terreu
commonli
isol
organ
although
itraconazol
previous
drug
choic
treat
da
find
show
combin
therapi
terbinafin
newer
treatment
improv
surviv
time
serum
creatinin
use
prognost
indic
surviv
time
disclosur
report
trichuri
vulpi
tv
parasit
canid
larg
intestin
worldwid
distribut
despit
epidemiolog
pathogen
impact
dog
remain
controversi
aim
current
retrospect
studi
describ
clinic
biolog
sign
treatment
respons
dog
natur
infect
tv
medic
databas
search
case
tv
egg
identifi
fecal
analysi
dog
classifi
tv
tv
parasit
speci
intens
tv
fecal
excret
fe
quantifi
number
tv
g
fece
dog
diagnos
comorbid
potenti
contribut
system
digest
sign
biolog
abnorm
anemia
hypoalbuminemia
exclud
clinic
sign
biolog
abnorm
cours
diseas
record
compar
group
associ
variabl
fe
statist
evalu
level
signific
set
p
dog
posit
tv
fecal
analysi
includ
studi
dog
dog
concurr
isol
parasit
toxocara
cani
ankylostomatida
capillaria
spp
isospora
spp
giardia
duodenali
median
age
infect
dog
year
overal
clinic
sign
includ
diarrhea
weight
loss
hematochezia
inappet
vomit
polyphagia
intussuscept
diagnos
dog
two
dog
show
lethargi
clinic
sign
like
due
moder
sever
anemia
digest
sign
acut
less
day
dog
chronic
remain
dog
biolog
abnorm
includ
anemia
eosinophilia
hypoalbuminemia
nak
ratio
normal
test
four
percent
dog
neither
clinic
biolog
sign
differ
weight
loss
frequent
p
signific
associ
found
clinic
sign
biolog
abnorm
fe
howev
nak
ratio
normal
test
found
among
dog
massiv
fe
complet
recoveri
antiparasit
treatment
obtain
dog
avail
n
one
dog
die
intussuscept
result
suggest
tv
pathogen
dog
lead
acut
chronic
digest
clinic
sign
hypoalbuminemia
anemia
electrolyt
disord
disclosur
report
antimicrobi
resist
increas
threat
human
anim
health
misus
antimicrobi
foster
resist
object
retrospect
studi
investig
pattern
antimicrobi
use
select
canin
diseas
switzerland
antimicrobi
prescript
respiratori
urinari
tract
infect
uti
acut
diarrhea
two
swiss
univers
hospit
privat
practic
review
class
antimicrobi
dosag
treatment
durat
assess
justif
score
js
appli
suffici
clinic
inform
avail
defin
appropri
antimicrobi
therapi
base
current
guidelin
appropri
incorrect
dosag
andor
durat
inappropri
antimicrobi
choic
overal
wrong
treatment
decis
dog
proven
suspect
upper
lower
respiratori
tract
infect
treat
antimicrobi
follow
class
potenti
aminopenicillin
fluoroquinolon
np
aminopenicillin
tetracyclin
cephalosporin
cephalosporin
lincosamid
macrolid
nitroimidazol
therapeut
decis
regard
antimicrobi
therapi
judg
appropri
inappropri
n
n
dog
proven
suspect
uti
receiv
antimicrobi
bacteri
etiolog
confirm
via
cultur
andor
sediment
examin
antimicrobi
class
use
potenti
aminopenicillin
fluoroquinolon
cephalosporin
cephalosporin
lincosamid
amphenicol
potenti
sulfonamid
antimicrobi
suscept
test
perform
case
bacteri
cultur
perform
antimicrobi
therapi
judg
appropri
inappropri
n
antimicrobi
prescrib
dog
acut
diarrhea
class
use
nitroimidazol
potenti
aminopenicillin
fluoroquinolon
tetracyclin
cephalosporin
antimicrobi
therapi
significantli
associ
presenc
bloodi
diarrhea
p
compli
current
guidelin
restrict
therapi
use
aminopenicillin
suspect
sepsi
result
studi
show
antimicrobi
use
commonli
compli
current
treatment
guidelin
dog
respiratori
urinari
tract
infect
acut
diarrhea
consequ
urgent
need
antimicrobi
stewardship
initiativesto
support
prudent
use
antimicrobi
anim
antibioticscoutch
comprehens
onlin
tool
base
current
guidelin
launch
decemb
impact
tool
veterinari
prescrib
habit
assess
futur
studi
disclosur
report
research
project
support
swiss
nation
scienc
foundat
project
accord
hanspet
naeg
overus
antibiot
common
problem
veterinari
medicin
contribut
develop
antimicrobi
resist
foster
prudent
antimicrobi
use
veterinarian
freeli
access
onlin
tool
contain
swiss
consensu
guidelin
prudent
antimicrobi
use
launch
decemb
http
wwwantibioticscoutch
aim
studi
compar
antimicrobi
prescript
cat
switzerland
introduct
antibioticscoutch
cat
present
one
univers
clinic
eight
privat
practicesclin
acut
upper
respiratori
tract
diseas
aurtd
felin
lower
urinari
tract
diseas
flutd
abscess
privat
practicesclin
includ
signal
clinic
symptom
diagnost
diagnosi
antimicrobi
therapi
assess
data
compar
publish
data
case
belong
diseas
categori
present
practiceclin
schmitt
et
al
justif
score
appli
evalu
accord
prescript
guidelin
complet
accord
differ
dosagedur
differ
antimicrobi
choic
antimicrobi
disagr
guidelin
prudent
use
assess
data
cat
aurtd
n
flutd
n
abscess
n
present
compar
data
case
frequenc
antimicrobi
prescript
decreas
p
declin
found
univers
clinic
p
well
privat
practicesclin
p
diseas
categori
aurtd
p
flutd
p
abscess
p
specif
prescript
critic
import
gener
cephalosporin
decreas
p
urin
analys
frequent
perform
privat
practiceclin
cat
flutd
p
despit
number
prescript
accord
guidelin
significantli
increas
aurtd
flutd
abscess
year
present
studi
report
reduct
antimicrobi
prescript
use
gener
cephalosporin
cat
switzerland
coincid
antibiot
stewardship
activ
includ
launch
antibioticscoutch
howev
adher
consensu
guidelin
still
poor
oral
prepar
aminopenicillin
cat
avail
switzerland
could
hamper
complianc
guidelin
thu
although
present
studi
indic
trend
toward
less
frequent
prescript
antimicrobi
cat
effort
necessari
promot
antimicrobi
stewardship
small
anim
medicin
disclosur
report
studi
support
swiss
nation
scienc
foundat
project
small
anim
veterinarian
commonli
face
contagi
zoonot
diseas
infect
multidrug
resist
organ
hand
hygien
hh
consid
one
import
infect
control
measur
healthcar
recent
studi
suggest
hh
complianc
small
anim
veterinari
institut
poor
comprehens
data
small
anim
clinic
practic
europ
lack
present
studi
evalu
hh
complianc
accord
world
health
organ
five
moment
hh
small
anim
clinic
practic
switzerland
use
cleanhand
applic
three
small
anim
clinic
one
one
small
primari
opinion
practic
includ
minimum
observ
clinic
observ
per
studi
area
prepar
area
intens
care
unit
icu
anim
hous
area
examin
area
consult
area
observ
practic
consult
area
anim
hous
area
obtain
five
moment
hh
includ
touch
patient
cleanasept
procedur
bodi
fluid
exposurerisk
touch
patient
touch
patient
surround
hand
disinfect
handrub
hand
wash
water
soap
consid
success
hh
procedur
frequenc
hh
confid
interv
base
jeffrey
approach
estim
use
softwar
r
version
total
observ
reveal
overal
hh
complianc
across
institut
rang
highest
complianc
observ
consult
area
follow
icu
examin
area
anim
hous
area
prepar
area
hh
commonli
perform
contact
bodi
fluid
patient
contact
least
common
prior
cleanasept
procedur
veterinarian
show
higher
adher
hh
veterinari
assist
studi
indic
overal
poor
adher
hh
small
anim
clinic
practic
switzerland
hh
remark
poor
critic
area
prepar
area
cleanasept
procedur
contrast
observ
human
hospit
adher
hh
lower
nurs
staff
doctor
conclus
studi
highlight
need
promot
hh
small
anim
medicin
special
emphasi
train
nurs
staff
personnel
prepar
area
disclosur
report
studi
support
swiss
feder
food
safeti
veterinari
offic
fsvo
project
intens
medic
care
companion
anim
close
contact
peopl
pose
risk
select
zoonot
transmiss
organ
mdro
infect
prevent
control
ipc
concept
key
measur
reduc
spread
mdro
data
ipc
standard
small
anim
clinic
practic
spars
goal
studi
assess
ipc
standard
environment
mdro
contamin
preval
mdro
carriag
veterinari
personnel
small
anim
clinicspractic
switzerland
three
larg
clinic
two
clinic
two
primari
opinion
practic
includ
structur
ipc
audit
perform
environment
sampl
collect
surfac
nasal
faecal
mdro
carriag
veterinari
staff
institut
g
assess
provid
kit
sampl
sampl
analys
mr
staphylococcu
aureu
mrsa
mr
pseudintermediu
mrsp
mr
staphylococci
mrcon
mr
macrococcu
spp
enterobacteriacea
esbl
enterobacteriacea
cpe
use
enrich
select
procedur
speci
identif
perform
ms
analysi
antibiot
resist
gene
identifi
pcr
sequenc
genet
related
assess
enterobacteriacea
multilocu
sequenc
type
mrsp
frequenc
mdro
detect
surfac
clinicspractic
respect
clinic
high
environment
contamin
coli
bla
bla
pneumonia
bla
mrsp
meca
clinic
b
mrcon
meca
clinic
c
macrococcu
spp
mecb
mecd
mrcon
meca
clinic
e
predomin
ipc
audit
reveal
deficit
ipc
organ
cleaningdisinfect
handperson
hygien
medic
prepar
antimicrobi
use
guidelin
clinic
veterinari
personnel
faecal
carriag
e
coli
e
coli
coli
nasal
carriag
mrsa
mrsp
mrcon
found
mdro
carriag
associ
work
place
profess
person
coli
bla
staff
member
clinic
b
relat
environment
isol
studi
document
major
deficit
ipc
standard
small
anim
clinic
switzerland
extens
variabl
environment
contamin
mdro
report
first
time
detect
cpe
environment
sampl
small
anim
clinic
faecal
carriag
relat
cpe
isol
staff
member
present
studi
highlight
potenti
small
anim
clinic
spread
mdro
need
promot
ipc
concept
institut
disclosur
report
studi
support
swiss
feder
food
safeti
veterinari
offic
fsvo
project
organ
mdro
repres
signific
threat
human
anim
health
esbl
cephalosporinas
cp
enterobacteriacea
particular
import
easili
transmit
resist
gene
mediat
resist
mani
antimicrobi
class
aim
studi
assess
preval
mdro
carriag
dog
cat
present
veterinari
clinicspractic
monitor
mdro
acquisit
hospit
studi
mdro
transmiss
among
pet
owner
determin
durat
carriag
prospect
longitudin
observ
studi
rectal
nasaloropharyng
swab
collect
cat
dog
present
veterinari
care
facil
anim
resampl
discharg
particip
owner
sampl
nasal
swabstool
sampl
carrier
resampl
month
nasaloropharyng
swab
analys
presenc
mr
staphylococcu
aureu
mrsa
mr
pseudintermediu
mrsp
mr
staphylococci
mrcon
mr
macrococcu
spp
rectal
swabsstool
cp
enterobacteriacea
enrich
isol
select
chromid
esbl
carba
plate
mrsa
select
agar
isol
identifi
via
ms
antibiot
suscept
test
measur
mic
clonal
determin
use
whole
genom
sequenc
wg
overal
admiss
preval
mdro
carriag
ci
ecoli
mrcon
predomin
overal
discharg
preval
ci
rang
institut
highest
discharg
preval
predomin
isol
k
pneumonia
ecoli
ecoli
isol
commonli
display
gene
bla
bla
bla
show
clonal
bla
suggest
transmiss
common
sourc
rather
de
novo
select
persist
cp
ecoli
k
pneumonia
shown
mdro
posit
anim
day
resist
bacteria
isol
owner
ecoli
mrcon
mrsa
carriag
persist
one
owner
day
transfer
ecoli
owner
dog
suspect
one
case
analysi
ongo
determin
related
isol
cohort
acquisit
rate
andor
cp
enterobacteriacea
high
vari
institut
mdro
carriag
observ
owner
carriag
persist
sever
month
find
show
veterinari
hospit
play
signific
role
select
transmiss
mdro
amongst
veterinari
patient
includ
bacteria
problemat
resist
profil
disclosur
report
project
fund
grant
swiss
feder
food
safeti
veterinari
offic
blv
hepat
encephalopathi
syndrom
neurolog
dysfunct
import
contributor
patient
morbid
dog
liver
diseas
prebiot
lactulos
nonabsorb
synthet
disaccharid
frequent
employ
treatment
canin
yet
incomplet
understood
mechan
action
human
link
dysbiosi
associ
worsen
morbid
mortal
impact
lactulos
amelior
dysbiosi
gener
modul
intestin
microbiota
controversi
unknown
dysbiosi
present
canin
influenc
lactulos
intestin
microbiota
also
assess
dog
aim
studi
therefor
examin
chang
faecal
microbiota
composit
lactulos
treatment
healthi
dog
total
healthi
privat
own
dog
enrol
prospect
cohort
studi
femal
male
median
age
year
rang
complet
studi
fulli
faecal
sampl
collect
weekli
dog
either
usual
diet
week
follow
standardis
commerci
diet
week
ad
oral
lactulos
mlkg
everi
hour
week
faecal
bacteri
dna
extract
follow
pcr
amplif
region
rrna
gene
illumina
standard
librari
prep
sequenc
perform
miseq
platform
data
analys
use
pipelin
week
lactulos
treatment
week
significantli
lower
faecal
microbiota
richnessdivers
observ
base
alpha
divers
metric
observ
oper
taxonom
unit
shannon
index
pielou
even
beta
divers
base
unifrac
distanc
also
significantli
differ
week
compar
week
bacteri
phylum
famili
level
week
associ
signific
increas
firmicut
actinobacteria
veillonellacea
bifidobacteriacea
decreas
bacteroidet
fusobacteria
bacteroidacea
fusobacteriacea
ruminococcacea
alcaligenacea
compar
week
final
extrapol
cirrhosi
dysbiosi
ratio
cdr
calcul
lower
valu
associ
dysbiosi
link
wors
outcom
human
cdr
increas
week
compar
week
conclus
lactulos
induc
revers
qualit
quantit
chang
faecal
microbiota
healthi
dog
possibl
explain
potenti
benefit
manag
disclosur
report
studi
support
royal
dick
school
veterinari
studi
clinic
research
grant
fund
sourc
involv
studi
design
collect
analysi
interpret
data
write
manuscript
decis
submit
manuscript
public
jj
univers
edinburgh
chancellor
fellow
base
roslin
institut
support
strateg
fund
biotechnolog
bioscienc
research
council
rjm
ms
support
bbsrc
institut
strateg
programm
fund
edinburgh
genom
univers
edinburgh
perform
dna
sequenc
gener
raw
data
edinburgh
genom
partli
support
core
grant
nerc
mrc
bbsrc
bacteri
cholecyst
debilit
diseas
dog
presenc
bacteria
bile
ill
dog
would
signific
bile
consid
steril
howev
preval
bactibilia
healthi
dog
unknown
primari
purpos
studi
determin
preval
bactibilia
healthi
dog
secondari
aim
determin
differ
bactibil
healthi
dog
occur
regard
serum
liver
enzym
activ
liver
gallbladd
histopatholog
healthi
abandon
dog
euthanas
reason
includ
prospect
studi
dog
deem
healthi
base
clinic
necropsi
examin
whole
blood
bile
gallbladd
wall
liver
sampl
collect
asept
dog
within
minut
euthanasia
submit
bacteri
cultur
cytolog
biochem
alkalin
phosphatas
alp
alanin
aminotransferas
alt
transferas
ggt
histopatholog
analys
agreement
cytolog
cultur
assess
cohen
analysi
analysi
varianc
serum
liver
enzym
activ
dog
bactibilia
without
perform
use
test
preval
bactibilia
dog
diagnos
cytolog
bile
cultur
poor
agreement
bile
cytolog
cultur
cohen
kappa
p
signific
differ
liver
enzym
concentr
found
bactibil
dog
signific
hepatobiliari
histopatholog
abnorm
present
bactibil
dog
preval
bactibilia
asymptomat
dog
signific
elev
liver
enzym
histopatholog
chang
disclosur
report
f
kettner
financi
relationship
indirectli
benefit
laboratori
servic
vetdiagnostix
use
studi
perform
bacteri
cultur
cytolog
biochem
histopatholog
analys
discuss
abstract
indirect
sharehold
vetdiagnostix
involv
manag
vetdiagnostix
cape
town
branch
liver
function
test
alway
normal
success
surgic
attenu
portosystem
shunt
pss
current
gold
standard
demonstr
absenc
portosystem
shunt
portal
scintigraphi
serum
hyaluron
acid
concentr
sha
dog
pss
increas
compar
healthi
dog
preliminari
studi
report
sha
decreas
week
surgic
attenu
extrahepat
pss
ehpss
aim
current
studi
serial
evalu
sha
dog
surgic
attenu
ehpss
determin
differ
sha
dog
close
versu
open
persist
multipl
acquir
pss
compar
sha
patient
ehpss
versu
liver
diseas
twenti
dog
surgic
treat
ehpss
dog
liver
diseas
includ
dog
ehpss
blood
sampl
taken
diagnosi
month
postop
control
visit
transsplen
portal
scintigraphi
perform
determin
shunt
closur
statu
dog
liver
diseas
sampl
singl
time
point
compris
maltes
dog
moder
increas
postprandi
bile
acid
liver
diseas
base
imag
n
dog
histolog
confirm
portal
vein
hypoplasia
n
histolog
confirm
chronic
hepat
n
sampl
analys
batch
use
commerci
avail
elisa
kit
hyaluronan
quantikin
r
system
minneapoli
ehpss
diagnosi
median
sha
ngml
ngml
success
surgeri
close
pss
sha
drop
ngml
ngml
wherea
dog
persist
portosystem
shunt
sha
remain
higher
median
ngml
ngml
test
reveal
signific
differ
sha
dog
close
versu
open
ehpss
p
p
p
month
postop
respect
median
sha
dog
liver
diseas
ngml
ngml
significantli
lower
compar
dog
moment
ehpss
diagnosi
p
dog
ehpss
sha
seem
promis
biomark
determin
ehpss
closur
surgic
attenu
addit
might
also
valuabl
differenti
dog
ehpss
dog
liver
diseas
disclosur
report
oncogen
mutat
well
describ
canin
transit
cell
carcinoma
tcc
urinari
bladder
urethra
mochizuki
et
al
et
al
studi
investig
preval
carcinoma
distribut
whole
canin
urinari
tract
dog
includ
studi
terrier
scottish
jack
russel
west
highland
white
airedal
fox
yorkshir
welsh
irish
soft
coat
wheaten
dog
breed
eg
mongrel
beagl
bearnais
mountain
dog
cocker
spaniel
age
median
year
formalin
fix
sampl
carcinoma
urinari
tract
renal
tubular
carcinoma
rca
n
tcc
renal
pelvi
rpca
n
tcc
urinari
bladder
ubtcc
n
tcc
urethra
utcc
n
tcc
simultan
urethra
urinari
bladder
stcc
n
histopatholog
diagnos
perform
use
qiaamp
dna
ffpe
tissu
kit
exon
chromosom
examin
presenc
taqman
snp
assay
statist
analys
perform
use
graphpad
prism
version
histolog
diagnosi
show
tubulopapilliform
rc
solid
prca
case
tcc
ubtc
utc
stcc
detect
rca
rpca
ubtcc
utcc
stcc
significantli
p
often
found
neoplasm
lower
urinari
tract
kidney
howev
signific
differ
preval
differ
site
tcc
urinari
bladder
andor
urethra
statist
correl
histolog
degre
tcc
lut
obviou
identifi
significantli
frequent
ubtcc
terrier
breed
p
utcc
breed
differ
signific
probabl
due
small
number
terrier
case
dog
braf
mutat
conclus
renal
carcinoma
mostli
caus
thu
tubular
pelvic
carcinoma
kidney
detect
analysi
cell
excret
within
urin
contrast
often
involv
pathogenesi
tcc
urinari
bladder
andor
urethra
use
excel
diagnost
tool
enorm
specifi
malign
site
carcinoma
lower
urinari
tract
disclosur
report
author
h
j
grassing
l
kempker
h
erhard
employ
laboklin
gmbh
co
kg
provid
get
recogn
treatment
option
patient
recurr
neoplast
diseas
howev
inform
efficaci
risk
chronic
side
effect
limit
veterinari
medicin
aim
studi
evalu
outcom
report
late
side
effect
dog
cat
receiv
progress
tumor
recurr
small
anim
cancer
patient
treat
includ
retrospect
studi
patient
characterist
tumor
type
local
pretreat
time
interv
initi
radiotherapi
radiat
protocol
late
side
effect
caus
death
surviv
time
analyz
patient
dog
cat
includ
studi
major
suffer
neck
tumor
protocol
one
except
five
anim
receiv
second
cours
fifteen
patient
initi
radiat
definit
anim
palli
intent
mean
time
interv
initi
radiotherapi
first
day
first
second
day
mean
total
late
respond
tissu
gy
initi
radiotherapi
late
side
effect
commonli
observ
skinhair
alway
score
mild
score
vrtog
chronic
ocular
side
effect
report
seven
patient
score
median
surviv
time
patient
day
conclus
studi
demonstr
palli
offer
treatment
option
incur
recurr
tumor
late
side
effect
mostli
mild
disclosur
report
target
toxin
promis
agent
design
target
receptor
uniqu
highli
express
cancer
cell
improv
tumor
specif
reduc
advers
event
ae
name
impli
bispecif
toxin
dual
target
abil
confer
greater
bind
affin
kill
abil
compar
monospecif
counterpart
ebat
bispecif
epiderm
growth
factor
egf
angiotoxin
develop
second
gener
biolog
drug
specif
target
tumor
cell
associ
vascular
inflammatori
stroma
sarcoma
therapi
consist
human
egf
target
egf
receptor
egfr
human
amino
termin
transferas
atf
urokinas
target
urokinas
plasminogen
activ
receptor
upar
genet
modifi
pseudomona
exotoxin
lead
inhibit
protein
synthesi
previous
report
ebat
safe
improv
overal
surviv
dog
splenic
hemangiosarcoma
hsa
minim
residu
diseas
set
ad
standard
care
soc
therapi
singl
cycl
three
treatment
studi
pseudomona
exotoxin
human
suggest
repeat
cycl
administr
may
prolong
remiss
wherea
optim
time
administr
target
toxin
chemotherapi
unclear
sarcoma
bispecif
toxin
studi
describ
herein
undertaken
prospect
determin
multipl
cycl
ebat
biolog
activ
dose
ugkg
given
intraven
concomit
reduc
interv
administr
target
toxin
doxorubicin
chemotherapi
would
improv
outcom
dog
splenic
hsa
elig
expand
dog
hsa
provid
macroscop
lesion
could
surgic
excis
treatment
includ
three
plan
cycl
ebat
administ
mondaywednesdayfriday
schedul
start
upon
recoveri
splenectomi
continu
one
week
prior
doxorubicin
event
interv
first
ebat
given
day
first
doxorubicin
reduc
compar
previou
trial
use
singl
cycl
ebat
doxorubicin
start
day
instead
day
dog
enrol
six
experienc
acut
hypotens
two
requir
hospit
elev
alt
observ
one
dog
surviv
benefit
seen
studi
overal
surviv
compar
contemporari
control
group
dog
stage
hemangiosarcoma
treat
soc
alon
repeat
dose
cycl
ebat
led
greater
incid
sever
ae
reduc
efficaci
compar
singl
cycl
ebat
delay
commenc
chemotherapi
disclosur
report
work
support
grant
offic
director
nation
institut
health
grant
nation
canin
cancer
foundat
grant
mason
cancer
center
univers
minnesota
sarcoma
translat
work
group
grant
akc
canin
health
foundat
us
public
health
servic
grant
award
nci
niaid
dhh
randi
shaver
cancer
research
commun
foundat
atwat
cancer
drug
develop
award
ceti
translat
award
univers
minnesota
mason
cancer
center
grant
greylong
author
grate
acknowledg
gener
support
angiosarcoma
awar
foundat
donat
anim
cancer
care
research
program
univers
minnesota
help
support
project
author
declar
patent
reduct
egfr
therapeut
toxic
relat
work
file
offic
technolog
commerci
aniv
lifesci
purchas
licens
therapeut
use
ebat
speci
applic
humor
hypercalcemia
malign
hhm
common
paraneoplast
syndrom
canin
lymphoma
alway
consid
neg
prognost
factor
howev
studi
analyz
role
hhm
lymphoma
type
lack
aim
studi
evalu
incid
hhm
among
differ
lymphoma
type
prognost
impact
surviv
retrospect
studi
data
dog
diagnos
untreat
lymphoma
analyz
inclus
criteria
avail
type
serumplasma
calcium
concentr
case
includ
hhm
present
patient
notabl
patient
affect
suffer
peripher
lymphoma
ptlc
lymphoma
hhm
occur
ptlc
case
patient
hhm
show
symptom
attribut
hypercalcemia
predominantli
polyuriapolydipsia
neurolog
somnol
weak
gastrointestin
manifest
inappet
dog
hhm
median
total
ioniz
calcium
mmoll
refer
interv
mmoll
refer
interv
respect
chemotherapi
calcium
concentr
return
normal
case
signific
differ
progress
free
surviv
vs
day
p
lymphoma
specif
surviv
vs
day
p
observ
hypercalcem
normocalcem
dog
subtyp
accord
result
hhm
unfavor
prognost
factor
associ
aggress
lymphoma
type
prospect
studi
assess
role
vitamin
pthrp
pth
hhm
warrant
disclosur
report
mast
cell
tumour
mct
repres
common
canin
skin
neoplasia
typic
affect
dog
median
age
year
mct
rare
report
puppi
junior
dog
therefor
littl
inform
exist
biolog
behaviour
treatment
requir
aim
retrospect
studi
describ
clinic
histopatholog
featur
prolifer
marker
mutat
outcom
mct
dog
less
sixteen
dog
includ
studi
cutan
mct
subcutan
mct
median
age
first
present
diagnosi
month
rang
month
rang
respect
male
entir
neuter
femal
entir
neuter
common
breed
labrador
golden
retriev
thirteen
cutan
mct
grade
ii
patnaik
grade
patnaikkiupel
grade
patnaikkiupel
kiupel
mitot
index
median
mitot
index
three
subcutan
mct
two
infiltr
growth
pattern
mitot
index
region
lymph
node
assess
case
mean
cytolog
histopatholog
metastas
identifi
dog
cutan
subcutan
assess
case
cutan
subcutan
mct
case
screen
mutat
identifi
cutan
exon
patient
underw
differ
treatment
modal
surgeri
corticosteroid
surgeri
chemotherapi
radiotherapi
radiotherapychemotherapi
recurr
identifi
case
median
time
day
rang
one
patient
receiv
corticosteroid
follow
recurr
day
initi
surgeri
achiev
complet
durabl
clinic
remiss
day
dog
receiv
surgeri
follow
chemotherapi
one
caseth
median
time
cohort
dog
day
rang
patient
aliv
evid
mct
end
studi
period
studi
suggest
mct
puppi
junior
dog
might
favour
outcom
despit
presenc
clinic
patholog
genet
characterist
would
predict
aggress
biolog
behaviour
dog
base
prognost
factor
might
need
stratifi
life
stage
disclosur
report
fund
project
anim
health
trust
doxorubicin
dox
one
effect
chemotherapeut
canin
lymphoma
besid
chronic
cardiotox
dox
trigger
acut
cardiac
arrhythmia
drug
infus
diphenhydramin
premed
commonli
use
histamin
releas
propos
mechan
arrhythmogenesi
studi
object
evalu
incid
sever
dox
cardiac
arrhythmia
dog
lymphoma
effect
diphenhydramin
premed
arrhythmia
number
sever
dox
infus
dog
cytologicallyhistopatholog
confirm
lymphoma
screen
echocardiogram
concurr
electrocardiogram
random
prospect
studi
receiv
premed
dox
premed
diphenhydramin
dox
receiv
diphenhydramin
dox
premed
dox
visit
holter
monitor
data
collect
hour
dox
hour
analyz
burdick
holter
analysi
softwar
commerci
avail
softwar
use
normal
test
analysi
individu
act
control
seventeen
dog
enrol
dog
complet
protocol
statist
differ
group
b
evalu
total
ventricular
prematur
complex
vpc
number
p
chang
vpcshour
p
total
atrial
prematur
complex
apc
number
p
chang
apcshour
p
arrhythmia
sever
score
p
studi
demonstr
dog
appropri
pretreat
cardiovascular
screen
dox
infus
induc
signific
arrhythmia
furthermor
data
suggest
diphenhydramin
may
alter
arrhythmia
number
sever
canin
dox
recipi
disclosur
report
ann
arbor
system
aa
remain
best
anatom
stage
human
diffus
larg
lymphoma
dlbcl
aa
divid
patient
four
stage
base
local
diseas
multipl
nodal
site
one
side
ii
dissemin
nodal
diseas
side
diaphragm
iii
extranod
site
iv
comparison
veterinari
stage
system
who
aa
consid
splenic
infiltr
nodal
involv
higher
stage
aim
retrospect
studi
compar
who
aa
predict
treatment
respons
surviv
canin
nodal
dlbcl
treat
chop
low
number
stage
iii
patient
n
system
exclud
nine
stage
iii
stage
iv
stage
v
case
who
stage
iii
stage
iv
case
aa
associ
who
grade
substag
treatment
respons
found
higher
aa
stage
associ
substag
b
p
p
neg
treatment
respons
p
higher
aa
decreas
progress
free
surviv
pf
vs
day
p
lymphoma
specif
surviv
lss
vs
day
p
higher
who
show
tendenc
toward
shorter
pf
vs
vs
day
p
lss
vs
vs
day
p
conclus
aa
could
predict
accur
prognosi
canin
nodal
dlbcl
prospect
studi
assess
aa
larger
cohort
patient
standard
stage
lymphoma
type
warrant
disclosur
report
positron
emiss
tomographi
pet
commonli
use
lymph
node
ln
metastasi
detect
human
medicin
studi
report
rang
accuraci
depend
tumor
type
grade
system
speci
studi
need
defin
role
pet
stage
veterinari
oncolog
patient
aim
studi
evalu
accuraci
pet
metastasi
detect
canin
oral
malign
melanoma
omm
dog
cytologicallyhistolog
diagnos
omm
elig
prospect
studi
pet
scan
headneck
use
perform
follow
comput
tomographi
bilater
mandibular
lymphadenectomi
perform
histopatholog
assess
scan
evalu
two
independ
observ
first
observ
blind
primari
tumor
later
grade
subject
compar
uptak
background
subsequ
observ
unblind
primari
tumor
inform
util
standard
uptak
valu
suv
quantif
evalu
interobserv
agreement
receiv
oper
characterist
roc
analysi
perform
twelv
dog
enrol
metastat
melanoma
identifi
mandibular
lymph
node
dog
interobserv
agreement
higher
suv
quantif
employ
k
versu
area
curv
improv
observ
use
method
vs
roc
analysi
identifi
suvmax
valu
cutoff
lead
sensit
specif
conclus
includ
assess
oral
caviti
use
quantif
improv
accuraci
pet
metastasi
detect
canin
patient
omm
disclosur
report
diarrhoea
cid
one
frequent
advers
event
associ
chemotherapi
dog
yet
current
consensu
regard
manag
metronidazol
frequent
prescrib
howev
evid
support
use
could
actual
associ
concern
gastrointestin
dysbiosi
diosmectit
natur
medic
clay
wide
use
treatment
acut
diarrhoea
human
strong
evid
vivo
vitro
multipl
speci
support
use
diosmectit
antidiarrh
aim
prospect
studi
investig
efficaci
diosmectit
manag
cid
dog
hypothesis
diosmectit
would
decreas
durat
cid
compar
standard
manag
dog
diagnos
neoplasia
undergo
dose
chemotherapi
june
januari
randomis
group
diosmectit
standard
group
randomli
develop
anoth
cid
event
diosmectit
administ
gkgday
po
divid
dose
initi
start
cid
standard
manag
consist
cours
metronidazol
mgkg
po
initi
diarrhoea
improv
hour
dog
assess
weekli
standard
qualiti
life
qol
diarrhoea
diari
form
fill
owner
physic
examin
perform
clinician
waltham
faec
score
system
use
grade
diarrhoea
dog
recruit
studi
period
grade
diarrhoea
event
record
among
diosmectit
standard
group
respect
median
durat
diarrhoea
significantli
shorter
versu
diosmectit
group
compar
standard
group
p
median
qol
score
significantli
higher
versu
diosmectit
group
compar
standard
group
p
manag
cid
dog
earli
administr
diosmectit
associ
faster
resolut
diarrhoea
compar
standard
manag
metronidazol
confirm
initi
hypothesi
diosmectit
appear
effect
manag
cid
dog
lead
improv
qualiti
life
whilst
decreas
antiobiot
usag
disclosur
report
diosmectit
use
studi
kindli
provid
vb
direct
ltd
form
vb
clay
g
powder
pot
vb
direct
ltd
involv
design
perform
studi
write
abstract
decis
submit
present
region
lymph
node
ln
assess
part
routin
stage
canin
mast
cell
tumour
mct
howev
region
ln
often
determin
base
anatom
locat
drain
ln
may
accur
identifi
order
overcom
issu
differ
techniqu
sentinel
lymph
node
sln
detect
report
ultrasound
ceu
describ
sensit
specif
techniqu
human
patient
wide
use
veterinari
medicin
primari
object
prospect
studi
report
sln
detect
rate
ceu
dog
diagnos
cutaneoussubcutan
mct
secondari
object
assess
safeti
techniqu
hypothesis
ceu
identifi
least
one
sln
dog
advers
reaction
would
occur
case
dog
undergo
routin
stage
cutaneoussubcutan
mct
june
march
recruit
routin
stage
includ
bloodwork
urinalysi
aspir
fna
region
ln
thorac
radiograph
abdomin
ultrasound
fna
liver
spleen
region
ln
assess
complet
ceu
identif
sln
premed
intramuscular
chlorpheniramin
administ
ml
sulfur
hexafluorid
microbubbl
inject
around
tumour
follow
local
massag
resid
train
diagnost
imag
examin
ultrasound
anatom
region
potenti
drain
ln
recommend
resid
train
oncolog
inject
site
check
follow
procedur
discharg
dog
owner
recommend
monitor
site
local
reaction
follow
coupl
day
dog
diagnos
cutaneoussubcutan
mct
recruit
least
one
sln
identifi
dog
sixteen
dog
sln
one
dog
sln
identifi
advers
reaction
procedur
record
among
dog
histopatholog
assess
sln
identifi
diagnos
nodal
metastasi
ceu
sensit
safe
techniqu
identif
sln
dog
mct
confirm
initi
hypothesi
techniqu
may
easili
incorpor
routin
stage
canin
mct
addit
studi
warrant
confirm
clinic
benefit
disclosur
report
tumour
nasal
caviti
paranas
sinus
account
approxim
canin
neoplasm
treatment
choic
intranas
tumor
radiotherapi
rhinotomi
associ
morbid
shorter
surviv
radiotherapi
object
studi
retrospect
analyz
outcom
dog
nasal
tumour
treat
surgic
patient
clinic
nasal
tumour
defin
clinic
sign
persist
month
sign
beyond
local
diseas
treat
surgeri
eighteen
dog
includ
twelv
carcinoma
adenocarcinoma
transit
type
carcinoma
adenosquam
sarcoma
chondrosarcoma
peripher
nerv
sheath
tumour
haemangiosarcoma
main
complain
sneez
nasal
discharg
epistaxi
percent
n
dog
present
epistaxi
clinic
sign
report
month
year
mean
month
prior
surgeri
surgeri
sole
treatment
dog
radiotherapi
surgeri
dog
blood
analysi
surgeri
includ
haematolog
biochemistri
coagul
time
one
dog
plan
surgeri
ct
imag
perform
n
dog
one
rhinoscopi
dorsal
rhinotomi
perform
dog
without
seriou
complic
exclud
one
dog
requir
blood
transfusiion
surgeri
nasal
pack
place
left
hour
dog
develop
mild
moder
facial
emphysema
nasal
discharg
resolv
within
two
three
week
thirteen
dog
die
die
local
tumour
progress
one
die
gi
bleed
renal
carcinoma
two
dog
second
surgeri
follow
relaps
time
data
submiss
three
dog
still
aliv
day
two
dog
lost
follow
day
surgeri
overal
median
surviv
time
day
signific
differ
surviv
outcom
accord
carcinoma
sarcoma
diagnos
histor
canin
nasal
tumour
treat
surgic
achiev
median
suriv
time
month
inferior
outcom
report
use
radiotherapi
case
seri
sever
surgic
complic
infrequ
studi
reveal
patient
experi
prolong
surviv
follow
surgeri
intranas
tumour
studi
necessari
better
defin
patient
group
disclosur
report
alimentari
lymphoma
one
common
form
neoplasia
felin
patient
chemotherapi
main
stay
therapi
decad
felin
alimentari
lymphoma
overal
respons
rate
report
overal
surviv
time
rang
day
year
depend
protocol
util
histolog
form
small
cell
lymphoma
treatment
gener
involv
use
glucocorticoid
combin
chlorambucil
leukeran
current
standard
protocol
use
drug
clinician
choos
continu
therapi
defin
period
time
month
indefinit
diseas
progress
patient
aim
studi
establish
foundat
use
radiat
therapi
felin
intermedi
small
cell
alimentari
lymphoma
altern
chronic
chemotherapi
patient
refractori
medic
manag
tamu
medic
record
search
case
util
helic
tomotherapi
treatment
intermedi
small
cell
alimentari
lymphoma
felin
patient
exclus
criteria
diseas
extens
beyond
intestin
liver
record
inform
includ
patient
signal
baselin
bloodwork
date
method
diagnosi
stage
diagnost
date
treatment
initi
chemotherapi
radiat
therapi
hematolog
abnorm
first
respons
durat
radiat
therapi
date
progress
andor
death
avail
patient
ten
cat
diagnos
alimentari
lymphoma
treat
radiat
seven
cat
diagnos
small
cell
lymphoma
treat
gy
total
three
diagnos
intermedi
cell
lymphoma
treat
gy
total
acut
effect
associ
radiat
therapi
observ
median
overal
surviv
time
cat
treat
radiat
therapi
day
median
overal
surviv
time
control
popul
receiv
chemotherapi
alon
day
radiat
therapi
appear
efficaci
well
toler
clinic
relev
advers
effect
report
addit
favor
advers
event
profil
radiat
extrem
conveni
patient
client
number
client
travel
long
distanc
treatment
monitor
client
complianc
satisfact
improv
due
varieti
factor
reduc
number
medic
hospit
visit
financi
burden
investig
potenti
use
radiat
therapi
intermedi
small
cell
alimentari
lymphoma
salvag
altern
oral
chemotherapi
felin
patient
warrant
disclosur
report
canin
enteropathi
ire
intestin
idiopath
inflamm
diet
antibiot
trial
fail
immunosuppress
need
number
transcript
factor
forkhead
box
regulatori
lymphocyt
investig
ibd
dog
associ
mortal
aim
studi
evalu
clinic
signific
prognost
role
histopatholog
chang
cell
clinic
respons
relaps
ccecai
cibdai
score
assess
present
month
diagnosi
endoscop
biopsi
histopatholog
featur
classifi
use
wsava
guidelin
score
moreov
four
morpholog
featur
evalu
presenc
crypt
distens
cd
lacteal
dilat
ld
mucos
fibrosi
mf
intraepitheli
lymphocyt
il
immunohistochemistri
perform
case
dog
classifi
respond
decreas
ccecai
cibdai
score
compar
decreas
ccecai
cibdai
compar
relaps
evalu
follow
clinic
score
differ
ccecai
cibdai
previou
closest
time
point
calcul
obtain
dccecai
cibdai
dccecai
cibdai
consid
relaps
associ
respons
relaps
categor
data
evalu
use
fisher
exact
test
test
dog
prospect
enrol
dog
belong
accord
cibdai
ccecai
score
respect
cibdai
ccecai
score
associ
clinic
respons
patient
relaps
dog
respect
cibdai
ccecai
associ
relaps
dog
histolog
wsava
moder
higher
respons
rate
sever
dog
p
howev
histolog
score
associ
relaps
rate
histolog
featur
associ
neither
respons
relaps
rate
presenc
il
associ
higher
cibdai
score
p
percentag
cell
associ
ccecai
cibdai
histolog
score
morpholog
featur
number
cell
differ
respond
relat
relaps
evalu
paramet
histolog
grade
seem
predict
clinic
respons
furthermor
none
clinic
histolog
paramet
includ
seem
predict
relaps
ire
dog
disclosur
report
tli
lack
specif
individu
certain
gastrointestin
condit
previous
report
cat
intestin
andor
hepat
diseas
human
chronic
enteropathi
suggest
enterocyt
synthet
small
amount
trypsin
verifi
speci
aim
present
studi
evalu
preval
signific
increas
tli
cat
dog
clinic
practic
result
serum
tli
measur
retrospect
review
sampl
anim
evalu
differ
diseas
two
veterinari
hospit
perform
outsid
laboratori
idexx
barcelona
use
radioimmunoassay
felin
canin
clinic
record
patient
elev
tli
level
ngl
dog
cat
review
sampl
dog
cat
evalu
tli
increas
dog
cat
cobalamin
avail
review
total
patient
without
correl
cobalamin
tli
result
p
patient
increas
tli
cpli
also
determin
andor
quantit
analys
result
consist
pancreat
among
patient
normal
cpli
result
pancreat
suspect
base
pancreat
histolog
n
abdomin
ultrasound
n
portal
hypertens
n
gastrointestin
diseas
n
diagnos
patient
gastrointestin
diseas
confirm
case
enteropathi
ibd
gastrointestin
neoplasia
pressumpt
patient
chronic
enteropathi
pancreat
suspect
patient
elev
tli
without
cpli
analys
patient
underli
diseas
confirm
gastrointestin
diseas
hepatopathi
renal
diseas
hypoadrenocortic
insulinoma
neoplasia
poliartr
patient
presumpt
diagnosi
like
underli
diseas
chronic
enteropathi
n
present
studi
case
increas
tli
without
pancreat
azotemia
confirm
suspect
underli
gastrointestin
diseas
coincid
previou
felin
human
find
fact
tli
perform
case
rule
exocrin
pancreat
insuffici
although
cobalamin
defici
link
increas
felin
tli
normal
supplement
studi
nt
detect
signific
correl
cobalamin
tli
level
yet
undefin
mechan
like
explain
product
tli
absenc
pancreat
inflamm
tli
level
must
care
interpret
anim
gastrointestin
diseas
disclosur
report
hypovitaminosi
link
system
inflamm
chronic
enteropathi
ce
cancer
dog
unknown
chang
serum
oh
seen
dog
acut
enteropathi
ae
studi
aim
investig
oh
dog
ae
compar
normal
dog
dog
ce
hypothes
dog
ae
significantli
differ
concentr
oh
compar
healthi
dog
similar
concentr
dog
ce
studi
approv
local
ethic
committe
client
own
adult
dog
recruit
prospect
ten
healthi
diagnos
ae
clinic
sign
hour
diagnos
ce
clinic
sign
week
serum
ioniz
calcium
total
calcium
phosphoru
magnesium
reactiv
protein
crp
measur
dog
dietari
vitamin
calcul
comparison
group
correl
perform
use
appropri
parametr
statist
p
signific
descript
statist
reveal
compar
group
apart
overweight
small
medium
breed
dog
p
ce
group
mean
sd
oh
nmoll
healthi
dog
nmoll
ae
nmoll
ce
statist
differ
group
p
neg
correl
oh
crp
p
dog
ae
observ
signific
differ
electrolyt
found
group
correl
oh
dietari
vitamin
conclus
pilot
studi
statist
signific
differ
oh
detect
group
disclosur
report
canin
acut
pancreat
ap
abdomin
ultrasound
us
diagnost
tool
involv
diagnosi
although
specif
recent
studi
relationship
us
clinicopatholog
featur
sever
canin
ap
avail
aim
studi
evalu
abdomin
ultrasound
featur
relat
canin
spec
cpl
sever
diseas
outcom
suspect
canin
ap
dog
suspect
ap
hospit
prospect
enrol
ap
suspect
base
compat
clinic
laboratori
paramet
abnorm
snap
cpl
test
idexx
laboratori
admiss
data
regard
abdomin
pain
record
serum
sampl
spec
cpl
sent
commerci
laboratori
idexx
laboratori
us
perform
present
everi
h
day
hospit
us
consid
consist
ap
hypoecho
enlarg
pancrea
irregular
shape
margin
surround
hyperecho
mesenteri
andor
abdomin
effus
recent
develop
canin
acut
pancreat
sever
cap
score
calcul
dog
divid
group
cap
mortal
rate
assess
hospit
discharg
us
posit
present
compar
presenc
abdomin
pain
mortal
rate
cap
use
fisher
exact
test
also
calcul
spec
cpl
valu
compar
positiveneg
us
present
use
dog
prospect
enrol
owner
inform
consent
seventeen
dog
die
hospit
dog
us
suggest
ap
present
us
becam
posit
within
day
hospit
us
group
n
thirteen
dog
remain
us
neg
group
associ
mortal
us
posit
found
dog
present
abdomin
pain
dog
show
abdomin
pain
significantli
higher
preval
posit
us
dog
without
abdomin
pain
p
cap
us
posit
associ
although
cap
associ
mortal
p
spec
cpl
significantli
differ
posit
neg
us
present
dog
neg
us
admiss
becam
posit
afterward
spec
cpl
mgl
interestingli
dog
group
despit
spec
cpl
mgl
dog
ap
chang
us
could
occur
later
hospit
although
presenc
abdomin
pain
present
may
suggest
us
posit
furthermor
us
posit
seem
relat
neither
spec
cpl
prognosi
sever
diseas
disclosur
report
belgian
shepherd
dog
bsd
consid
increas
risk
gastric
carcinoma
gc
mucou
metaplasia
glandular
dysplasia
human
gastric
mucos
atrophi
metaplasia
dysplasia
link
gc
perform
prospect
clinic
trial
explor
earli
diagnosi
condit
gastroscopi
histolog
mucos
biopsi
conduct
investig
possibl
associ
clinic
sign
atrophi
metaplasia
dysplasia
gc
onlin
survey
recruit
anamnesi
laboratori
minim
databas
perform
canin
chronic
enteropathi
clinic
activ
index
ccecai
sign
gastroesophag
reflux
ger
use
ascrib
dog
two
group
without
sign
gastric
diseas
group
ccecai
andor
ger
group
b
ccecai
ger
gastric
inflamm
includ
mucos
fibrosi
glandular
atrophi
histolog
assess
accord
standard
guidelin
world
small
anim
veterinari
associ
mucou
metaplasia
glandular
dysplasia
rate
present
absent
group
includ
dog
median
age
year
mean
ccecai
group
b
includ
dog
median
age
year
logist
regress
analysi
detect
statist
differ
histolog
find
group
b
concern
mucos
atrophi
b
metaplasia
b
dysplasia
b
gc
b
independ
group
numer
bsd
atrophi
follow
dysplasia
metaplasia
gc
six
dog
gc
five
also
atrophi
four
metaplasia
six
dysplasia
fisher
exact
test
reveal
signific
associ
gc
metaplasia
p
dysplasia
p
atrophi
p
neoplasm
gastric
adenocarcinoma
tubular
type
partli
complet
diffus
type
includ
four
carcinoma
one
mucin
adenocarcinoma
studi
bsd
show
high
proport
gastric
mucos
patholog
chang
regardless
clinic
sign
gastric
diseas
even
gc
present
repeatedli
occult
entiti
signific
associ
metaplasia
dysplasia
gc
support
indic
endoscop
affect
bsd
extens
endoscop
screen
seem
howev
unrealist
earli
diagnosi
due
occurr
occult
diseas
address
problem
research
serum
biomark
gc
pursu
futur
studi
also
revis
diagnost
criteria
atrophi
keyword
gastric
carcinoma
atroph
gastriti
metaplasia
dysplasia
dog
disclosur
report
statement
disclosur
marcu
viniciu
candido
author
follow
disclosur
relat
present
employeesalari
marcu
viniciu
candido
work
zoo
southern
brazil
research
variou
topic
teacher
anatomi
exot
anim
medicin
work
privat
practition
companion
anim
endoscopi
sinc
current
phd
student
work
endoscopi
also
treat
patient
exot
anim
clinic
small
anim
hospit
univers
helsinki
grantsresearch
phd
student
univers
helsinki
finland
candido
receiv
research
grant
nation
research
council
ciencia
sem
fronteira
cnpq
brazil
person
fund
finnish
foundat
veterinari
research
research
materi
grant
finnish
veterinari
foundat
doctor
program
clinic
veterinari
scienc
univers
helsinki
finland
travel
grant
speak
consult
given
lectur
wild
zoo
exot
pet
anim
husbandri
medicin
welfar
event
held
sever
veterinari
faculti
brazil
well
congress
meet
grupo
fowler
wild
anim
veterinari
associ
brazil
conbravet
brazilian
congress
veterinari
medicin
other
investmentscommerci
interest
none
gift
hospit
travel
support
marcu
viniciu
candido
travel
support
finnish
veterinari
foundat
doctor
program
clinic
veterinari
scienc
univers
helsinki
finland
particip
ecvim
includ
indirect
benefit
none
statement
disclosur
pernilla
author
follow
disclosur
relat
employeesalari
employ
univers
helsinki
faculti
veterinari
medicin
section
veterinari
patholog
partial
fund
diagnost
incom
client
biopsi
among
biopsi
relat
submit
abstract
grantsresearch
receiv
research
grant
topic
relat
submit
abstract
finnish
foundat
veterinari
research
finnish
veterinari
foundat
svenska
kulturfonden
speak
consult
none
investmentscommerci
interest
none
gift
hospit
travel
support
none
includ
indirect
benefit
none
thoma
spillmann
author
follow
disclosur
relat
present
employeesalari
thoma
spillmann
hill
professor
small
anim
clinic
nutrit
veterinari
univers
hannov
germani
sinc
employ
professor
small
anim
intern
medicin
veterinari
faculti
univers
helsinki
finland
grantsresearch
thoma
spillmann
receiv
research
grant
german
research
societi
finnish
foundat
veterinari
research
finnish
veterinari
foundat
phd
student
receiv
grant
doctor
program
clinic
veterinari
scienc
univers
helsinki
finland
center
intern
mobil
cimo
finland
finnish
foundat
veterinari
research
finnish
veterinari
foundat
finnish
cultur
foundat
emil
aaltonen
foundationfinland
alfr
kordelin
foundationfinland
agriasweden
swedish
kennel
club
research
foundat
ulla
yard
foundationsweden
ciencia
sem
fronteirasbrazil
archimed
foundationestonia
speak
consult
thoma
spillmann
consult
ipsat
finland
given
lectur
behalf
royal
canin
hill
iam
purina
triolabfinland
zoetisfinland
finnish
associ
veterinari
practition
german
small
anim
veterinari
associ
british
small
anim
veterinari
associ
estonian
small
anim
veterinari
associ
world
small
anim
veterinari
associ
feder
european
companion
anim
veterinari
associ
european
colleg
small
anim
intern
medicin
companion
anim
investmentscommerci
interest
none
gift
hospit
travel
support
thoma
spillmann
travel
support
attend
congress
research
teach
visit
univers
iam
royal
canin
hill
finnish
veterinari
foundat
european
erasmu
program
equip
materi
donat
clinic
research
receiv
endoscopi
unit
hospit
district
helsinki
uusimaafinland
olympusfinland
pulsion
munichgermani
biophys
assay
lab
biopal
worcest
mausa
includ
indirect
benefit
resid
salari
resid
program
royal
canin
cobalamin
defici
common
find
dog
diagnos
chronic
enteropathi
ce
due
low
absorpt
andor
bacteri
competit
describ
import
hypocobalaminaemia
prognosi
patient
cobalamin
supplement
highli
recommend
treatment
ce
constitut
therapeut
challeng
new
approach
includ
stem
cell
therapi
aim
evalu
serum
concentr
cobalamin
dog
diagnos
ce
stem
cell
use
absenc
cobalamin
administr
twenti
dog
diagnos
ce
includ
studi
show
persist
gastrointestin
sign
respons
convent
treatment
diet
antibiot
andor
immunosupressorsimmunomodul
administr
histopatholog
evid
intestin
inflamm
studi
approv
ethic
committe
univers
extremadura
singl
dose
canin
mesenchym
stem
cell
msc
allogen
adipos
origin
x
cell
per
kilogram
weight
parenter
administ
blood
sampl
obtain
prior
msc
administr
subsequ
cobalamin
checkup
perform
month
blood
sampl
submit
refer
laboratori
laboklin
madrid
spain
clinic
improv
assess
time
point
clinic
activ
index
cibdai
clinic
normal
data
analyz
use
test
repeat
measur
anova
follow
dunn
holm
sidak
test
p
consid
signific
result
express
mean
se
mean
begin
studi
dog
present
hypocobalaminaemia
pgml
laboratori
refer
valu
statist
signific
differ
observ
cobalamin
valu
pgml
analyz
pgml
pgml
pgml
month
treatment
p
signific
differ
observ
pretreat
valu
obtain
one
month
msc
administr
pgml
cibdai
significantli
improv
checkup
rang
twelv
month
cibdai
group
treat
msc
result
demonstr
administr
msc
lead
increas
serum
cobalamin
dog
diagnos
ce
increas
associ
improv
clinic
statu
therefor
msc
therapi
consid
treatment
dog
affect
ce
due
posit
impact
prognosi
fund
federfs
disclosur
report
mr
ignacio
verdejo
first
author
behalf
author
declar
present
work
exclus
fund
project
junta
de
extremadura
federfs
fund
author
declar
commerci
interest
conflict
interest
veterinari
laboratori
laboklin
particip
design
write
fund
present
work
chronic
inflammatori
enteropathi
cie
compris
import
group
diseas
dog
biomark
routin
measur
eg
serum
cobalamin
albumin
fecal
calprotectin
appear
clinic
util
dog
cie
potenti
aid
cie
subclassif
base
respons
treatment
ie
diagnosi
enteropathi
fre
vs
enteropathi
ire
ratio
nlr
recent
shown
diagnost
prognost
potenti
human
inflammatori
bowel
diseas
ibd
nlr
also
appear
use
diagnosi
dog
hypoadrenocortic
nlr
evalu
report
dog
cie
data
dog
diagnos
cie
receiv
steroid
week
prior
diagnost
evalu
veterinari
center
use
studi
nlr
calcul
neutrophil
countlymphocyt
count
evalu
potenti
relationship
sever
clinic
sign
ccecai
score
system
n
serum
albumin
cobalamin
concentr
n
histolog
lesion
sever
grade
system
n
serum
fecal
concentr
inflammatori
marker
n
respons
treatment
fre
vs
ire
n
statist
signific
set
p
nlr
rang
median
dog
cie
nlr
significantli
higher
dog
sever
clinic
sign
compar
dog
mild
p
moder
p
clinic
diseas
nlr
correl
overal
histolog
score
p
significantli
higher
dog
histolog
lesion
compat
enteropathi
p
hypoalbuminemia
p
hypocobalaminemia
significantli
associ
higher
nlr
nlr
correl
significantli
serum
p
protein
p
decoy
receptor
advanc
glycat
end
product
p
fecal
inhibitor
p
serum
fecal
calprotectin
concentr
dog
ire
n
significantli
higher
nlr
median
dog
fre
median
n
p
nlr
best
distinguish
dog
ire
fre
sensit
specif
find
suggest
neutrophil
play
role
system
inflammatori
respons
associ
cie
dog
nlr
ie
leukogram
chang
canin
cie
similar
magnitud
human
ibd
nlr
easili
obtain
routin
hematolog
potenti
aid
subclassif
dog
cie
potenti
util
nlr
monitor
dog
cie
requir
investig
disclosur
report
applic
calprotectin
bind
protein
famili
potenti
marker
inflamm
dog
mainli
origin
granulocyt
increas
canin
calprotectin
concentr
detect
fece
serum
sampl
dog
chronic
inflammatori
enteropathi
cie
howev
intestin
mucos
calprotectin
concentr
extens
investig
canin
cie
evalu
mucos
concentr
calprotectin
dog
cie
comparison
healthi
beagl
dog
use
turbidimetr
immunoassay
petia
method
clinic
chemistri
analyz
addit
assess
associ
mucos
calprotectin
level
canin
clinic
ibd
activ
index
cibdai
histopatholog
find
clinic
outcom
serum
albumin
concentr
intestin
mucos
biopsi
collect
dog
cie
duodenum
n
ileum
n
colon
n
caecum
n
archiv
intestin
tissu
sampl
healthi
beagl
dog
serv
control
duodenum
n
ileum
n
colon
n
caecum
n
data
present
median
interquartil
rang
comparison
healthi
beagl
mucos
calprotectin
concentr
higher
duodenum
vs
p
colon
vs
p
histolog
sever
significantli
associ
mucos
calprotectin
level
p
total
histopatholog
score
lymphoplasmacyt
infiltr
duodenum
epitheli
injuri
colon
duoden
calprotectin
concentr
higher
hypoalbuminem
dog
normoalbuminem
dog
vs
small
number
hypoalbuminem
dog
n
result
descript
report
signific
associ
mucos
calprotectin
level
cibdai
score
clinic
outcom
studi
show
mucos
calprotectin
concentr
increas
duodenum
colon
dog
cie
result
provid
support
evid
potenti
diagnost
valu
mucos
fecal
calprotectin
concentr
dog
cie
prospect
research
need
assess
valu
measur
mucos
calprotectin
concentr
clinic
practic
relationship
mucos
fecal
calprotectin
inflammatori
marker
dog
cie
disclosur
report
human
ibd
ratio
nlr
associ
activ
bowel
inflamm
correl
clinic
laboratori
indic
far
nlr
dog
evalu
oncolog
patient
septic
periton
aim
studi
evalu
nlr
canin
enteropathi
ire
dog
present
two
veterinari
facil
veterinari
teach
hospit
privat
veterinari
center
final
diagnosi
ire
retrospect
includ
canin
chronic
enteropathi
clinic
activ
index
ccecai
score
assess
dog
present
diagnosi
ire
set
histopatholog
perform
endoscop
biopsi
classifi
use
current
wsava
guidelin
lacteal
dilat
ld
crypt
abscess
cd
also
record
nlr
calcul
dog
serum
total
protein
albumin
cholesterol
protein
crp
also
record
test
perform
evalu
nlr
differ
ccecai
categori
differ
histolog
grade
spearman
correl
test
perform
nlr
total
protein
albumin
cholesterol
crp
use
compar
nlr
dog
without
ld
cd
receiv
oper
characterist
curv
roc
built
obtain
optim
valu
nlr
differenti
dog
without
ld
fisher
exact
test
perform
presenc
ld
nlr
group
nlr
significantli
differ
ccecai
score
categori
p
nlr
neg
correl
total
protein
p
r
albumin
p
r
cholesterol
p
r
signific
correl
crp
nlr
found
nlr
differ
histolog
grade
dog
without
cd
contrarili
nlr
higher
dog
ld
p
valu
nlr
detect
ld
sensit
specif
far
first
report
evalu
nlr
ire
dog
result
suggest
nlr
could
easi
feasibl
econom
addit
tool
evalu
diseas
sever
ire
dog
moreov
nlr
seem
good
correl
essenti
biochemistri
paramet
evalu
dog
enteropathi
furthermor
interest
data
associ
nlr
histolog
lymphangectasia
disclosur
report
modul
oral
absorpt
therapeut
drug
small
intestin
mani
drug
serv
substrat
p
gp
includ
chemotherapeut
agent
vincristin
doxorubicin
parasiticid
macrocycl
lacton
antidiarrh
agent
loperamid
due
signific
influenc
drug
disposit
risk
sever
advers
drug
reaction
seen
defect
p
gp
function
routin
screen
drug
candid
transport
common
practic
human
drug
discoveri
howev
current
vitro
system
evalu
drug
transport
veterinari
medicin
avail
laboratori
recent
develop
ex
vivo
canin
enteroid
ent
system
accur
mimic
cellular
molecular
featur
intestin
epithelium
vivo
aim
research
evalu
function
activ
express
canin
ent
vs
intestin
tissu
express
assess
use
qpcr
intestin
tissu
ent
ileum
healthi
diseas
dog
immunofluoresc
stain
canin
ileal
ent
transwel
cultur
perform
assess
local
transport
function
assay
perform
use
fluoresc
dye
substrat
without
verapamil
inhibitor
use
compar
mean
lumin
fluoresc
intens
obtain
imagej
test
use
compar
mean
quantit
cycl
obtain
qpcr
p
consid
statist
signific
gene
express
significantli
differ
ent
epitheli
layer
intestin
mucosa
quantit
cycl
valu
express
mean
sd
organoid
ple
rw
hc
tissu
ple
rw
hc
p
confirm
ent
express
compar
amount
report
vivo
tissu
dog
cultur
primari
canin
ent
transwel
show
apic
express
consist
vivo
observ
verapamil
significantli
reduc
fluoresc
lumen
ent
min
p
min
p
indic
transport
success
block
summari
gene
express
local
function
canin
ent
similar
intestin
tissu
origin
deriv
novel
ent
model
serv
use
ex
vivo
system
oral
drug
transport
relat
safeti
studi
veterinari
medicin
disclosur
report
chronic
enteropathi
ce
common
caus
morbid
dog
chronic
enteropathi
diagnos
dog
chronic
gastrointestin
clinic
sign
week
inflammatori
chang
intestin
biopsi
underli
caus
determin
base
thorough
standardis
diagnost
workup
base
respons
therapi
ce
enteropathi
signific
proport
dog
ce
howev
limit
public
describ
clinic
efficaci
commerci
avail
food
use
treat
ce
studi
evalu
respons
dog
ce
commerci
avail
dietet
food
hill
prescript
diet
id
sensit
canin
dri
dog
underw
standard
diagnost
evalu
receiv
concurr
anthelmint
antibiot
glucocorticoid
gastroprotect
therapi
clinic
efficaci
dietari
treatment
assess
compar
canin
inflammatori
bowel
diseas
activ
index
cibdai
median
day
dietari
therapi
found
cibdai
significantli
decreas
follow
introduct
dietet
food
median
cibdai
score
pre
treatment
post
treatment
p
studi
demonstr
dietet
food
use
success
manag
ce
dog
disclosur
report
although
studi
fund
owner
got
food
hill
free
trial
dietari
fat
composit
shown
modul
fecal
microbiota
composit
impact
host
health
diet
link
reduc
fecal
microbi
divers
increas
firmicut
bacteroidet
ratio
system
lp
inflamm
diet
may
modul
fecal
microbiota
data
avail
impact
diet
canin
mucos
microbiota
aim
studi
investig
chang
composit
mucos
microbiota
serum
metabolom
beagl
dog
fed
two
ration
vari
content
dietari
fat
eight
healthi
adult
beagl
dog
fed
control
diet
fat
follow
diet
starch
contain
either
fat
fat
week
random
order
endoscop
biopsi
small
larg
intestin
sera
collect
analysi
mucos
microbiota
metabolom
profil
respect
dietari
intervent
fluoresc
situ
hybrid
fish
use
array
ie
total
bacteria
firmicut
clostridium
cluster
xiva
enterobacteriacea
quantifi
colon
mucos
bacteria
distinct
compart
serum
metabolom
profil
result
differ
diet
quantifi
target
approach
analyz
sampl
use
mass
spectrometri
biocrat
absoluteidq
hr
kit
metabolit
chang
diet
analyz
pca
hca
univari
statist
p
valu
consid
statist
signific
analysi
fish
show
mucos
bacteria
locat
within
adher
mucu
differ
total
number
spatial
distribut
bacteria
within
mucosa
dog
fed
control
diet
versu
differ
bacteri
group
clostridium
spp
significantli
p
increas
adher
mucu
dog
fed
versu
chang
mucos
bacteria
accompani
alter
serum
metabolom
dog
fed
either
perturb
lipid
metabol
predomin
primarili
involv
differ
glycerophospholipid
gpl
includ
phosphatidylcholin
pc
acylcarnitin
ac
gpl
significantli
p
reduc
dog
fed
compar
control
ration
convers
also
result
lower
p
concentr
lipid
metabolit
select
amino
acid
result
indic
enhanc
dietari
fat
modifi
mucos
microbiota
serum
metabolom
healthi
dog
consumpt
high
fat
diet
implic
canin
health
modul
host
immun
respons
associ
chang
gut
microbi
composit
disclosur
report
chronic
enteropathi
ce
common
caus
persist
recurr
gastrointestin
sign
dog
enteropathi
fre
enteropathi
enteropathi
ire
differ
etiolog
howev
clinic
sign
overlap
distinguish
among
disord
may
challeng
reliabl
diagnost
tool
repres
sequenti
treatment
use
diet
antimicrobi
immunosuppress
drug
analysi
erythrocyt
membran
lipidom
repres
power
tool
human
assess
quantiti
qualiti
fatti
acid
fa
membran
fa
remodel
physiolog
patholog
condit
aim
studi
compar
fa
membran
profil
healthi
dog
hd
n
dog
ce
ie
week
dog
receiv
dietari
supplement
exclud
studi
erythrocyt
membran
isol
blood
cluster
fa
satur
sfa
palmit
stearic
mufa
palmitol
oleic
vaccen
polyunsatur
linol
arachidon
eicosapentaeno
docosahexaeno
fa
determin
result
refer
one
fa
cluster
relev
lipid
paramet
sfamufa
sfapufa
pufa
balanc
unsatur
peroxid
index
calcul
hd
dog
male
neuter
femal
steril
median
age
month
ce
dog
male
femal
steril
median
age
month
among
ce
dog
diagnos
fre
ire
undergo
diagnost
trial
lost
diminish
valu
palmit
acid
p
increas
valu
stearic
acid
p
decreas
total
sfa
p
observ
ce
group
among
ce
dog
show
increas
valu
p
arachidon
p
acid
differ
observ
level
two
group
unsatur
p
peroxid
p
index
found
significantli
increas
ce
dog
interestingli
dog
fre
ire
dog
similar
erythrocyt
membran
lipidom
profil
object
statist
analysi
due
low
number
dog
group
result
point
import
balanc
arachidon
acid
acid
level
inflammatori
condit
ce
erythrocyt
membran
lipidom
dog
may
success
appli
dog
ce
provid
import
inform
lead
person
intervent
target
decreas
inflamm
increas
protect
compon
disclosur
report
serum
cobalamin
concentr
frequent
assess
companion
anim
especi
face
patient
chronic
gastrointestin
sign
although
clinician
attent
mainli
focus
patient
hypocobalaminaemia
recent
studi
human
cat
suggest
high
serum
cobalamin
concentr
could
associ
specif
condit
neoplasia
liver
diseas
addit
may
marker
sever
aim
retrospect
studi
therefor
identifi
condit
associ
hypercobalaminaemia
dog
determin
whether
could
use
marker
diseas
sever
patient
medic
record
dog
serum
cobalamin
measur
novemb
decemb
practic
unit
kingdom
review
dog
exclud
receiv
cobalamin
supplement
time
prior
analysi
signal
clinic
sign
laboratori
imag
find
record
case
case
classifi
differ
diseas
categori
consensu
depend
final
diagnosi
valu
express
percentag
median
variabl
compar
group
use
fischer
exact
test
one
dog
includ
studi
divid
three
group
hypocobalaminaemia
dog
normal
serum
cobalamin
concentr
dog
hypercobalaminaemia
dog
age
distribut
significantli
differ
group
p
hypercobalaminaem
dog
significantli
younger
median
age
month
rang
dog
hypercobalaminaemia
present
diarrhoea
vomit
inappet
lethargi
andor
weight
loss
significantli
differ
group
condit
associ
hypercobalaminaemia
includ
gastrointestin
hepat
neurolog
endocrin
renal
pancreat
miscellan
diseas
among
neoplasia
distribut
significantli
differ
hypocobalaminaem
normocobalaminaem
dog
significantli
dog
high
serum
folat
concentr
hypercobalaminaemia
group
compar
group
p
dog
hypoalbuminaemia
anaemia
high
alt
activ
andor
hypocholesterolaemia
also
compar
three
cobalamin
group
statist
differ
identifi
associ
found
hypercobalaminaemia
paramet
test
diseas
sever
result
suggest
hypercobalaminaemia
dog
commonli
seen
gastrointestin
hepat
diseas
speci
also
seen
endocrin
neurolog
condit
interestingli
hyperfolataemia
commonli
seen
hypercobalaminaemia
unknown
whether
reflect
activ
dysbiosi
disclosur
report
vivo
studi
physiolog
gastrointestin
tract
git
live
anim
meet
seriou
technic
difficulti
ethic
question
therefor
much
attent
given
recent
year
develop
vitro
model
mimic
metabol
process
git
aim
present
work
valid
scime
simul
canin
intestin
microbiom
shime
model
simul
human
intestin
microbiom
ecosystem
consid
physiolog
paramet
dog
differ
diet
differ
microbiolog
popul
compar
vivo
microbi
popul
faecal
sampl
donor
dog
fresh
faec
collect
four
healthi
dog
inocul
scime
system
experi
last
day
conduct
duplic
give
two
differ
type
feed
donor
model
valid
evalu
analysi
microbi
activ
quantif
scfa
lactat
ammonium
composit
colon
microbiota
studi
qpcr
use
primer
target
firmicut
bacteroidet
bifidobacteria
lactobacilli
enterobacteriacea
illumin
sequenc
total
bacteri
popul
differ
effect
composit
canin
intestin
microflora
experi
time
promot
among
firmicut
result
obtain
highlight
abil
signific
increas
p
amount
acidaminococcacea
otu
lumen
level
enterococcacea
p
bacteroidet
display
decreas
p
speci
belong
famili
bacteroidacea
otu
lumen
level
addit
signific
growth
p
famili
coriobacteriacae
akkermansiacea
famili
otu
lumen
level
absent
inoculum
littl
increas
experi
enterobacteriacea
otu
record
signific
increas
p
interest
result
regard
scfa
promot
signific
increas
p
concentr
especi
amount
butyr
averag
mmoll
acet
averag
mmoll
branch
fatti
acid
averag
mmoll
final
studi
highlight
abil
scime
model
increas
also
ammonium
level
show
averag
concentr
mgl
proxim
colon
mgl
distal
colon
follow
novel
model
allow
growth
bacteria
present
origin
inoculum
offer
relev
technolog
platform
simul
intestin
ecosystem
evalu
pharmaceut
nutraceut
effect
dog
microbiota
disclosur
report
inflammatori
bowel
diseas
ibd
common
caus
chronic
gastrointestin
diseas
dog
current
paradigm
ibd
involv
complex
interact
environment
factor
intestin
microbiota
dysregul
host
respons
receptor
tlr
recogn
bacteri
molecular
pattern
pamp
previou
studi
mrna
report
inflam
duoden
colon
mucosa
ibd
dog
compar
asymptomat
healthi
beagl
aim
studi
evalu
express
receptor
immunohistochemistri
colon
biopsi
isol
dog
ibd
compar
asymptomat
control
ten
dog
ibd
includ
studi
diagnosi
base
clinic
sign
least
week
durat
presenc
lymphocyt
plasmacyt
andor
eosinophil
inflamm
colon
biopsi
exclus
caus
chronic
gastrointestin
sign
nine
dog
includ
control
group
colon
biopsi
process
immunohistochemistri
use
antibodi
express
tlr
differ
sampl
grade
express
strong
express
pathologist
blind
fashion
detect
epitheli
cell
lamina
propria
cell
contrast
detect
epitheli
cell
stain
restrict
leucocyt
lamina
propria
statist
differ
found
tlr
express
compar
ibd
dog
asymptomat
dog
although
epitheli
express
tend
higher
ibd
group
p
knowledg
studi
describ
first
time
pattern
express
colon
dog
suggest
express
poorli
affect
ibd
experi
warrant
larger
number
patient
intestin
segment
duodenum
ileum
analyz
whether
epitheli
express
might
correl
clinic
activ
histopatholog
score
disclosur
report
work
fund
hill
pet
nutrit
acut
chronic
pancreat
human
result
significantli
lower
level
serum
vitamin
vitamin
e
due
antioxid
stress
part
inflammatori
respons
knowledg
studi
vitamin
e
level
serum
dog
pancreat
perform
far
aim
retrospect
studi
evalu
level
serum
vitamin
e
routin
diagnost
sampl
dog
pancreat
compar
control
group
dog
diseas
dog
pancreat
includ
studi
dog
serum
pancreat
lipas
concentr
clinic
symptom
pancreat
like
vomit
abdomin
pain
inappet
receiv
medic
treatment
far
addit
dog
pancreat
diagnos
histolog
pancreat
tissu
biopsi
dog
control
group
serum
pancreat
lipas
valu
clinic
symptom
concurr
diseas
pancreat
serum
vitamin
e
level
measur
hplc
cool
serum
within
hour
sampl
dog
pancreat
significantli
higher
p
level
serum
vitamin
averag
rang
dog
control
group
averag
rang
studi
dog
also
significantli
higher
p
serum
vitamin
e
level
averag
rang
control
group
averag
rang
studi
suggest
dog
pancreat
differ
metabol
vitamin
e
compar
dog
diseas
human
pancreat
cours
pancreat
releas
vitamin
e
blood
stream
due
necrot
process
tissu
may
discuss
speci
disclosur
report
author
employe
commer
laboratori
laboklin
studi
financ
laboklin
endoscopi
gastrointestin
tract
often
part
diagnost
protocol
canin
acut
chronic
gastroenteropathi
analyz
properli
intestin
wall
fundament
distend
lumen
usual
inflat
air
human
medicin
well
known
ga
insuffl
gi
air
carbon
dioxid
colonscopi
induc
pain
patient
frequent
use
touch
water
instead
air
distend
lumen
random
control
trial
suggest
introduct
water
distend
lumen
colon
decreas
spasm
musculatur
bowel
pain
significantli
increas
visual
mucos
textur
adenoma
detect
rate
studi
first
veterinari
medicin
compar
gi
water
immers
wi
duodenoscopi
anesthet
dog
order
evalu
eventu
differ
procedur
nocicept
qualiti
mucos
visual
dog
subject
endoscopi
gener
anesthesia
includ
studi
evalu
differ
nocicept
anesthesia
heart
rate
arteri
blood
pressur
sistol
diastol
mean
measur
throughout
procedur
divid
four
step
baselin
water
air
outcom
random
sequenc
gi
wi
appli
dilat
duoden
lumen
everi
condit
mucos
imag
bowel
record
everi
dog
two
imag
gi
wi
record
subject
textur
analysi
use
imag
process
approach
like
skeleton
entropi
evalu
subject
blind
evalu
three
expert
endoscopist
consid
architectur
intestin
textur
systemat
signific
differ
detect
cardiovascular
paramet
textur
analysi
gi
wi
except
subject
evalu
endoscopist
identifi
wi
imag
qualit
better
result
studi
highlight
algic
answer
chang
two
method
mayb
influenc
drug
use
endoscopi
well
control
nocicept
give
deep
anesthesia
base
evalu
endoscopist
wi
allow
get
better
qualiti
imag
detail
visual
intestin
villi
still
confirm
object
textur
analysi
disclosur
report
hemodynam
chang
associ
mitral
valv
degener
mvd
activ
neurohumor
mechan
maintain
adequ
cardiac
output
capillari
perfus
pressur
predomin
sympathet
andor
diminish
vagal
tone
link
diseas
progress
scarc
inform
autonom
nervou
system
an
dynam
mvd
progress
avail
veterinari
literatur
knowledg
an
imbal
dog
mvd
prior
receiv
cardiac
pharmacotherapi
evalu
sought
analyz
heart
rate
variabl
hrv
assess
an
activ
dog
preclin
yet
untreat
clinic
mvd
dog
echocardiograph
confirm
mvd
retrospect
divid
three
group
accord
acvim
consensu
statement
n
n
c
n
control
group
label
n
n
includ
healthi
normal
dog
dog
receiv
physic
examin
electrocardiographi
ecg
complet
echocardiographi
thorac
radiographi
bloodwork
heart
rate
variabl
evalu
use
time
frequenc
domain
ecg
record
signific
decreas
time
domain
paramet
shown
group
c
compar
group
n
paramet
includ
sd
normal
interv
sdnn
p
squar
success
differ
normal
heartbeat
rmssd
p
percentag
adjac
normal
interv
differ
ms
p
addit
signific
increas
lf
p
decreas
hf
p
band
observ
group
c
compar
group
n
lfhf
ratio
significantli
increas
group
c
p
rel
group
group
compar
sdnn
show
significantli
lower
valu
p
studi
show
dog
aclin
mvd
sympathet
parasympathet
tone
might
remain
unchang
clinic
sign
develop
despit
presenc
structur
remodel
onset
clinic
sign
like
trigger
an
imbal
due
sympathet
tone
activ
vagal
tone
withdraw
moreov
sdnn
independ
marker
risk
mortal
may
paramet
abl
distinguish
aclin
dog
without
cardiomegali
find
may
futur
implic
regard
choic
made
around
best
time
pharmacotherapi
onset
well
around
effect
order
ad
specif
medic
pharmacotherapi
regimen
administ
dog
mvd
disclosur
report
therapeut
monitor
serum
digoxin
level
avoid
digoxin
intox
perform
least
day
begin
therapi
lab
discourag
use
blood
collect
tube
contain
gel
potenti
absorpt
digoxin
gel
result
underestim
serum
digoxin
concentr
aim
studi
compar
serum
digoxin
concentr
blood
collect
serum
tube
without
gel
blood
sampl
taken
syring
needl
jugular
vein
dog
treat
digoxin
dog
half
blood
sampl
put
tube
contain
gel
ngc
vacutain
z
half
sampl
put
gel
contain
gc
tube
bd
stt
ii
advanc
ngc
tube
sent
referr
lab
synlab
belgium
immedi
analysi
gc
tube
kept
uncentrifug
refriger
day
analysi
perform
analys
carri
lab
use
architect
ci
system
abbott
diagnost
us
median
digoxin
concentr
quartil
ngc
tube
gc
tube
agreement
two
method
shown
mean
bia
narrow
rang
agreement
lower
level
agreement
upper
level
agreement
mean
bia
exceed
method
qualiti
specif
total
allow
error
plot
data
show
signific
differ
data
set
serum
digoxin
concentr
decreas
collect
tube
contain
gel
kept
refriger
day
analysi
blood
collect
serum
tube
contain
gel
use
therapeut
monitor
serum
digoxin
level
disclosur
report
right
ventricular
rv
strain
analysi
use
speckl
track
echocardiographi
focus
assess
longitudin
strain
strain
rate
variabl
dog
howev
rv
contract
also
character
transvers
deform
strain
compon
investig
dog
therefor
evalu
abil
transvers
rv
strain
strain
rate
obtain
speckl
track
echocardiographi
healthi
dog
dog
pulmonari
hypertens
identifi
dog
pulmonari
hypertens
addit
examin
relationship
transvers
strain
strain
rate
variabl
heart
rate
age
bodyweight
healthi
dog
tricuspid
regurgit
tr
veloc
left
atrial
size
dog
pulmonari
hypertens
acquir
echocardiograph
cineloop
left
apic
view
optim
right
ventricl
analyz
transvers
rv
free
wall
strain
strain
rate
dog
healthi
dog
dog
pulmonari
hypertens
use
softwar
dog
classifi
pulmonari
hypertens
base
tr
jet
veloc
msec
classifi
dog
moder
pulmonari
hypertens
tr
veloc
msec
sever
pulmonari
hypertens
tr
veloc
msec
seven
dog
healthi
dog
pulmonari
hypertens
exclud
analysi
low
qualiti
imag
healthi
dog
strain
strain
rate
show
relationship
heart
rate
bodi
weight
age
dog
pulmonari
hypertens
strain
strain
rate
show
weak
neg
relationship
tr
veloc
relationship
left
atrial
size
although
transvers
rv
strain
strain
rate
show
neg
relationship
class
pulmonari
hypertens
use
identifi
dog
pulmonari
hypertens
transvers
rv
strain
strain
rate
use
speckl
track
echocardiographi
obtain
dog
help
identifi
dog
pulmonari
hypertens
disclosur
report
blockad
system
pivot
strategi
manag
congest
heart
failur
chf
blocker
arb
perceiv
offer
complet
neurohormon
suppress
treatment
chf
directli
occupi
angiotensin
ii
receptor
site
howev
whether
combin
therapi
arb
current
chf
treatment
clinic
increment
benefit
unknown
dog
myxomat
mitral
valv
diseas
mmvd
retrospect
cohort
studi
conduct
dog
symptomat
mmvd
treat
standard
protocol
control
n
addit
arb
case
n
irbesartan
mgkgday
n
telmisartan
mgkgday
n
convent
treatment
initi
analysi
homogen
two
group
physic
examin
comprehens
blood
test
profil
cbc
serum
biochemistri
sdma
radiograph
echocardiograph
data
collect
subsequ
clinic
indic
compar
time
point
arb
given
three
six
month
addit
surviv
analysi
also
perform
use
curv
month
treatment
degre
increas
clinic
paramet
relat
renal
function
significantli
higher
control
case
group
p
bun
vs
creatinin
vs
sdma
vs
sodium
level
vs
differ
heart
rate
vs
blood
pressur
vs
baselin
significantli
lower
case
group
p
furthermor
increas
level
vs
also
greater
control
p
howev
statist
differ
found
thorac
radiograph
echocardiograph
indic
group
compar
surviv
curv
two
group
reveal
overal
surviv
advantag
arb
treatment
result
suggest
arb
combin
ongo
convent
chf
treatment
may
provid
addit
renoprotect
effect
dog
mmvd
disclosur
report
insert
arteri
cathet
essenti
open
heart
surgeri
femor
arteri
one
commonli
use
arteri
open
heart
surgeri
dog
although
peripher
arteri
dorsali
pedi
use
veterinari
medicin
recent
year
littl
known
use
open
heart
surgeri
dog
therefor
compar
convent
manag
via
femor
arteri
retrospect
review
case
involv
mitral
valv
repair
cardiopulmonari
bypass
septemb
novemb
compar
success
cathet
placement
cathet
insert
remov
time
advers
event
oper
time
femor
peripher
arteri
studi
includ
dog
five
underw
cathet
insert
femor
arteri
group
f
either
dorsali
pedi
n
caudali
median
n
peripher
arteri
group
p
group
f
requir
median
min
rang
min
cathet
insert
median
min
rang
min
cathet
remov
three
dog
group
f
bled
heparin
infus
surgeri
bleed
group
p
puls
palpabl
immedi
surgeri
good
pressur
waveform
obtain
periop
period
blood
collect
unev
advers
event
surgeri
group
oper
time
differ
significantli
two
group
result
suggest
periop
manag
peripher
arteri
open
heart
surgeri
effect
safe
disclosur
report
critic
hill
patient
acut
congest
heart
failur
chf
may
often
show
haemoconcentr
dysnatremia
dyskalemia
increas
azotemia
due
aggress
diuret
therapi
haemoconcentr
associ
lower
risk
mortal
dysnatremia
dyskalemia
associ
higher
mortal
human
medicin
aim
studi
retrospect
evalu
impact
diuret
therapi
chf
select
laboratori
paramet
mortal
dog
clinic
radiolog
evid
chf
confirm
echocardiographi
includ
blood
sampl
collect
throughout
hospit
present
discharg
venou
blood
ga
analysi
vbga
serum
creatinin
scr
blood
urea
nitrogen
bun
microhematocrit
htc
total
protein
tp
length
hospit
stay
acvim
class
clinic
indic
record
haemoconcentr
defin
simultan
increas
htc
total
protein
total
dog
male
femal
mean
age
year
mean
weight
kg
includ
dog
previou
episod
chf
mean
length
stay
hour
treatment
protocol
includ
singl
furosemid
endoven
bolu
mgkg
follow
multipl
mgkg
bolushour
respiratori
rate
reach
rate
dog
receiv
mgkg
mgkg
furosemid
hour
respect
ten
dog
receiv
higher
furosemid
dose
torasemid
bolu
haemoconcentr
reach
dog
consid
vbga
biochemistri
result
number
dog
show
valu
respect
hyponatremia
hypernatremia
hypokalemia
hyperkalemia
hypocloremia
increas
bun
increas
scr
dog
experienc
cardiac
death
hospit
remain
dog
day
admiss
stepwis
backward
regress
demonstr
haemoconcentr
hr
disnatremia
hr
influenc
outcom
statist
signific
correl
pearson
seen
furosemid
dose
kalemia
r
p
bun
scr
r
p
correl
seen
furosemid
dose
variabl
scr
bun
htc
scr
htc
conclus
haemoconcentr
disnatremia
affect
outcom
dog
chf
haemoconcentr
associ
lower
risk
mortal
consid
target
chf
therapi
diuret
therapi
increas
electrolyt
disord
due
loop
diuret
inhibit
renal
na
k
cl
cotransport
henl
loop
disnatremia
risk
factor
advers
outcom
diuret
dose
haemoconcentr
nt
play
direct
role
induc
renal
disfunct
disclosur
report
heart
failur
caus
haemostat
complic
due
platelet
activ
human
veterinari
medicin
especi
cat
hypertroph
cardiomyopathi
enough
inform
molecular
relationship
hemostasi
cardiovascular
diseas
dog
thu
studi
aim
elabor
hemostasi
coagul
chang
platelet
proteom
profil
dog
natur
occur
heart
failur
materi
studi
consist
total
dog
differ
breed
age
sex
two
differ
group
design
control
n
test
group
n
base
physic
laboratori
cardiolog
examin
result
dog
includ
control
healthi
group
dog
stage
c
heart
failur
accord
acvim
classif
enrol
test
group
platelet
isol
perform
dog
platelet
pellet
store
c
analys
platelet
proteom
identifi
use
esiqtofm
method
global
clot
time
pt
aptt
measur
well
platelet
proteom
n
match
previous
describ
protein
cani
lupu
familiali
compar
control
least
p
level
chang
proteom
n
consid
statist
signific
compar
control
group
platelet
proteom
guanin
protein
subunit
apolipoprotein
apolipoprotein
clusterin
level
increas
wherea
serinethreonin
protein
phosphatas
catalyt
subunit
creatin
kinas
myotrophin
level
decreas
testgroup
pt
aptt
valu
test
group
longer
control
valu
p
result
platelet
protein
identifi
present
studi
could
potenti
biomark
diagnosi
heart
failur
therefor
protein
need
valid
field
studi
also
proteom
provid
detail
inform
heart
failur
process
disclosur
report
low
serum
oh
associ
cardiovascular
cv
diseas
peopl
dog
aim
determin
oh
metabolit
oh
lower
cat
cardiomyopathi
cm
vs
normal
cat
associ
certain
clinic
variabl
exist
cm
cat
n
enrol
patient
veterinari
medic
center
iowa
state
isu
tuft
univers
cm
cat
congest
heart
failur
exclus
criteria
includ
hypertens
hyperthyroid
clinic
relev
system
includ
kidney
diseas
normal
cat
n
recruit
isu
cm
cat
although
normal
cat
ultim
enrol
cat
eat
commerci
cat
food
cv
exam
blood
pressur
echocardiograph
data
collect
collect
serum
frozen
analyz
oh
posit
correl
correl
coeffici
p
howev
neither
significantli
differ
cm
group
pair
wilcoxson
linear
regress
analysi
assess
impact
cm
statu
age
sex
among
enrol
cat
show
age
signific
oh
p
statist
model
includ
variabl
confound
multicollinear
therefor
simpl
linear
regress
test
relationship
vitamin
statu
clinic
variabl
signific
relationship
found
oh
age
surviv
time
azotemia
categori
left
atrial
enlarg
left
ventricular
fraction
shorten
fs
account
age
fs
surviv
time
remain
signific
oh
conclud
vitamin
statu
cat
significantli
associ
cm
disclosur
report
desmin
intermedi
filament
cardiomyocyt
critic
maintain
architectur
mechan
integr
contract
cell
aggreg
desmin
impair
protein
qualiti
control
system
includ
heat
shock
protein
hsp
govern
correct
protein
fold
report
human
rodent
model
hypertroph
cardiomyopathi
hcm
incorrect
fold
desmin
lead
aberr
accumul
within
cardiomyocyt
studi
aim
characteris
express
localis
desmin
chaperon
hsp
felin
hcm
residu
left
ventricular
lv
tissu
necropsi
normal
hcm
cat
use
immunoblot
desmin
normalis
gapdh
fluoresc
immunohistochemistri
perform
transvers
section
lv
anoth
normal
hcm
cat
minimum
imag
captur
magnif
longitudin
transvers
use
fluoresc
quantif
protein
localis
diagnos
made
histopatholog
clinic
assess
u
test
spearman
rho
test
use
result
express
median
rang
immunoblot
one
control
record
age
yr
control
document
young
adult
median
age
hcm
cat
yr
protein
level
desmin
control
hcm
group
p
protein
level
control
hcm
group
p
protein
express
desmin
highli
correl
r
p
immunohistochemistri
median
age
yr
control
cat
hcm
group
p
control
desmin
appear
stripe
intercal
disc
scarc
amount
perinuclear
aggreg
observ
cardiomyocyt
close
epicardium
hcm
cat
dissoci
desmin
intercal
disc
frequent
find
clump
aggreg
seen
transvers
section
cardiomyocyt
limit
peripheri
epicardium
averag
mean
intens
fluoresc
hcm
group
control
group
p
hcm
cat
desmin
structur
disorganis
might
compromis
integr
contractil
apparatu
presenc
desmin
aggreg
suggest
protein
qualiti
control
measur
fail
restor
proteostasi
hcm
affect
heart
despit
correspond
increas
chaperon
protein
disclosur
report
atrial
fibril
af
common
canin
supraventricular
arrhythmia
usual
observ
larg
breed
dog
cardiac
diseas
associ
left
atrial
enlarg
although
epidemiolog
data
risk
factor
af
report
studi
thoroughli
examin
preval
risk
factor
arrhythmia
dog
myxomat
mitral
valv
diseas
mmvd
aim
studi
estim
preval
af
larg
popul
dog
mmvd
identifi
risk
factor
af
develop
anim
medic
databas
three
veterinari
teach
hospit
retrospect
review
inclus
criteria
diagnosi
mmvd
complet
cardiovascular
assess
ie
physic
examin
thorac
radiographi
echocardiographi
cardiac
rhythm
assess
via
routin
minut
ecg
andor
good
qualiti
ecg
trace
echocardiograph
examin
least
minut
durat
dog
multipl
examin
observ
period
data
recent
exam
consid
select
clinic
echocardiograph
paramet
compar
use
univari
differ
multivari
logist
regress
model
total
dog
enrol
includ
dog
acvim
stage
c
respect
pulmonari
hypertens
ph
diagnos
dog
atrial
fibril
diagnos
dog
preval
univari
analys
show
mix
breed
male
gender
decompens
acvim
stage
left
atrial
ratio
laao
normal
left
ventricular
diastol
diamet
presenc
ph
significantli
associ
develop
af
also
continu
variabl
la
bodi
weight
bw
fraction
shorten
fs
veloc
e
wave
significantli
differ
p
af
case
evalu
autocorrel
andor
interact
predictor
two
multivari
model
obtain
laao
odd
ratio
bw
fs
la
decompens
acvim
stage
fs
signific
predictor
af
model
respect
la
cm
sensit
specif
predict
develop
af
atrial
fibril
uncommon
complic
canin
mmvd
significantli
associ
advanc
stage
diseas
increas
la
dimens
bw
decreas
systol
function
associ
develop
af
dog
mmvd
disclosur
report
degen
mitral
valv
diseas
dmvd
common
acquir
heart
diseas
dog
high
predisposit
cavali
king
charl
spaniel
ckc
breed
echocardiograph
assess
diseas
base
evalu
atrial
ventricular
dimens
left
atrial
la
diamet
measur
one
strongest
predictor
clinic
outcom
la
diamet
usual
evalu
right
parastern
transaort
view
compar
aortic
ao
diamet
la
ao
ratio
howev
la
dilat
develop
direct
therefor
la
ao
ratio
may
reliabl
earli
detect
la
dilat
measur
la
volum
recent
recommend
dog
use
monoplan
biplan
simpson
modifi
method
disc
smod
method
alm
object
prospect
studi
therefor
compar
differ
echocardiograph
method
evalu
la
volum
larg
popul
ckc
assess
la
volum
accord
dmvd
sever
studi
popul
consist
ckc
either
healthi
affect
dmvd
median
weight
kg
interquartil
rang
iqr
ratio
accord
acvim
classif
dog
identifi
dmvd
lesion
stage
stage
respect
past
current
congest
heart
failur
chf
stage
c
refractori
chf
stage
dog
mitral
regurgit
mr
adequ
quantif
proxim
isoveloc
surfac
area
method
n
median
regurgit
fraction
rf
monoplan
smod
alm
use
left
apic
view
overestim
la
volum
comparison
biplan
alm
respect
monoplan
alm
overestim
la
volum
comparison
monoplan
smod
left
atrial
volum
significantli
increas
acvim
stage
among
dog
la
volum
assess
biplan
alm
significantli
lower
dog
mild
mr
rf
median
volum
mlkg
iqr
dog
higher
mr
median
volum
mlkg
iqr
p
conclus
studi
demonstr
import
la
volum
measur
ckc
dmvd
especi
among
dmvd
dog
result
suggest
categori
dog
rf
actual
show
la
dilat
howev
appar
use
la
ao
ratio
calcul
thu
potenti
lead
misdiagnosi
dmvd
stage
disclosur
report
fondat
un
coeurvetoquinol
sponsor
clinic
research
assist
posit
alfort
cardiolog
unit
intravascular
hemolysi
identifi
human
patient
moder
sever
aortic
stenosi
underli
mechan
impli
shear
stress
exert
erythrocyt
high
veloc
flow
stenot
orific
similar
data
current
avail
veterinari
medicin
aim
prospect
studi
therefor
document
hematolog
abnorm
dog
arteri
stenosi
ie
aortic
stenosi
pulmon
stenosi
ps
evalu
maxim
mean
pressur
gradient
well
featur
stenot
lesion
number
locat
associ
erythrocyt
abnorm
studi
sampl
consist
dog
median
age
year
interquartil
rang
iqr
year
ratio
commonli
recruit
breed
french
bulldog
n
white
swiss
shepherd
n
english
bulldog
n
boxer
n
golden
retriev
n
chihuahua
n
breed
n
among
studi
popul
dog
ps
median
maxim
valu
mmhg
mmhg
mmhg
iqr
mmhg
ps
respect
includ
dog
show
obstruct
lesion
subvalvular
stenosi
dog
ps
valvular
stenosi
dog
ps
supravalvular
stenosi
dog
ps
hematolog
abnorm
detect
dog
n
schizocyt
found
dog
median
proport
cell
iqr
acanthocyt
dog
median
proport
cell
iqr
hemolyt
anemia
dog
ps
hemoglobinemia
gdl
signific
associ
identifi
abnorm
echocardiograph
paramet
three
dog
hemolyt
anemia
maxim
mmhg
mmhg
interestingli
dog
highest
maxim
also
sever
anemia
schizocytosi
abnorm
decreas
resolv
balloon
valvuloplasti
conclus
result
show
red
blood
cell
abnorm
acanthocytosi
schizocytosi
common
dog
congenit
arteri
stenosi
thu
suggest
turbul
blood
flow
stenot
orific
induc
mechan
erythrocyt
damag
prospect
studi
need
better
document
find
elucid
precis
mechan
red
cell
damag
use
hematolyt
marker
eg
lactat
dehydrogenas
hemosiderinuria
etc
perform
human
patient
disclosur
report
torasemid
loop
diuret
whose
safeti
efficaci
demonstr
dog
congest
heart
failur
chf
torasemid
character
longer
durat
action
potent
diuret
action
higher
bioavail
furosemid
howev
best
knowledg
studi
focus
efficaci
safeti
torasemid
cat
chf
object
retrospect
studi
therefor
describ
clinic
echocardiograph
characterist
document
clinic
outcom
cat
chf
treat
oral
torasemid
identifi
potenti
advers
event
relat
torasemid
administr
felin
popul
case
record
cat
treat
torasemid
review
studi
popul
consist
cat
median
age
year
interquartil
rang
iqr
ratio
major
domest
shorthair
cat
cat
present
dyspnea
relat
chf
pleural
effus
pulmonari
edema
associ
ascit
cat
caus
chf
determin
cat
echocardiographi
hypertroph
restrict
dilat
arrhythmogen
right
ventricular
cardiomyopathi
aortic
valv
congenit
abnorm
left
atrium
la
dilat
cat
median
iqr
normal
valu
median
torasemid
dosag
initi
mgkgday
iqr
avail
cat
torasemid
dosag
increas
cat
due
persist
chf
sign
median
time
treatment
initi
dosag
chang
day
median
dosag
mgkgday
addit
furosemid
ad
hour
torasemid
intak
cat
median
time
treatment
initi
furosemid
initi
day
median
dosag
mgkgday
treatment
includ
benazepril
pimobendan
clopidogrel
aspirin
spironolacton
regress
clinic
sign
observ
cat
remark
advers
event
death
report
cat
euthan
result
chf
worsen
n
aortic
thromboembol
n
death
relat
chf
cat
median
surviv
time
torasemid
prescript
day
conclus
best
knowledg
first
descript
torasemid
use
cat
chf
drug
well
toler
case
case
seri
illustr
therapeut
interest
torasemid
cat
need
confirm
prospect
clinic
trial
disclosur
report
fondat
un
coeurvetoquinol
sponsor
clinic
research
assist
posit
alfort
cardiolog
unit
torasemid
loop
diuret
use
dog
congest
heart
failur
chf
altern
furosemid
studi
compar
furosemid
torasemid
dog
refractori
chf
spars
medic
databas
teach
hospit
review
search
dog
myxomat
mitral
valv
diseas
experienc
chf
receiv
torasemid
second
line
diuret
treatment
failur
furosemid
studi
group
dog
clinic
echocardiograph
radiograph
laboratori
find
annot
surviv
time
also
report
calcul
first
episod
chf
control
group
dog
dog
similar
cardiac
diseas
never
receiv
torasemid
also
select
data
collect
time
first
chf
first
examin
concomit
last
examin
avail
sex
distribut
equal
two
group
p
group
mix
breed
overrepres
besid
furosemid
torasemid
medic
use
control
cardiac
diseas
compar
admiss
differ
group
regard
age
p
bodi
weight
p
left
ventricular
diastol
intern
diamet
normal
bodi
weight
lviddn
p
left
atrial
aortic
ratio
la
ao
p
tricuspid
regurgit
peak
veloc
p
creatinin
p
potassium
p
serum
level
differ
preval
atrial
fibril
group
p
overal
number
decompens
experienc
dog
higher
studi
group
compar
control
group
p
last
examin
la
ao
higher
studi
group
compar
control
p
total
maxim
dose
furosemid
mgkgday
studi
group
mgkgday
control
group
p
initi
dose
torasemid
use
mgkgday
compar
first
last
examin
within
two
group
bodi
weight
reduc
studi
group
p
la
ao
p
creatinin
p
increas
number
decompens
record
torasemid
initi
reduc
significantli
p
within
control
group
creatinin
increas
p
dog
die
cardiac
relat
caus
differ
surviv
two
group
p
median
surviv
day
studi
group
day
control
group
torasemid
appear
effect
second
line
diuret
chf
control
dog
myxomat
mitral
valv
diseas
offer
life
expect
compar
superior
furosemid
alon
disclosur
report
atrial
fibril
af
occur
dog
myxomat
mitral
valv
diseas
mmvd
consequ
left
atrial
la
dilat
predict
occurr
might
benefici
consequ
retrospect
studi
evalu
use
echocardiographi
predict
first
occurr
af
dog
mmvd
medic
databas
two
veterinari
teach
hospit
review
search
dog
mmvd
develop
af
follow
year
studi
group
last
echocardiograph
examin
obtain
sinu
rhythm
use
deriv
select
variabl
use
success
statist
comparison
dog
af
control
dog
match
bodi
weight
bw
class
heart
failur
la
dimens
express
ratio
la
aortic
diamet
la
ao
never
develop
af
compar
follow
period
select
echocardiograph
exam
review
singl
board
certifi
cardiologist
sever
variabl
lv
la
dimens
function
la
volum
obtain
particular
lv
intern
diamet
diastol
systol
obtain
absolut
valu
index
bw
la
dimens
express
absolut
valu
la
ao
moreov
la
volum
measur
maxim
minim
la
expans
peak
p
wave
index
bw
sever
index
la
function
calcul
volum
peak
e
wave
veloc
e
ratio
wave
durat
also
measur
la
speckl
track
echocardiographi
ste
carri
peak
atrial
longitudin
strain
pal
peak
atrial
contract
strain
contract
strain
index
measur
dog
mmvd
includ
dog
develop
af
dog
maintain
sinu
rhythm
differ
term
bw
p
sex
distribut
p
class
heart
failur
p
among
test
echocardiograph
variabl
la
diamet
p
lv
intern
diamet
diastol
index
bw
p
differ
significantli
group
differ
term
la
ao
p
lv
intern
diamet
diastol
systol
index
bw
p
p
respect
la
volum
function
paramet
among
variabl
pal
valu
differ
significantli
af
group
mean
valu
control
group
mean
valu
p
absolut
cardiac
dimens
well
la
ste
particular
pal
use
echocardiograph
predictor
develop
af
dog
mmvd
disclosur
report
lorenz
plot
lp
represent
heart
rate
variabl
summar
graphic
interv
record
holter
monitor
hm
use
lp
pattern
lpp
diagnos
rhythm
disturb
studi
peopl
littl
known
anim
aim
studi
analyz
graphic
featur
lp
evalu
diagnost
valu
lpp
identifi
arrhythmia
dog
hm
hour
valid
data
obtain
dog
sinu
rhythm
sr
differ
type
tachyarrhythmia
use
one
oper
blind
underli
rhythm
diagnosi
review
autom
analys
order
assess
hm
qualiti
manual
correct
softwar
misinterpret
make
rhythm
diagnosi
cardiac
rhythm
classifi
sr
sr
frequent
prematur
ectop
complex
sr
pec
either
supraventricular
ventricular
atrial
fibril
af
af
frequent
ventricular
prematur
complex
af
vpc
hm
lp
gener
softwar
use
rr
interv
lp
studi
qualit
quantit
distinct
lpp
creat
adapt
previous
recogn
pattern
human
diagnost
accuraci
lp
analysi
predict
underli
cardiac
rhythm
evalu
calcul
correspond
sensit
se
specif
sp
one
hundr
nineteen
hm
analyz
includ
sr
sr
pec
af
af
vpc
ten
distinct
lpp
identifi
comet
case
torpedo
case
case
diamond
case
diamond
central
silent
zone
case
combin
one
pattern
doubl
dsl
case
tripl
case
quadrupl
case
fan
case
fan
dsl
case
pool
togeth
singl
normal
pattern
comet
torpedo
diamond
predict
presenc
sr
se
sp
respect
two
lp
diamond
pattern
holter
diagnosi
sr
pec
dsl
pattern
indic
presenc
sr
pec
se
sp
respect
tripl
quadrupl
side
lobe
pattern
exclus
associ
sr
vpc
fan
configur
consid
togeth
fan
fan
dsl
pattern
indic
af
se
sp
three
case
fan
dsl
associ
af
vpc
conclus
differ
cardiac
rhythm
associ
peculiar
lpp
analysi
hold
relev
diagnost
valu
dog
sr
andor
tachyarrhythmia
disclosur
report
lorenz
plot
lp
gener
continu
electrocardiograph
ecg
record
provid
visual
represent
rhythm
pattern
studi
sought
character
lp
pattern
common
rhythm
dog
twenti
holter
record
free
patholog
arrhythmia
ten
record
supraventricular
prematur
complex
spvc
complex
supraventricular
ectopi
ventricular
prematur
complex
vpc
complex
ventricular
ectopi
atrial
fibril
af
second
degre
atrioventricular
block
avb
pace
rhythm
retrospect
evalu
util
lp
gener
beat
origin
color
code
pattern
found
arrhythmia
group
describ
arrhythmia
number
lp
shape
measur
report
normal
holter
record
uniformli
show
torch
morpholog
variabl
silent
zone
prematur
beat
associ
doubl
tripl
side
lobe
pattern
variat
result
multipl
coupl
interv
variabl
paus
complex
ectop
rhythm
evidenc
small
data
point
concentr
lower
left
corner
lp
record
af
uniformli
show
fan
pattern
consist
random
atrioventricular
nodal
conduct
record
avb
show
island
pattern
consist
variabl
atrioventricular
nodal
conduct
pace
rhythm
torpedo
shape
rhythm
complet
control
pacemak
specif
lp
pattern
identifi
common
cardiac
rhythm
dog
support
mechan
rhythm
incorpor
lp
arrhythmia
interpret
may
aid
mechanist
understand
turn
may
advanc
understand
approach
diagnosi
treatment
arrhythmia
dog
disclosur
report
transcathet
pulmonari
valv
implant
therapeut
approach
approv
us
food
drug
administr
human
patient
fail
pulmonari
conduit
fail
bioprosthet
surgic
pulmonari
valv
report
first
case
success
transcathet
implant
stent
valv
pulmonari
posit
dog
congenit
pulmonari
valv
diseas
kg
beagl
dog
refer
visit
percutan
balloon
valvuloplasti
perform
month
correct
sever
type
valvular
pulmon
stenosi
peak
pressur
gradient
dp
mmhg
procedur
mmhg
hour
later
time
present
dog
letharg
echocardiographi
reveal
mild
pulmon
stenosi
dp
mmhg
associ
sever
pulmonari
regurgit
proxim
width
ratio
assess
doppler
mode
secondari
major
right
ventricular
right
atrial
dilat
despit
medic
therapi
worsen
right
heart
dilat
observ
two
month
later
transcathet
pulmonari
valv
implant
use
valv
system
decid
comput
tomographi
scan
perform
one
week
surgeri
accur
assess
pulmonari
coronari
arteri
morpholog
perform
measur
pulmonari
annulu
right
ventricular
outflow
tract
maxim
diamet
aneurysm
pulmonari
trunk
plicat
arteri
wall
confirm
initi
minim
invas
approach
via
left
jugular
vein
selding
techniqu
unsuccess
due
size
outer
diamet
deliveri
system
therefor
convert
left
intercost
thoracotomi
deliveri
approach
prep
time
neck
area
case
convers
dog
recov
unev
discharg
day
procedur
right
heart
dilat
disappear
within
day
dog
still
well
three
month
valv
implant
case
illustr
pulmonari
transcathet
stent
valv
implant
technic
feasibl
dog
sever
pulmonari
valv
diseas
stent
valv
altern
surgeri
sourc
tremend
develop
human
medicin
foreseen
veterinari
cardiolog
way
benefit
revolut
disclosur
report
melodi
valv
kindli
offer
medtron
minnesota
usa
boxer
dog
breed
itali
regul
boxer
club
boxer
club
itali
bci
draft
guidelin
select
dog
morpholog
attitudin
standard
given
high
preval
congenit
heart
diseas
boxer
dog
bci
establish
cardiovascular
screen
mandatori
admiss
select
process
screen
data
collect
either
cardiologist
oper
select
practic
exam
train
exam
differ
oper
examin
boxer
find
compar
variabl
compar
also
three
measur
dog
perform
oper
variabl
current
refer
interv
aortic
annulu
dimens
account
bodi
weight
bw
object
studi
analys
aortic
annulu
dimens
base
sex
bw
dog
four
thousand
two
hundr
one
boxer
dog
free
cardiovascular
diseas
includ
studi
cardiovascular
screen
conduct
includ
spectral
color
flow
doppler
transthorac
echocardiographi
tte
perform
follow
publish
recommend
sixteen
dog
exclud
analysi
due
lack
data
sex
annulu
less
mm
remain
analysi
sampl
dog
dog
divid
male
femal
weight
quartil
subsequ
normal
valu
confid
interv
annulu
analys
entir
sampl
gender
weight
quartil
sex
weight
interact
regard
result
objectifi
aortic
annulu
dimens
increas
increas
bw
valu
obtain
test
sex
use
weight
quartil
sex
weight
interact
anova
test
bonferroni
correct
multipl
comparison
case
signific
level
p
lower
case
exclud
analysi
measur
annulu
less
mm
mostli
femal
p
averag
weight
lower
kg
se
p
compar
case
analys
conclus
say
bw
base
confid
interv
may
help
screen
dog
heart
diseas
discrimin
normal
aortic
annulu
dimens
disclosur
report
variou
factor
influenc
surviv
dog
mitral
valv
diseas
mvd
dilat
cardiomyopathi
dcm
canin
cardiovascular
patient
inflammatori
antioxid
marker
investig
term
associ
surviv
yet
thu
investig
associ
inflammatori
white
blood
cell
wbc
neutrophil
neut
monocyt
mono
count
protein
crp
tumour
necrosi
oxid
stress
malondialdehyd
vitamin
e
glutathion
peroxidas
gpx
marker
surviv
dog
mvd
dcm
dog
mvd
dcm
dog
intern
cardiac
health
council
class
isachc
dog
isachc
ii
dog
isachc
iii
includ
studi
dog
censor
surviv
time
count
day
admiss
blood
sampl
collect
day
death
euthanasia
marker
analys
use
cox
model
hazard
ratio
hr
confid
interv
ci
correspond
p
valu
calcul
valu
p
consid
signific
test
perform
surviv
time
respect
diseas
type
mvd
dcm
signific
found
p
although
dog
mvd
median
day
averag
longer
surviv
time
dcm
median
day
univari
cox
model
perform
everi
marker
follow
marker
significantli
associ
surviv
hr
ci
p
valu
wbc
neut
mono
crp
gpx
interpret
result
increas
neut
unit
increas
risk
death
increas
gpx
ug
haemoglobin
unit
decreas
risk
death
furthermor
cox
model
fit
isachc
addit
marker
covari
sinc
surviv
signific
respect
isachc
class
test
p
model
effect
marker
decreas
howev
gpx
neut
remain
significantli
associ
surviv
result
suggest
increas
inflamm
decreas
activ
antioxid
enzym
gpx
associ
decreas
surviv
canin
mvd
dcm
patient
even
isachc
consid
model
may
conclud
select
inflammatori
oxid
stress
marker
predict
surviv
disclosur
report
brachycephal
obstruct
airway
syndrom
boa
characteris
variou
upper
airway
abnorm
could
potenti
trigger
remodel
right
heart
aim
studi
evalu
echocardiograph
characterist
symptomat
boa
asymptomat
french
bulldog
fb
pug
dog
diagnos
boa
accord
clinic
sign
anatom
abnorm
fifteen
fb
boa
asymptomat
pug
boa
asymptomat
underw
complet
echocardiograph
examin
left
right
heart
accord
guidelin
breed
echocardiograph
paramet
dog
clinic
sign
boa
compar
asymptomat
dog
furthermor
boa
fb
compar
boa
pug
variabl
index
normal
distribut
variabl
compar
independ
normal
distribut
data
test
use
statist
signific
defin
p
signific
differ
age
weight
boa
fb
asymptomat
fb
boa
fb
significantli
lower
vena
cava
collaps
index
p
larger
right
ventricular
intern
diamet
mid
caviti
rvidmid
p
larger
index
rvidmid
p
higher
tricuspid
valv
tv
e
wave
veloc
p
lower
peak
systol
tricuspid
annular
veloc
st
p
compar
asymptomat
fb
statist
differ
asymptomat
boa
pug
age
weight
echocardiograph
paramet
signific
differ
weight
fb
pug
found
howev
boa
fb
younger
p
boa
fb
compar
boa
pug
show
lower
collaps
index
p
larger
index
right
ventricular
longitudin
intern
diamet
rvidlong
p
larger
index
right
ventricular
area
rva
diastol
p
larger
index
rva
systol
p
larger
index
right
atrial
area
p
larger
index
lvidd
p
higher
mitral
annular
plane
excurs
maps
p
higher
mitral
valv
mv
e
veloc
p
higher
mv
wave
p
higher
tv
p
higher
peak
systol
annular
veloc
left
free
wall
em
p
boa
fb
right
ventricl
larger
compar
asymptomat
fb
suggest
remodel
right
heart
higher
tv
e
veloc
might
suggest
higher
right
atrial
pressur
lower
st
might
suggest
decreas
right
ventricular
systol
function
boa
fb
lower
vena
cava
collaps
index
boa
fb
compar
asymptomat
fb
might
due
higher
right
atrial
pressur
boa
dog
breed
specif
refer
rang
recommend
evalu
right
heart
echocardiograph
differenti
boa
asymptomat
brachycephal
dog
seem
challeng
disclosur
report
pimobendan
inodil
wide
use
canin
cardiolog
increas
life
expect
dog
heart
failur
moreov
abl
enhanc
right
ventricular
rv
systol
function
healthi
diseas
canin
patient
studi
focus
evalu
effect
pimobendan
cat
report
exist
regard
effect
right
heart
aim
present
studi
analyz
chang
rv
right
atrial
ra
echocardiograph
paramet
healthi
cat
singl
oral
dose
pimobendan
eleven
appar
healthi
cat
use
studi
cat
deem
healthi
basi
clinic
examin
cardiac
auscult
blood
pressur
measur
blood
work
convent
echocardiographi
includ
rv
wall
thick
diastol
rv
intern
diamet
diastol
systol
short
axi
view
rv
fraction
shorten
fs
rv
area
diastol
systol
apic
view
fraction
area
chang
tricuspid
annular
plane
systol
excurs
tissu
doppler
imag
deriv
tricuspid
annulu
systol
wave
veloc
ra
maxim
minim
diamet
ra
fs
cat
scan
follow
standard
techniqu
gentli
manual
restrain
cat
scan
total
eight
time
differ
time
point
two
subsequ
day
first
day
cat
scan
time
hour
follow
day
cat
receiv
echocardiographi
time
hour
singl
dose
mg
pimobendan
administ
oral
none
cat
show
advers
reaction
drug
data
obtain
differ
time
point
day
time
day
time
day
time
pimobendan
administr
pool
togeth
statist
comparison
perform
two
global
time
point
pimobendan
administr
among
test
variabl
differ
pimobendan
administr
particular
heart
rate
p
rv
fs
p
rv
fraction
area
chang
p
tissu
doppler
imag
deriv
tricuspid
annulu
systol
wave
veloc
p
increas
significantli
side
rv
intern
diamet
diastol
p
systol
p
ra
maxim
p
minim
p
diamet
reduc
pimobendan
administr
pimobendan
appear
safe
administ
healthi
cat
abl
induc
signific
increas
rv
ra
systol
properti
disclosur
report
envenom
european
adder
vipera
beru
common
season
present
small
anim
practic
norway
cardiac
arrhythmia
observ
patient
studi
describ
time
cours
sever
limit
cardiac
auscult
short
electrocardiogram
ecg
insensit
detect
arrhythmia
mani
may
go
undetect
aim
studi
describ
preval
natur
arrhythmia
detect
dog
first
hour
post
envenom
investig
associ
arrhythmia
grade
serum
cardiac
specif
troponin
ctni
marker
myocardi
cell
injuri
snakebit
sever
score
ss
score
present
dog
bitten
vipera
beru
includ
prospect
cohort
studi
ambulatori
ecg
aecg
place
dog
present
hour
arrhythmia
grade
assign
base
frequenc
sever
arrhythmia
aecg
record
modifi
previous
describ
grade
system
serum
obtain
present
h
h
h
day
post
bite
ctni
analysi
ss
score
record
upon
admiss
use
previous
describ
grade
system
four
dog
ss
score
mild
ss
score
moder
sever
observ
fourteen
four
dog
respect
seventeen
dog
rais
ctni
concentr
minimum
one
time
point
ten
dog
elev
ctni
present
h
h
h
nine
dog
arrhythmia
grade
thirteen
dog
develop
patholog
arrhythmia
grade
arrhythmia
ventricular
origin
sever
complex
ventricular
arrhythmia
grade
observ
dog
grade
arrhythmia
persist
day
two
concentr
ctni
present
significantli
higher
dog
develop
patholog
arrhythmia
compar
p
one
dog
patholog
arrhythmia
normal
ctni
concentr
time
point
ss
score
significantli
associ
arrhythmia
grade
initi
ctni
concentr
peak
ctni
day
one
studi
show
rais
ctni
concentr
ventricular
arrhythmia
common
follow
vipera
beru
envenom
dog
highlight
valu
prolong
ecg
monitor
patient
dog
develop
patholog
arrhythmia
could
differenti
base
ss
score
normal
ctni
concentr
rule
develop
patholog
arrhythmia
studi
disclosur
report
unsur
relev
joann
harri
director
heartvet
provid
ecg
interpret
holter
rental
servic
e
point
septal
separ
epss
distanc
maxim
earli
diastol
motion
septal
mitral
valv
leaflet
interventricular
septum
measur
use
record
epss
import
index
diagnosi
occult
symptomat
dilat
cardiomyopathi
dcm
recent
report
european
screen
guidelin
dcm
doberman
pinscher
epss
measur
right
parastern
long
axi
view
rpla
right
parastern
short
axi
view
rpsa
howev
previou
studi
assess
epss
valu
differ
use
differ
echocardiograph
view
therefor
aim
studi
compar
epss
valu
obtain
rpla
rpsa
view
differ
canin
breed
prospect
observ
studi
dog
present
istituto
veterinario
di
novara
routin
screen
purpos
dog
underw
complet
clinic
echocardiograph
examin
perform
right
left
later
recumb
simultan
ecg
trace
measur
epss
obtain
rpla
rpsa
view
measur
perform
offlin
oper
od
evalu
cardiac
cycl
mean
valu
calcul
total
healthi
dog
includ
golden
retriev
doberman
pinscher
english
bulldog
labrador
retriev
czechoslovakian
wolf
studi
includ
femal
male
median
age
year
rang
year
median
bodi
weight
kg
rang
kg
mean
epss
measur
rpla
rpsa
view
mm
mm
respect
epss
significantli
higher
measur
rpsa
rpla
view
p
mean
differ
mm
epss
measur
obtain
rpla
rpsa
view
might
use
interchang
greater
later
torsion
movement
heart
obtain
short
axi
view
respiratori
phase
cardiac
cycl
might
reason
higher
valu
epss
obtain
rpsa
view
find
could
taken
account
adequ
echocardiograph
evalu
diagnosi
studi
larger
canin
popul
warrant
confirm
result
disclosur
report
effect
long
air
travel
anim
heart
diseas
investig
studi
assess
chang
physic
condit
anim
mitral
valv
diseas
flight
target
case
profil
dog
mitral
valv
diseas
underw
air
travel
undergo
mitral
valv
repair
jasmin
veterinari
cardiovascular
medic
center
septemb
march
flight
event
chang
exercis
intoler
appetit
respiratori
rate
frequenc
cough
gastrointestin
sign
presenc
syncop
evalu
also
presenc
absenc
event
relat
heart
diseas
discharg
rate
studi
case
board
cabin
patient
abl
return
home
dog
without
surgeri
two
dog
develop
event
relat
mitral
valv
diseas
left
atrium
ruptur
pulmonari
edema
respect
dog
left
atrial
ruptur
die
surgeri
receiv
cardiac
medic
flight
dog
develop
pulmonari
edema
also
miss
dose
journey
respond
medic
therapi
land
dog
acvim
classif
stage
case
show
chang
physic
condit
exercis
intoler
appetit
flight
none
chang
requir
treatment
two
dog
show
gastrointestin
symptom
vomit
diarrhea
flight
three
patient
develop
diarrhea
flight
among
patient
show
respiratori
symptom
flight
show
respiratori
distress
show
wors
cough
dog
syncop
episod
flight
howev
none
dog
faint
flight
one
dog
syncop
although
dog
mitral
valv
diseas
may
show
clinic
chang
relat
air
travel
transient
allevi
symptomat
treatment
cardiac
diseas
relat
symptom
prevent
manag
medic
time
alarm
clock
devic
travel
across
timezon
avoid
medic
error
may
caus
inexperienc
move
misread
clock
due
time
differ
may
suffici
avert
mitral
valv
diseas
relat
event
suffici
alert
conclus
long
distanc
air
travel
patient
mitral
valv
diseas
safe
perform
carri
routin
care
medic
adher
disclosur
report
acut
myocardi
infarct
ami
common
caus
human
ischem
heart
diseas
pathogenesi
involv
atherosclerosi
coronari
arteri
platelet
activ
thrombosi
vasospasm
anecdot
inform
canin
ami
exist
postmortem
descript
arteriosclerosi
myocardi
ischem
injuri
congest
heart
failur
avail
clinic
data
regard
diagnosi
ami
lack
case
seri
describ
possibl
predispos
factor
clinic
electrocardiograph
echocardiograph
find
dog
presumpt
diagnosi
myocardi
infarct
databas
veterinari
clinic
retrospect
screen
dog
presumpt
diagnosi
ami
suspicion
base
echocardiograph
region
wall
motion
abnorm
hypokinesia
akinesia
dyskinesia
initi
present
andor
elev
serum
cardiac
troponin
ctni
without
obviou
caus
thirteen
dog
presumpt
diagnosi
ami
identifi
histori
clinic
data
ctni
electrocardiograph
echocardiograph
find
review
data
express
median
rang
three
thirteen
case
west
higland
white
terrier
median
age
year
bodi
weight
kg
factor
predispos
thrombosi
identifi
dog
postop
neoplast
hemolyt
anemia
hypothyroid
common
clinic
find
arrhythmia
normal
heart
rate
tachycard
bradycard
weak
syncop
ctni
sever
elev
ngl
rang
test
case
identifi
ecg
abnorm
ventricular
arrhythmia
degre
atrioventricular
block
sinu
rhythm
right
axi
deviat
st
segment
abnorm
present
dog
region
wall
motion
abnorm
affect
variou
myocardi
segment
left
ventricular
free
wall
apex
interventricular
septum
observ
first
exam
visit
dog
abnorm
segment
appear
thin
hyperecho
dog
echocardiogram
systol
dysfunct
observ
dog
present
three
dog
surviv
discharg
postmortem
exam
perform
dog
show
sever
extens
myocardi
necrosi
hemorrhag
andor
replac
myocardi
tissu
fibrou
tissu
histopatholog
largest
case
seri
dog
presumpt
diagnosi
ami
although
ami
remain
rare
condit
consid
differenti
diagnosi
dog
predispos
condit
arrhythmia
elev
ctni
andor
segment
wall
motion
abnorm
howev
find
may
becom
appar
acut
phase
disclosur
report
accur
clinic
nutrit
assess
bodi
condit
score
dog
easi
subject
method
therefor
make
object
nutrit
assess
examin
morphometr
method
result
high
correl
coeffici
r
occur
length
sternal
process
sciatic
process
ideal
bodi
weight
ibw
studi
present
calip
estim
ibw
measur
length
appli
find
calip
prepar
length
ibw
appear
simultan
ideal
bodi
weight
calip
weight
correspond
either
bodi
fat
percentag
length
sternal
process
sciatic
process
measur
clinic
veterinarian
use
calip
ten
dog
visit
anim
hospit
use
veterinarian
ask
assess
ibw
determin
callip
differ
ibw
base
experi
correl
coeffici
bodi
length
ibw
r
ibw
correspond
bodi
fat
percentag
hand
correl
coeffici
two
r
ibw
correspond
bodi
fat
percentag
clinic
veterinarian
also
repli
questionnair
survey
bodi
weight
correspond
bodi
fat
percentag
closer
ibw
assess
experi
bodi
fat
percentag
bc
scale
correspond
median
suggest
japanes
clinic
veterinarian
evalu
nutrit
assess
set
ibw
higher
found
life
span
extend
dietari
restrict
dog
point
view
veterinarian
set
ibm
lower
assess
result
also
larg
differ
correl
coeffici
measur
bodi
length
measur
clinic
veterinarian
differ
caus
larg
variat
bodi
length
measur
veterinarian
regard
may
necessari
creat
manual
bodi
length
measur
dog
improv
measur
accuraci
disclosur
report
hypothyroid
may
major
implic
delay
gallbladd
empti
role
pathogenesi
gallbladd
mucocel
extrahepat
biliari
diseas
merit
investig
aim
studi
evalu
incid
extrahepat
biliari
diseas
hypothyroid
dog
record
dog
diagnos
hypothyroid
examin
presenc
absenc
extrahepat
biliari
diseas
mucocel
colecist
colelitiasi
gallblad
mass
forti
nine
dog
serum
elev
gamma
glutamyl
transferas
alkalin
phosphatas
alanin
aminotransferas
total
bilirubin
enlarg
gallbladd
fine
striat
immobil
stellat
bile
pattern
thicken
gallbladd
wall
biliari
sludg
hyperechogen
gallbladd
mass
older
dog
small
breed
overrepres
dog
present
clinic
sign
vomit
anorexia
lethargi
diarrhea
andor
fever
thirti
four
dog
diagnos
extrahepat
biliari
diseas
gallbladd
mucocel
n
dog
cholelitiasi
n
dog
colecyst
n
dog
upon
ultrasound
examin
histologicmacroscop
evalu
cultur
sensit
test
incid
gallbladd
mucocel
found
highest
follow
cholelitiasi
colecyst
studi
suggest
hyporthiroid
dog
present
acut
ill
laboratori
evid
hepatobiliari
diseas
undergo
evalu
presenc
extrahepat
biliari
diseas
biliari
mucocel
cholelitiasi
colecyst
disclosur
report
thyroid
scintigraphi
indispens
diagnosi
stage
treatment
plan
thyroid
carcinoma
howev
literatur
pertechnet
scintigram
find
dog
scarc
nearli
absent
emiss
comput
tomographi
spect
similar
human
medicin
use
spect
could
increas
sensit
detect
metastas
aim
retrospect
studi
describ
planar
spect
imag
result
canin
thyroid
tumor
compar
thorac
radiographi
detect
thorac
metastas
thyroid
scintigraphi
avail
dog
present
clinic
present
surgic
resect
dog
confirm
diagnosi
thyroid
neoplasia
base
histopatholog
cytolog
andor
abnorm
radionuclid
accumul
dog
unilater
tumor
bilater
ectop
tumor
one
dog
ectop
unilater
tumor
dog
bilater
mass
ectop
tumor
dog
tumor
extent
hinder
accur
local
uptak
rel
parotid
salivari
gland
thyroidsalivari
ts
ratio
increas
dog
median
ts
ratio
decreas
dog
median
ts
ratio
compar
salivari
gland
median
ts
ratio
dog
dog
multipl
mass
uptak
extent
differ
level
variou
mass
homogen
uniform
uptak
pattern
present
dog
heterogen
uptak
pattern
dog
dog
multipl
mass
variou
uptak
pattern
present
dog
euthyroid
hyperthyroid
hypothyroid
major
hyperthyroid
dog
dog
increas
radionuclid
uptak
spect
imag
avail
dog
dog
spect
reveal
tracer
uptak
level
thorax
suggest
distant
metastas
dog
thorac
radiograph
perform
metastas
detect
dog
major
dog
scintigraphi
perform
use
dog
scintigram
perform
dog
spect
imag
reveal
thorac
metastasi
clearli
identifi
studi
first
describ
planar
spect
imag
larg
number
dog
thyroid
tumor
result
suggest
spect
imag
superior
thorac
radiographi
detect
metastas
disclosur
report
ultrasonographi
commonli
use
diagnost
workup
dog
hyperadrenocortic
hac
support
diagnosi
rule
diseas
help
differenti
type
hac
studi
establish
refer
rang
ultrasonograph
adren
gland
thick
base
weight
categori
howev
use
rang
dog
hac
evalu
therefor
four
weight
categori
use
order
avoid
larg
variat
weight
within
group
aim
studi
establish
new
refer
rang
adren
gland
thick
healthi
dog
evalu
sensit
rang
detect
adrenomegali
dog
hac
describ
ultrasonograph
adren
find
dog
hac
total
clinic
healthi
dog
prospect
includ
adren
thick
sagitt
plane
measur
dog
use
follow
weight
categori
dog
kg
dog
kg
dog
kg
dog
kg
refer
rang
percentil
left
adren
gland
maximum
thick
follow
mm
dog
kg
mm
dog
kg
mm
dog
kg
mm
dog
kg
wherea
right
adren
gland
maximum
thick
follow
mm
dog
kg
mm
dog
kg
mm
dog
kg
mm
dog
kg
addit
dog
hac
retrospect
includ
dog
classifi
weight
categori
use
healthi
dog
dog
kg
dog
kg
dog
kg
dog
kg
overal
sensit
detect
unilater
bilater
adrenomegali
ultrasound
examin
dog
dog
hac
ultrasonograph
classifi
dog
symmetr
adrenomegali
consist
hac
dog
unilater
adrenomegali
atrophi
contralater
adren
gland
unilater
bilater
adrenomegali
malign
featur
ultrasound
examin
consist
hac
dog
equivoc
adren
asymmetri
dog
normal
adren
gland
thick
overal
sensit
ultrasonographi
detect
adrenomegali
use
four
weight
categori
left
right
adren
gland
thick
although
dog
hac
ultrasonograph
find
consist
either
hac
equivoc
adren
asymmetri
common
find
dog
hac
occur
dog
disclosur
report
clinic
relev
ultrasonographi
canin
primari
adren
insuffici
evalu
studi
retrospect
evalu
larg
canin
popul
refer
facil
diagnost
perform
ultrasonograph
assess
adren
gland
dimens
distinguish
dog
primari
adren
insuffici
expos
group
dog
without
primari
adren
insuffici
non
group
group
includ
consecut
dog
diagnos
primari
adren
insuffici
base
signal
histori
clinicopatholog
test
cbc
serum
biochemistri
urinalys
acth
stimul
test
result
includ
basal
plasma
acth
serum
aldosteron
determin
group
includ
dog
without
primari
adren
insuffici
individu
match
group
dog
breed
sex
sexual
statu
age
month
reduc
technolog
bia
group
dog
select
took
place
contigu
time
period
group
dog
recruit
dog
receiv
mitotan
trilostan
steroid
medic
clinic
evalu
exclud
group
ultrasonograph
adren
length
al
caudal
cranial
pole
thick
cdt
crt
respect
determin
longitudin
imag
group
compar
median
iqr
right
left
cdt
group
cm
cm
respect
group
cm
cm
respect
p
valu
comparison
median
iqr
right
left
crt
group
cm
cm
respect
group
cm
cm
respect
p
valu
comparison
median
right
left
al
group
cm
cm
respect
group
cm
cm
respect
p
valu
comparison
analysi
roc
curv
global
diagnost
accuraci
separ
group
group
result
right
left
cdt
respect
right
left
crt
respect
right
left
al
respect
studi
show
group
sonograph
adren
gland
measur
significantli
lower
compar
group
strengthen
role
adren
ultrasonographi
reliabl
screen
test
dog
suspect
primari
adren
insuffici
disclosur
report
bind
capac
human
sera
thyroxin
absenc
condit
would
reduc
thyroid
bind
capac
tbc
eg
ill
nti
pregnanc
free
fatti
acid
sera
may
dilut
without
affect
measur
result
free
use
appropri
analyt
techniqu
equilibrium
dialysi
howev
condit
associ
reduc
tbc
result
may
decreas
dilut
low
free
dilut
profil
use
determin
valid
free
method
human
dog
cat
tbc
much
lower
clear
equival
dilut
would
would
caus
decreas
measur
free
analyt
impact
physiolog
state
includ
nti
investig
analyt
method
less
resist
effect
sampl
dilut
may
suscept
interfer
lower
tbc
eg
nti
consequ
may
gener
diagnost
mislead
result
surplu
serum
sampl
dog
cat
select
physiolog
state
analys
equilibrium
dialysi
method
equilibrium
dialysi
antech
laboratori
analogu
chemiluminesc
method
immulit
veterinari
free
siemen
without
dilut
hepe
buffer
sampl
includ
normal
cat
nmoll
hyperthyroid
cat
suspect
canin
nti
normal
tsh
suspect
felin
nti
felin
lipaemia
percentag
decreas
could
calcul
sampl
report
limit
assay
howev
sampl
decreas
dilut
compar
decreas
dilut
sampl
percentag
decreas
could
calcul
steepest
declin
concentr
beyond
suspect
felin
nti
sampl
least
declin
normal
cat
veterinari
sampl
suscept
effect
sampl
dilut
therefor
condit
reduc
tbc
report
human
sera
method
suscept
dilut
method
human
physiolog
state
demonstr
greater
declin
measur
serial
dilut
studi
could
determin
whether
comparison
undilut
dilut
result
within
individu
sampl
could
differenti
nti
thyroid
dysfunct
diagnost
challeng
case
disclosur
report
nationwid
laboratori
consult
dechra
veterinari
product
consult
previou
studi
suggest
pancreat
could
signific
comorbid
diabet
cat
even
absenc
digest
sign
studi
diabet
cat
pancreat
lack
potenti
surviv
factor
popul
unknown
main
object
review
epidemiolog
biolog
ultrasonograph
find
cat
concurr
chronic
pancreat
cp
diabet
mellitu
dm
document
chronolog
diseas
surviv
time
st
potenti
prognost
factor
cat
diagnos
cp
dm
retrospect
recruit
veterinari
teach
hospit
nation
veterinari
school
alfort
januari
june
cat
signal
medic
histori
physic
find
biochemistri
panel
complet
blood
count
standard
urin
analysi
abdomin
ultrasonographi
us
avail
st
known
case
potenti
prognost
factor
includ
elev
hepat
enzym
hyperbilirubinemia
hypokalemia
episod
ketoacidosi
histori
hospit
us
featur
suggest
biliari
tract
diseas
evalu
associ
criteria
st
test
univari
analysi
log
rank
test
signific
set
p
median
age
studi
popul
year
recruit
cat
previous
overweight
weight
loss
frequent
biochem
abnorm
includ
elev
liver
enzym
hyperproteinemia
hyperbilirubinemia
hypokalemia
median
surviv
time
mst
day
mortal
rate
cat
least
one
us
find
compat
biliari
tract
diseas
significantli
higher
mst
also
time
shorter
p
studi
criteria
associ
st
outcom
cat
suffer
cp
dm
may
favor
howev
mst
cat
diagnos
concurr
diseas
least
one
ultrasonograph
find
compat
biliari
tract
diseas
shorter
cat
without
biliari
lesion
us
disclosur
report
qualiti
life
research
among
diabet
dog
owner
emphas
neg
impact
diabet
mellitu
dm
treatment
owner
lifestyl
even
lead
euthanasia
sid
insulin
inject
regimen
reduc
impact
prospect
clinic
field
studi
evalu
efficaci
sid
administ
prozinc
insulin
dog
diagnos
dm
line
seven
visit
occur
period
day
veterinarian
permit
switch
bid
treatment
basi
clinic
sign
maximum
blood
glucos
bg
minimum
bg
obtain
satisfactori
diabet
control
defin
improv
glycem
laboratori
paramet
clinic
sign
thirti
dog
enrol
withdrew
earli
n
consent
withdrawn
n
complianc
n
lack
improv
overal
dog
show
satisfactori
diabet
control
day
sid
treat
dog
bid
treat
dog
dog
satisfactori
control
achiev
sid
bid
insulin
dog
sid
bid
studi
conclus
show
improv
one
clinic
sign
pupd
bodi
weight
mean
bg
decreas
mgdl
minimum
bg
mgdl
fructosamin
clinic
hypoglycemia
observ
two
sid
treat
dog
recov
feed
sid
prozinc
effect
safe
control
dm
major
dog
particularli
dog
disclosur
report
sjm
niessen
consult
work
dechra
purina
boehring
ingelheim
c
kroh
employe
boehring
ingelheim
maruyama
employe
boehring
ingelheim
k
jerrentrup
employe
boehring
ingelheim
keller
employe
boehring
ingelheim
r
klee
employe
boehring
ingelheim
mori
consult
work
boehring
ingelheim
sako
consult
boehring
ingelheim
cush
diseas
cd
common
canin
endocrinopathi
due
deregul
secret
acth
pituitari
microadenoma
macroadenoma
recent
studi
focus
histopatholog
find
canin
pituitari
gland
identifi
overrepresent
brachycephal
dog
bd
among
macroadenoma
disregard
secretori
statu
therefor
hypothesis
pituitari
tumor
size
brachycephal
morphotyp
associ
dog
cd
medic
record
dog
cd
present
intern
medicin
unit
referr
hospit
retrospect
evalu
inclus
criteria
clinic
sign
suggest
hyperadrenocortic
hyperadrenocortic
confirm
least
endocrin
test
brain
abdomin
ct
scan
indic
pituitari
origin
macroadenoma
diagnos
pituitari
heightbrain
area
ratio
pb
skull
index
si
skull
calcul
differenti
bd
dog
nbd
si
accuraci
distinguish
bd
nbd
breed
test
calcul
area
curv
auc
receiv
oper
characterist
roc
curv
optim
select
base
valu
youden
index
correl
si
pb
evalu
use
spearman
test
hundr
twenti
dog
includ
median
rang
age
first
clinic
sign
year
accord
breed
bd
nbd
unclassifi
auc
confid
interv
roc
curv
si
distinguish
bd
nbd
use
sensibl
specif
si
morphotyp
distinct
respect
median
rang
pb
bd
nbd
respect
correl
could
establish
si
pb
p
brachycephal
morphotyp
quantit
evalu
associ
pituitari
tumor
size
dog
cd
result
contrast
previou
studi
focus
pituitari
sampl
collect
mainli
necropsi
embrac
dog
without
cd
sole
inclus
dog
cd
studi
may
explain
discrep
possibl
predisposit
bd
undifferenti
rapidli
grow
pituitari
tumor
remain
assess
disclosur
report
critic
corticosteroid
insuffici
circi
inadequ
corticosteroid
activ
relat
patient
current
degre
stress
ill
circi
occur
human
patient
dog
sepsi
studi
investig
frequenc
circi
system
inflammatori
respons
syndrom
sir
dog
associ
circi
hypotens
mortal
prospect
studi
perform
decemb
may
ethic
approv
sir
diagnos
dog
present
least
two
follow
criteria
admiss
icu
rectal
temperatur
heart
rate
bpm
respiratori
rate
bpm
white
blood
cell
x
x
band
neutrophil
dog
exclud
histori
suspect
adren
ill
receiv
glucocorticoid
within
previou
hour
long
act
formul
within
previou
month
drug
known
affect
axi
acth
stimul
test
perform
dog
immedi
inclus
studi
dog
cortisol
differ
stimul
basal
cortisol
support
diagnosi
circi
blood
pressur
ii
ramsey
medic
measur
dog
hypotens
defin
mean
arteri
pressur
map
mmhg
inform
surviv
day
admiss
collect
dog
divid
survivor
dog
euthan
financi
reason
exclud
test
test
data
normal
age
basal
cortisol
map
compar
dog
without
circi
cortisol
basal
cortisol
map
compar
survivor
use
associ
circi
hypotens
mortal
evalu
fisher
exact
test
analys
consid
signific
dog
met
inclus
criteria
enrol
studi
circi
hypotens
detect
dog
respect
age
map
basal
cortisol
hypotens
similar
dog
without
circi
dog
die
within
day
admiss
independ
factor
hypotens
basal
hypercortisolemia
associ
higher
risk
death
p
p
respect
circi
seem
occur
frequent
sir
dog
howev
presenc
hypotens
basal
hypercortisolemia
associ
increas
mortal
risk
disclosur
report
prednisolon
commonli
use
drug
cat
potenti
advers
effect
includ
hyperglycaemia
gih
diabet
mellitu
gidm
predispos
factor
develop
overal
incid
rate
gih
gidm
current
unknown
aim
studi
evalu
incid
rate
gih
gidm
evalu
predispos
risk
factor
gih
gidm
cat
receiv
prednisolon
electron
record
tertiari
referr
centr
search
cat
receiv
prednisolon
dose
mgkgday
week
durat
data
avail
week
studi
period
januari
june
total
cat
includ
studi
cat
cat
diagnos
gih
gidm
nine
cat
develop
gidm
requir
insulin
therapi
euthan
due
diabet
ketoacidosi
remain
cat
identifi
gih
none
requir
insulin
treatment
twelv
cat
develop
gih
gidm
within
month
initi
prednisolon
therapi
remain
two
cat
develop
gidm
month
four
cat
develop
gidmgih
year
age
comparison
cat
develop
gih
gidm
show
statist
differ
baselin
blood
glucos
presenc
glucosuria
bodi
weight
bodi
condit
score
trend
toward
cat
develop
gidmgih
receiv
mgkg
start
dose
seen
howev
statist
signific
p
conclud
tertiari
referr
popul
approxim
cat
receiv
prednisolon
develop
gih
gidm
atrend
toward
cat
receiv
higher
dose
prednisolon
like
develop
gihgidm
disclosur
report
mani
diabet
dog
cat
requir
small
dose
insulin
may
administ
syring
devic
import
small
dose
administ
accur
magnitud
potenti
dosag
error
appreci
aim
studi
compar
accuraci
precis
insulin
syring
pen
devic
determin
accur
precis
insulin
dose
deliv
u
dose
dispens
time
five
contain
insulin
glargin
five
contain
insulin
detemir
five
contain
insulin
lispro
five
contain
insulin
glargin
five
u
five
u
contain
insulin
five
veterinarian
use
ml
uml
insulin
syring
dose
weigh
immedi
use
precis
balanc
resolut
g
intend
deliv
dose
compar
tend
deliv
less
insulin
intend
dose
underdosag
invers
proport
dose
accuraci
differ
intend
deliv
dose
signific
use
juniorstar
vetpen
u
insulin
dosag
u
use
ml
insulin
syring
intend
dose
significantli
overdos
attempt
deliv
u
respect
significantli
underdos
u
respect
use
uml
syring
intend
dose
significantli
overdos
attempt
deliv
u
respect
six
ml
uml
insulin
syring
coeffici
variat
precis
diminish
increas
dose
insulin
precis
six
convers
precis
use
ml
uml
syring
insulin
dosag
u
respect
precis
improv
insulin
dosag
u
devic
except
juniorstar
vetpen
u
unaccept
inaccur
deliv
u
dose
insulin
accuraci
improv
higher
dose
dispens
deliveri
u
dose
result
suffici
accur
compar
intend
dose
use
uml
syring
conclus
tend
accur
lower
dosag
syring
tend
accur
higher
dosag
disclosur
report
federico
fracassi
financi
support
dechra
msd
speak
consult
boehring
ingelheim
dechra
msd
royal
canin
hill
purina
la
vallonea
stefania
golinelli
consult
dechra
electrolyt
abnorm
dog
primari
hypoadrenocortic
ph
wide
describ
fraction
excret
fe
urinari
electrolyt
fee
yet
evalu
furthermor
mineralocorticoid
supplement
monitor
base
blood
sodium
na
potassium
k
concentr
possibl
fee
could
add
use
inform
regard
monitor
treatment
aim
studi
evalu
fee
dog
ph
group
follow
dog
acut
adren
insuffici
aai
dog
treat
ph
td
fludrocortison
desoxycorticosteron
pival
docp
dog
ph
treat
docp
classifi
well
control
na
k
ri
hyponatremia
andor
hyperkalemia
hypernatremia
andor
hypokalemia
respect
dog
well
control
classifi
base
drug
administr
time
day
docp
inject
respect
dog
typic
ph
hyponatremia
andor
hyperkalemia
time
diagnosi
includ
healthi
dog
hd
use
control
serum
urin
chemistri
perform
combin
sampl
use
autom
analys
fee
calcul
nonparametr
test
use
compar
fee
among
group
data
express
median
rang
p
consid
signific
seven
dog
aai
td
hd
enrol
td
docp
fludrocortison
dog
evalu
fe
sodium
fena
clorid
fecl
calcium
feca
elev
aai
fena
fecl
feca
significantli
lower
td
fena
fecl
feca
still
significantli
higher
compar
hd
fena
fecl
feca
aai
td
significantli
higher
fe
k
fek
compar
hd
fena
fek
significantli
differ
among
group
nevertheless
despit
signific
dog
lower
fena
higher
fek
compar
control
dog
fena
vs
fek
vs
feca
significantli
lower
compar
well
control
dog
feca
fena
fecl
fek
differ
significantli
among
group
nonetheless
despit
signific
show
increas
trend
time
although
signific
feca
lower
day
docp
dog
aai
high
fena
fecl
feca
decreas
treatment
studi
necessari
clarifi
clinic
util
fee
dog
treat
ph
disclosur
report
federico
fracassi
financi
support
dechra
msd
speak
consult
boehring
ingelheim
dechra
msd
royal
canin
hill
purina
la
vallonea
francesco
dondi
financi
support
zoeti
speak
consult
boehring
ingelheim
la
vallonea
ultrasonographi
sensit
method
measur
adren
gland
size
reliabl
indic
adren
gland
size
maximum
diamet
caudal
pole
thick
howev
pituitari
hyperadrenocortic
increas
preval
dog
inform
scientif
literatur
correl
bodyweight
age
size
adren
gland
dog
gener
upper
limit
mm
recent
one
retrospect
studi
suggest
mm
valu
dog
kg
anoth
found
age
depend
size
aim
examin
adren
gland
thick
dog
retrospect
studi
result
dog
healthi
diagnos
pituitari
hyperadrenocortic
use
diagnosi
pituitari
hyperadrenocortic
base
clinic
symptom
dexamethason
supress
test
bodyweight
rang
kg
age
rang
year
correl
bodyweight
age
adren
gland
thick
analys
healthi
dog
n
subgroup
kg
n
compar
dog
diagnos
pituitari
hyperadrenocortic
kg
n
data
analysi
descript
statist
use
p
signific
correl
adren
gland
size
bodyweight
entir
rang
kg
signific
correl
subgroup
dog
kg
age
depend
found
signific
differ
adren
gland
size
dog
kg
weight
adren
gland
size
normal
distribut
group
dog
weight
less
kg
thick
left
adren
gland
caudal
pole
mm
right
adren
gland
size
mm
normal
rang
left
adren
gland
size
mm
mm
right
one
ci
compar
data
healthi
dog
dog
pituitari
hyperadrenocortic
result
mm
optim
upper
valu
dog
kg
valu
provid
sensit
specif
left
adren
gland
sensit
specif
right
one
diagnos
pituitari
hyperadrenocortic
use
ultrasonographi
differ
result
left
right
side
caus
difficult
imag
right
side
organ
result
strenghten
find
avail
literatur
regard
bodyweight
correl
could
find
age
depend
disclosur
report
nasal
polyposi
patholog
unknown
etiolog
rare
describ
canin
speci
provok
chronic
clinic
symptom
includ
discharg
sneez
stertor
diagnosi
base
diagnost
imag
endoscop
aspect
histolog
exam
nasal
biopsi
rhinotomi
despit
possibl
surgic
complic
possibl
relaps
date
first
choic
retrospect
studi
look
case
nasal
polyp
year
dog
princip
mix
breed
male
femal
adult
elderli
patient
less
year
old
present
sneez
stertor
nasal
discharg
clinic
exam
show
case
frontonas
deform
clear
presenc
newli
form
polypoid
tissu
nostril
open
nasolacrim
duct
computer
tomographi
reveal
abnorm
compat
newli
form
endonas
tissu
case
respect
anterograd
rhinoscopi
reveal
newli
form
tissu
smooth
transluc
surfac
pink
color
elast
consist
complet
occupi
nasal
meatu
dog
nasopharynx
well
histolog
exam
show
exophyt
structur
bound
respiratori
epithelium
often
hyperplast
squamou
metaplasia
stroma
rule
myxoid
fibrillari
surround
serou
mucu
gland
present
highli
variabl
quantiti
corium
inflammatori
infiltr
polymorph
stroma
show
area
hyperplasia
mesenchym
andor
hyperplasia
dilat
vascular
system
seriou
dysplasia
observ
case
twelv
subject
underw
medic
treatment
underw
medic
treatment
endoscop
debulk
mix
techniqu
extern
grasp
forcep
plu
diod
laser
w
continu
rhythm
fiber
patient
underw
surgic
rhinotomi
dog
treat
prednisolon
despit
clinic
improv
constant
relaps
subject
underw
endoscop
debulk
show
clinic
improv
symptom
absenc
relaps
month
case
month
case
conclus
nasal
polyposi
infrequ
patholog
present
seriou
clinic
symptom
even
young
subject
tend
relaps
therapi
endoscop
debulk
less
invas
altern
tradit
surgeri
even
though
prevent
relaps
medium
long
term
disclosur
report
reticulocyt
haemoglobin
content
chr
siemen
advia
diagnost
marker
iron
defici
human
dog
idexx
procyt
dx
new
paramet
analysi
iron
defici
veterinari
use
aim
prospect
studi
evalu
clinic
diagnost
util
compar
chr
diagnosi
felin
erythropoiesi
ile
first
refer
interv
ri
chr
establish
analys
healthi
cat
second
cat
classifi
ile
low
plasma
iron
low
transferrin
satur
tf
combin
either
anaemia
andor
alter
red
blood
cell
rbc
indic
requir
diagnosi
ile
haematolog
variabl
paramet
iron
metabol
well
serum
amyloid
compar
group
correl
chr
assess
ri
chr
pg
pg
respect
respect
iron
haematolog
variabl
cat
classifi
ile
cat
compar
cat
ile
cat
significantli
lower
median
valu
chr
unexpectedli
hct
hgb
mch
rbc
significantli
decreas
ile
cat
addit
ile
cat
significantli
increas
median
saa
valu
correl
chr
moder
rs
small
bia
pg
chr
may
suitabl
earli
indic
ile
especi
use
addit
paramet
iron
metabol
moder
correl
chr
like
due
speci
differ
methodolog
disclosur
report
miriam
keiner
none
n
bauer
bayer
anim
health
gmbh
dfg
eickemey
gkf
idexx
laboratori
inc
norma
fuji
scil
anim
care
ushio
inc
moritz
bayer
anim
health
gmbh
dvg
eickemey
idexx
laboratori
inc
msd
anim
health
norma
scil
anim
care
synlab
ushio
inc
addit
hypophosphatemia
metabol
acidosi
common
complic
chronic
kidney
diseas
cat
use
standard
approach
metabol
acidosi
diagnos
base
concentr
arteri
blood
aim
studi
assess
possibl
use
valu
anion
gap
ag
correct
anion
gap
agcorr
chloridesodium
ratio
diagnosi
metabol
acidosi
studi
carri
cat
sex
year
old
control
c
group
consist
healthi
cat
cat
diagnos
ckd
base
blood
creatinin
sdma
urea
level
includ
studi
group
cat
ckd
divid
four
group
ii
iii
iv
depend
iri
stage
arteri
venou
blood
collect
anim
paramet
balanc
abb
ph
measur
arteri
blood
concentr
na
k
albumin
measur
venou
blood
base
obtain
result
valu
ag
agcorr
calcul
use
follow
formula
ag
na
k
agcorr
ag
gl
albakt
gl
gl
upper
refer
limit
serum
albumin
cat
albakt
measur
albumin
concentr
studi
cat
na
analysi
arteri
blood
reveal
presenc
metabol
acidosi
cat
group
iv
remain
group
abb
paramet
within
refer
rang
valu
ag
agcorr
cat
group
ii
iii
iv
significantli
lower
group
c
valu
cat
group
ii
iii
iv
significantli
higher
cat
group
c
follow
conclus
drawn
base
obtain
result
abb
analysi
base
classic
model
enabl
detect
abb
disturb
cat
stage
iv
kidney
diseas
analysi
ag
agcorr
clna
valu
enabl
diagnosi
abb
disturb
cat
stage
ii
iii
iv
kidney
diseas
analysi
chang
ion
concentr
ckd
accur
tool
diagnos
abb
disturb
classic
model
disclosur
report
aerosol
therapi
cat
chronic
respiratori
condit
commonli
aerosol
chamber
specif
design
use
cat
util
depend
type
chamber
certain
clean
procedur
recommend
differ
manufactur
prevent
bacteri
contamin
aim
studi
investig
chamber
adequ
decontamin
use
differ
recommend
clean
steril
procedur
standard
bacteri
contamin
purpos
chamber
rc
chamber
rc
cegla
medizintechnik
n
aerokat
ak
trudel
medic
intern
n
evalu
standard
bacteri
contamin
perform
use
previous
establish
serial
dilut
aliquot
ml
appli
pipett
three
locat
chamber
hour
chamber
cleanedsteril
accord
manufactur
instruct
rc
includ
clean
procedur
use
special
bag
microwav
minut
watt
n
placement
boil
water
minut
n
ak
place
lukewarm
water
clean
deterg
minut
n
air
dri
chamber
swab
taken
three
defin
area
chamber
mask
valv
chamber
appli
incub
hour
three
clean
protocol
bacteri
growth
could
detect
chamber
test
studi
show
manufactur
recommend
clean
procedur
adequ
bacteri
decontamin
felin
inhal
chamber
achiev
disclosur
report
hemolyt
anaemia
imha
common
hematolog
disord
dog
primari
secondari
character
antibodi
product
imha
requir
detail
diagnost
pathway
well
complex
therapeut
approach
includ
blood
transfus
unfortun
imha
present
high
mortal
rate
especi
within
day
onset
retrospect
studi
evalu
clinic
alter
influenc
choic
perform
blood
transfus
imha
patient
b
blood
transfus
could
addit
therapeut
approach
c
applic
leukocyt
ratio
prognosi
case
imha
primari
secondari
admit
veterinari
teach
hospit
may
juli
includ
signal
histori
clinic
sign
paramet
surviv
rate
collect
patient
divid
two
group
patient
imhant
treat
immunosuppress
therapi
alon
primari
n
secondari
n
patient
imhat
receiv
also
blood
transfus
primarili
pack
rbc
primari
n
secondari
n
collect
paramet
group
statist
compar
imhat
patient
compar
imhant
patient
primari
secondari
caus
present
wors
mark
accord
tokyo
score
system
tss
chi
squar
p
lower
erythrocyt
count
p
hemoglobin
concentr
p
platelet
count
p
higher
valu
band
neutrophil
p
band
neutrophil
lymphocyt
ratio
p
band
neutrophilneutrophil
lymphocyt
ratio
p
lower
valu
lymphocyt
monocyt
ratio
p
higher
valu
protein
p
activ
partial
thromboplastin
time
p
lower
surviv
rate
day
logrank
p
day
blood
transfus
perform
base
sever
clinic
sign
imhat
patient
show
sever
diseas
accord
tss
greater
acut
inflammatori
condit
coagul
defect
high
death
rate
among
imhat
patient
day
relat
critic
condit
probabl
desir
benefit
blood
transfus
nt
reach
howev
link
blood
transfus
relat
wors
clinic
sign
imhat
patient
could
final
leukocyt
ratio
dog
affect
imha
assess
first
time
far
proven
use
marker
acut
inflamm
could
prognost
valu
disclosur
report
leishmaniasi
zoonosi
caus
leishmania
spp
chronic
often
fatal
diseas
human
dog
left
untreat
recent
year
microrna
mirna
group
small
rna
abl
regul
gene
express
shown
play
critic
role
develop
function
immun
respons
circul
mirna
highli
degrad
transport
myceli
vesicl
exosom
becom
stabl
protect
rnase
degrad
reliabl
diagnost
biomark
diseas
patient
use
murin
anim
role
play
exosom
mirna
explor
leishmania
infect
reduct
activ
abund
mirna
present
liver
tissu
obtain
littl
known
role
exosom
mirna
canin
leishmaniasi
cl
particular
interact
exosom
lipid
alter
aim
studi
isolatecharacter
exosom
canin
serum
obtain
healthi
dog
evalu
qualityquant
exosom
mirna
protein
evalu
express
serum
exosom
healthi
dog
leishmaniot
dog
blood
sampl
collect
routin
hematologicalbiochem
analys
healthi
dog
therapi
biochem
panel
complet
serum
cholesterol
profil
hdl
ldl
serum
exosom
isol
use
kit
character
flow
cytometri
electron
microscopi
express
analyz
via
quantit
differ
two
group
statist
analyz
p
valu
consid
signific
first
studi
show
detect
circul
serum
exosom
content
dog
affect
cl
serum
exosom
nm
diamet
contain
mirna
isol
concentr
mirna
protein
recov
albumin
hdl
decreas
wherea
total
protein
ldl
significantli
increas
affect
compar
healthi
dog
shown
experiment
studi
perform
mice
signific
decreas
express
seen
leishmania
infect
dog
compar
healthi
one
studi
suggest
alter
circul
lipoprotein
associ
low
express
exosom
indic
liver
dysfunct
dog
natur
affect
leishmania
infantum
disclosur
report
veterinari
medicin
although
red
blood
cell
rbc
iron
serum
level
seem
influenc
inflamm
specif
investig
regard
red
blood
cell
paramet
iron
serum
level
enteropath
cat
lack
aim
studi
investig
type
anemia
serum
iron
level
cat
intestin
involv
retrospect
review
conduct
medic
record
cat
present
univers
veterinari
teach
hospit
look
ultrasonograph
sign
concurr
inflamm
least
two
organ
among
liver
pancrea
intestin
cat
includ
inform
clinic
sign
laboratori
test
cbc
serum
iron
level
avail
cat
met
inclus
criteria
enrol
studi
patient
divid
two
group
accord
ultrasonograph
sign
cat
concurr
involv
pancrea
liver
intestin
group
n
cat
concurr
involv
two
organ
pancrea
liver
intestin
group
b
n
differ
group
statist
investig
test
iron
unpair
anemia
paramet
categor
data
analyz
fisher
exact
test
cat
show
anemia
frequent
mild
hct
moder
hct
microcytosi
infrequ
find
two
cat
microcytosi
anemia
hypoferremia
concurr
hypoferremia
serum
iron
mcgdl
present
cat
concurr
anemia
observ
cat
without
associ
two
paramet
hypoferremia
anemia
sever
group
median
serum
iron
mcgdl
mean
rbc
p
group
b
median
serum
iron
mcgdl
mean
rbc
moreov
anemia
frequent
present
group
p
roc
curv
use
determin
optim
serum
iron
identifi
cat
intestin
involv
cat
serum
iron
lower
mcgdl
frequent
belong
group
sensit
specif
p
plausibl
hypothesi
origin
anemia
presenc
chronic
diseas
decreas
serum
iron
level
may
consid
marker
inflamm
enteropath
cat
intestin
inflamm
may
caus
sever
hypoferremia
erythropoiesi
suppress
anemia
disclosur
report
lung
ultrasound
lu
use
detect
artifact
b
line
anim
trauma
pulmonari
edema
syndrom
scan
protocol
use
previou
studi
includ
four
anatom
site
hemithorax
vet
blue
scan
intercost
space
region
base
protocol
advantag
quickli
assess
critic
ill
patient
respiratori
distress
howev
unclear
result
vet
blue
protocol
correl
find
entir
thorax
scan
et
present
studi
aim
compar
frequenc
number
b
line
well
parenchym
abnorm
vet
blue
et
protocol
hypothes
b
line
would
frequent
detect
et
significantli
affect
final
conclus
dog
variou
clinic
problem
cardiac
diseas
cardiorespiratori
comorbid
respiratori
diseas
problem
recruit
prospect
studi
dog
uncoop
critic
ill
toler
two
scan
protocol
exclud
scan
perform
singl
clinician
complet
lu
train
session
thorax
dog
first
scan
vet
blue
protocol
et
without
hair
clip
compar
vet
blue
protocol
b
line
significantli
frequent
et
vs
p
assess
sever
b
line
absent
rare
numer
confluent
show
sever
et
b
line
vet
blue
protocol
p
nevertheless
final
conclus
drawn
base
posit
site
b
line
per
hemithorax
use
previou
studi
final
conclus
two
protocol
significantli
differ
p
agreement
two
protocol
substanti
kappa
detect
parenchym
lesion
two
protocol
significantli
differ
p
conclus
result
suggest
lu
find
vet
blue
protocol
substanti
agre
et
howev
brought
mind
sever
lesion
lu
may
underestim
use
region
base
protocol
disclosur
report
studi
support
ministri
scienc
technolog
taiwan
sever
prospect
observ
studi
provid
data
plasma
homocystein
concentr
healthi
cat
reveal
variabl
investig
conduct
healthi
laboratori
cat
suggest
impair
homocystein
metabol
individu
use
methionin
load
test
aim
studi
determin
differ
metabolom
profil
healthi
cat
exhibit
low
high
plasma
homocystein
concentr
respect
use
frozen
plasma
sampl
healthi
adult
cat
previous
enrol
prospect
observ
studi
aim
determin
refer
interv
plasma
homocystein
concentr
felin
speci
extract
individu
high
plasma
homocystein
concentr
select
individu
low
plasma
homocystein
concentr
plasma
sampl
subject
target
metabolom
analysi
use
absoluteidq
kit
biocrat
life
scienc
ag
assess
six
biochem
class
acylcarnitin
amino
acid
biogen
amin
glycerophospholipid
sphingolipid
hexos
orthogon
partial
discrimin
analysi
identifi
model
discrimin
plasma
sampl
two
popul
healthi
cat
perform
model
confirm
analysi
varianc
base
analysi
differenti
metabolit
identifi
cat
high
plasma
homocystein
concentr
exhibit
higher
concentr
glycerophospholipid
sphingolipid
biogen
amin
amino
acid
acylcarnitin
show
lower
concentr
amino
acid
glycerophospholipid
biogen
amin
compar
cat
low
homocystein
concentr
first
studi
investig
felin
metabolom
relat
plasma
homocystein
concentr
result
suggest
variabl
plasma
homocystein
concentr
healthi
cat
may
associ
metabol
peculiar
sever
discrimin
amino
acid
biogen
amin
involv
pathway
methionin
metabol
addit
higher
concentr
plasmalogen
cat
high
plasma
homocystein
concentr
may
indic
enhanc
oxid
stress
increas
activ
protect
mechan
oxid
stress
disclosur
report
evid
human
rat
cat
suggest
acut
pancreat
complic
hemolysi
includ
hemolysi
imha
studi
investig
associ
imha
pancreat
dog
case
control
studi
nest
retrospect
cohort
studi
includ
group
dog
match
age
breed
sexual
statu
dog
imha
clinic
healthi
dog
sick
dog
without
imha
dog
hct
refer
interv
ri
posit
membran
antibodi
test
acut
pancreat
diagnos
dog
amylas
lipas
concentr
ri
mgdl
mgdl
respect
crp
concentr
mgdl
ri
anorexia
andor
vomit
frequenc
pancreat
compar
among
group
fisher
exact
test
admiss
dog
imha
without
pancreat
dog
imha
without
pancreat
develop
pancreat
switch
imha
pancreat
group
day
pancreat
event
free
plasma
hemoglobin
hbfp
dog
imha
pancreat
time
pancreat
diagnosi
without
pancreat
present
calcul
hbfp
hbtot
rbc
x
chcm
x
mcv
compar
test
roc
curv
analysi
use
identifi
best
hbfp
cutoff
valu
youden
index
discrimin
imha
dog
without
pancreat
rel
risk
rr
develop
pancreat
dog
imha
hbfp
concentr
youden
index
calcul
final
mortal
imha
dog
without
pancreat
evalu
chi
squar
test
present
frequenc
pancreat
significantli
p
higher
dog
imha
compar
control
respect
period
dog
imha
develop
pancreat
imha
dog
pancreat
n
significantli
p
higher
hbpf
median
gdl
rang
compar
imha
dog
without
pancreat
n
median
gdl
rang
youden
index
hbpf
gdl
sensit
specif
auc
ci
p
dog
imha
hbpf
concentr
gdl
result
increas
risk
pancreat
rr
ci
differ
mortal
p
imha
dog
without
pancreat
dog
imha
increas
risk
pancreat
sever
dog
develop
pancreat
diagnosi
imha
may
suggest
imha
may
caus
pancreat
hbfp
trigger
disclosur
report
sepsi
lead
caus
death
veterinari
patient
remain
challeng
diagnosi
prompt
accur
manner
procalcitonin
pct
studi
extens
human
medicin
commonli
use
biomark
sepsi
littl
inform
regard
pct
biomark
sepsi
dog
exist
control
studi
evalu
kinet
pct
sepsi
aim
studi
evalu
respons
serum
pct
dog
experiment
induc
endotoxemia
hypothes
pct
would
rapidli
detect
serum
inject
lp
would
remain
elev
least
hour
six
healthi
mix
breed
dog
includ
studi
experiment
endotoxemia
induc
inject
healthi
dog
lipopolysaccharid
lp
ugkg
iv
vital
sign
monitor
serial
blood
sampl
collect
measur
serum
pct
hour
follow
lp
inject
differ
mean
serum
pct
serial
time
point
assess
use
mix
effect
model
dog
develop
lethargi
gastrointestin
sign
within
minut
lp
administr
within
hour
lp
administr
dog
experienc
decreas
mean
arteri
pressur
map
within
hour
lp
administr
dog
develop
fever
dog
serum
pct
concentr
baselin
hour
post
lp
administr
p
averag
peak
hour
averag
serum
pct
concentr
remain
significantli
elev
time
point
hour
post
lp
administr
elev
hour
remain
baselin
hour
result
current
studi
suggest
pct
express
respons
experiment
induc
endotoxemia
kinet
pct
express
favor
support
use
biomark
sepsi
dog
addit
chang
serial
measur
agreement
clinic
evalu
improv
pct
may
addit
role
prognost
therapeut
disclosur
report
fund
studi
provid
part
ontario
veterinari
colleg
depart
clinic
studi
last
year
increas
obes
incid
canin
speci
enshrin
relev
import
worldwid
diseas
recent
obes
associ
impair
immun
chronic
inflamm
human
well
mous
model
increas
concentr
leptin
cytokin
describ
obes
dog
reduc
number
regulatori
cell
treg
report
viscer
adipos
tissu
blood
obes
human
recent
also
labrador
retriev
obes
dog
moreov
evid
address
possibl
impact
obes
cardiovascular
apparatu
dog
aim
studi
investig
effect
weight
loss
program
metabol
immunolog
profil
blood
leptin
level
cardiovascular
paramet
obes
dog
ten
overweight
dog
ob
bc
recruit
studi
underw
blood
test
complet
blood
count
serum
biochemistri
blood
level
assay
cell
ratio
b
cell
treg
cell
flow
cytometri
measur
serum
leptin
elisa
kit
assess
cardiovascular
function
blood
pressur
measur
electrocardiographi
echocardiographi
five
month
commerci
avail
weight
loss
diet
ten
normal
weight
bc
healthi
dog
repres
control
group
ctr
regard
metabol
profil
mild
signific
decreas
total
cholesterol
signific
decreas
triglycerid
serum
level
p
observ
obes
dog
signific
differ
biochem
paramet
well
haematolog
valu
two
observ
time
concern
cardiovascular
paramet
signific
differ
observ
particularli
systol
arteri
blood
pressur
valu
refer
rang
time
ob
elev
serum
leptin
concentr
decreas
significantli
p
weight
loss
howev
remain
higher
compar
ctr
ob
dog
show
signific
low
level
p
treg
compar
ctr
increas
weight
loss
data
suggest
derang
combin
high
leptin
level
might
character
obes
dog
absenc
cardiovascular
alter
furthermor
basi
result
may
suggest
probabl
dog
greater
reduct
fat
mass
weight
loss
program
necessari
order
restor
immunolog
balanc
disclosur
report
data
canin
life
expect
import
owner
veterinarian
assur
compani
spars
europ
unit
kingdom
except
especi
franc
aim
retrospect
cohort
studi
determin
life
expect
caus
death
dog
seen
toulous
veterinari
teach
hospit
tvth
franc
effect
variou
factor
breed
gender
size
data
databas
tvth
search
dog
record
dead
septemb
record
screen
determin
age
death
classifi
caus
neoplast
cardiovascular
behavior
dermatolog
endocrinolog
gastroenterolog
hematopoiet
infecti
musculoskelet
neurolog
ophthalmolog
reproduct
respiratori
trauma
uronephrolog
caus
breed
weight
categori
kg
record
specifi
result
analyz
use
commerci
softwar
log
rank
test
use
life
expect
effect
breed
gender
reproduct
statu
weight
categori
assess
test
multivari
analysi
total
dog
belong
breed
includ
number
dog
breed
vari
caus
death
weight
could
identifi
dog
respect
median
life
expect
dog
year
rang
weight
signific
effect
longev
dog
kg
n
dog
kg
n
live
respect
longer
median
year
shorter
median
year
dog
weight
n
kg
n
median
longev
year
respect
p
factor
significantli
associ
increas
longev
dog
femal
spay
mix
breed
p
neoplasia
common
caus
death
especi
boxer
bernes
breed
influenc
caus
death
signific
p
brittani
spaniel
die
mostli
dermatolog
disord
cavali
king
charl
bulldog
respiratori
caus
cavali
king
charl
spitz
cardiovascular
diseas
year
common
caus
trauma
infect
compar
whole
popul
intact
femal
like
die
endocrinolog
caus
neuter
femal
neoplast
disord
p
studi
suggest
canin
longev
highli
influenc
weight
domin
caus
death
french
dog
vari
breed
gender
reproduct
statu
studi
enlarg
first
opinion
practic
disclosur
report
addit
respiratori
difficulti
brachycephal
obstruct
airway
syndrom
boa
caus
exercis
intoler
daili
habitu
physic
activ
quantifi
count
acceleromet
measur
frequenc
durat
intens
activ
first
aim
studi
establish
cut
point
sedentari
moder
high
activ
second
compar
activ
level
french
bulldog
moder
sever
sign
boa
boa
french
bulldog
none
mild
sign
boa
normocephal
dog
cut
point
actic
accelomet
read
sedentari
lie
slight
movement
trunk
moder
high
trot
speed
kmh
collect
epoch
length
sedentari
epoch
high
epoch
activ
upper
limit
sedentari
lower
limit
high
activ
defin
mean
x
sd
sd
moder
valu
boa
n
dog
boa
n
dog
normocephal
n
dog
compar
bodi
size
wore
actic
collar
seven
consecut
day
statist
comparison
activ
level
group
perform
anova
method
tukey
correct
use
comparison
sedentari
activ
establish
cut
point
high
activ
dog
spent
time
sedentari
activ
boa
dog
dog
control
mean
sd
signific
differ
found
boa
normocephal
dog
sedentari
high
activ
percentag
p
p
respect
conclus
dog
mark
boa
sign
spend
less
time
high
activ
time
sedentari
activ
normocephal
dog
disclosur
report
protein
crp
acut
phase
protein
dog
recent
shown
particularli
use
discrimin
bacteri
bronchopneumonia
pulmonari
diseas
promis
guid
antibiot
therapi
durat
howev
public
dog
infect
bordetella
bronchiseptica
bb
specif
distinguish
other
experiment
studi
high
elev
crp
identifi
dog
inocul
bb
nevertheless
amplitud
increas
crp
dog
bb
describ
aim
studi
describ
valu
crp
dog
lower
airway
bb
infect
without
radiograph
pulmonari
involv
magnitud
crp
elev
also
compar
dog
diagnos
bacteri
aspir
bronchopneumonia
abp
sixteen
dog
lower
airway
bb
infect
dog
abp
select
includ
dog
crp
valu
thorac
radiograph
diagnosi
avail
bb
infect
confirm
bacteri
cultur
andor
quantit
pcr
bronchoalveolar
lavag
fluid
abp
diagnos
base
compat
histori
physic
examin
radiograph
find
favor
evolut
empir
antimicrobi
therapi
median
age
dog
bb
infect
abp
year
respect
p
eleven
dog
bb
infect
alveolar
lesion
radiograph
one
dog
anoth
bacteri
coinfect
crp
valu
mildli
elev
dog
dog
without
alveolar
lesion
respect
p
median
crp
valu
significantli
higher
dog
alveolar
lesion
compar
dog
without
alveolar
lesion
mgl
versu
mgl
p
durat
clinic
sign
longer
week
bb
dog
durat
differ
dog
normal
elev
valu
well
dog
without
alveolar
lesion
dog
bb
infect
alveolar
lesion
median
crp
valu
significantli
lower
dog
abp
versu
mgl
p
rang
elev
crp
overlap
two
group
mgl
mgl
respect
conclus
regardless
presenc
alveolar
lesion
bb
may
suspect
cough
dog
normal
slightli
elev
crp
suggest
crp
good
marker
hep
guid
type
durat
treatment
bordetellosi
disclosur
report
prolong
tissu
hypoxia
caus
chronic
pulmonari
diseas
commonli
cite
import
mechan
develop
secondari
physiolog
appropri
polycythemia
howev
preval
sever
polycythemia
describ
detail
dog
chronic
hypox
pulmonari
diseas
dog
median
age
interquartil
rang
year
chronic
pulmonari
diseas
document
chronic
hypoxia
partial
pressur
arteri
oxygen
mmhg
least
two
separ
arteri
blood
ga
measur
minimum
month
apart
retrospect
identifi
patient
record
dog
sight
hound
breed
exclud
diagnosi
base
thorough
clinic
examin
includ
bronchoscopi
brochoalveolar
lavag
thorac
comput
tomographi
lung
histopatholog
combin
aforement
statist
correl
red
blood
cell
paramet
analyz
use
pearson
correl
coeffici
group
compris
west
highland
white
terrier
canin
idiopath
pulmonari
fibrosi
dog
breed
follow
lung
diseas
chronic
bronchiti
eosinophil
bronchopneumopathi
interstiti
lung
diseas
dog
chronic
respiratori
sign
cough
andor
tachypnea
chronic
diffus
radiograph
lung
chang
final
diagnosi
establish
median
durat
hypoxia
month
iqr
month
mean
end
period
mmhg
sd
std
mmhg
red
blood
cell
paramet
measur
end
hypoxemia
period
within
laboratori
refer
rang
major
dog
erythrocyt
count
erytr
normal
dog
mean
std
rang
laboratori
refer
rang
hemoglobin
concentr
hb
normal
dog
mean
std
gl
rang
gl
laboratori
refer
rang
gl
hematocrit
hkr
normal
dog
mean
std
rang
laboratori
refer
rang
mark
polycythemia
hematocrit
note
dog
red
blood
cell
paramet
correl
sever
hypoxia
correl
erytr
r
p
hb
r
p
hkr
r
p
result
indic
polycythemia
uncommonli
encount
dog
chronic
hypox
pulmonari
diseas
encount
mild
increas
red
blood
cell
paramet
note
disclosur
report
sj
viitanen
receiv
research
grant
project
studi
describ
abstract
finnish
foundat
veterinari
research
finnish
veterinari
foundat
sj
viitanen
receiv
salari
recid
program
partial
support
royal
canin
aim
studi
investig
three
differ
score
system
canin
sinonas
aspergillosi
csa
order
predict
whether
indic
persist
csa
endoscop
medic
record
dog
treat
csa
review
inclus
criteria
presenc
full
medic
histori
radiolog
investig
meticul
debrid
fungal
plaqu
endoscop
day
treatment
dog
fulfil
inclus
criteria
includ
studi
dog
csa
grade
score
given
accord
sharp
time
diagnosi
rhinoscop
score
accord
zonderland
given
endoscop
examin
score
modifi
author
creat
three
categori
sever
mild
csa
score
moder
csa
score
sever
csa
score
amount
fungal
plaqu
consid
mild
countabl
moder
partial
occupi
sinonas
caviti
abund
obliter
sinonas
caviti
clinic
score
propos
schuller
modifi
use
assess
patient
prior
endoscop
dog
classifi
clinic
sign
report
mild
occasion
sneez
occasion
revers
sneez
serou
mucoid
discharg
moder
mucopurul
discharg
frequent
sneez
frequent
revers
sneez
sever
sever
mucopurul
discharg
stertor
persist
revers
sneez
persist
sneez
epistaxi
gener
malais
clinic
sign
three
score
system
statist
analis
explicitli
address
question
chanc
predict
persist
fungal
infect
base
score
system
outcom
ye
score
method
consid
predict
fungal
infect
persist
conting
tabl
score
system
comput
null
hypothesi
independ
score
method
persist
fungal
infect
statist
test
exact
test
accord
statist
result
sharp
grade
score
system
consid
significantli
associ
persist
persist
fungal
infect
endoscop
therefor
consid
predictor
fungal
infect
persist
sharp
score
system
fisher
endoscop
strongli
recommend
assess
csa
treatment
effect
sharp
grade
score
use
predict
treatment
outcom
dog
treat
one
hour
clotrimazol
infus
sharp
grade
score
might
appli
also
differ
method
treat
csa
studi
warrant
disclosur
report
compon
therapi
involv
separ
whole
blood
wb
compon
pack
red
blood
cell
plasma
specif
replac
therapi
reduc
transfus
reaction
cat
blood
transfus
commonli
collect
use
open
system
administ
wb
part
challeng
prepar
compon
small
blood
volum
felin
blood
high
erythrocyt
sediment
rate
therefor
syring
contain
collect
blood
place
upright
plasma
remov
red
cell
shortli
collect
separ
storag
plasma
prbc
aim
studi
assess
characterist
felin
prbc
unit
obtain
blood
sediment
collect
storag
day
blood
collect
fourteen
felin
blood
donor
three
ml
syring
blood
ratio
use
open
system
cbc
perform
donor
three
syring
allow
sediment
approx
hour
room
temperatur
plasma
asept
express
plain
transfer
bag
rbc
express
anoth
transfer
bag
ml
prbc
unit
store
refriger
sampl
use
blood
bag
segment
prepar
time
day
storag
blood
prbc
unit
follow
paramet
evalu
hematolog
paramet
rbc
hb
hct
wbc
plt
ii
percentag
hemolysi
iii
morpholog
index
prbc
unit
score
base
echinocyt
transform
normal
discocyt
iv
aerob
anaerob
blood
cultur
prbc
unit
donor
prbc
unit
signific
increas
rbc
count
mean
increas
hb
concentr
gdl
hct
percentag
signific
reduct
found
plt
count
compar
prbc
signific
increas
found
percentag
hemolysi
morpholog
index
signific
reduct
rbc
count
hct
percentag
wbc
count
median
plt
count
median
blood
cultur
neg
bacteri
growth
prbc
unit
obtain
sediment
donat
blood
appear
suitabl
blood
compon
treatment
normovolem
anemia
howev
storag
day
suggest
canin
felin
prbc
unit
result
signific
hematolog
chang
could
reduc
oxygen
deliveri
transfus
disclosur
report
veget
foreign
bodi
frequent
caus
cough
dog
spring
summer
franc
result
varieti
clinic
sign
endoscop
abnorm
aim
studi
describ
foreign
bodi
locat
rate
retriev
success
complic
macroscop
endoscop
find
dog
veget
foreign
bodi
fifti
two
dog
includ
retrospect
evalu
medic
record
dog
admit
bronchial
veget
foreign
bodi
diagnosi
base
direct
visualis
bronchoscop
exam
surgic
retriev
male
femal
includ
studi
half
hunt
dog
durat
clinic
sign
rang
day
cough
main
clinic
sign
foreign
bodi
remov
bronchu
case
bronchu
case
right
left
bronchi
case
endoscop
retriev
success
case
nine
dog
need
surgic
treatment
surviv
rate
endoscop
imag
review
dog
show
purul
exsud
ventral
larynx
region
trachea
bronchi
foreign
bodi
locat
presenc
larg
bronchial
nodul
irregular
mucos
surfac
frequent
observ
mild
bleed
main
complic
retrospect
studi
confirm
safeti
use
bronchoscopi
diagnosi
treatment
bronchial
veget
foreign
bodi
dog
mucos
nodul
associ
purul
materi
within
airway
frequent
endoscop
find
disclosur
report
dolichocephal
breed
predispos
sinonas
aspergillosi
brachycephal
dog
affect
sinc
disrupt
resid
microbiom
may
contribut
diseas
pathogenesi
modul
immun
respons
sinc
microbiota
dictat
type
relationship
hypothet
differ
predisposit
nasal
diseas
dog
could
associ
differ
core
nasal
microbiota
breed
healthi
dog
recruit
includ
medium
larg
dog
dolichocephal
breed
dc
brachycephal
dog
bc
terrier
dog
dog
older
month
dog
live
either
rural
n
urban
domest
condit
n
nasal
swab
obtain
anesthesia
bank
batch
analysi
dna
extract
pcr
target
region
rdna
perform
amplicon
sequenc
miseq
illumina
sequenc
taxonom
assign
microbiota
commun
analysi
done
mothur
otu
cluster
distanc
analysi
ecolog
index
show
bacteri
rich
p
p
significantli
higher
bc
group
compar
two
group
amova
analysi
indic
bc
group
differ
compar
dc
group
bc
vs
dc
p
bc
vs
p
differ
bacteri
load
group
effect
live
condit
nasal
microbi
popul
predominantli
compos
phyla
proteobacteria
mainli
repres
famili
moraxellacea
actinobacteria
firmicut
bacteroidet
agreement
previou
studi
howev
within
breed
group
rel
abund
phyla
highli
variabl
signific
differ
found
group
famili
level
rel
abund
pasteurellacea
significantli
higher
bc
group
distinct
speci
genera
found
indic
discrimin
p
among
speci
genera
bc
group
speci
group
studi
mainli
demonstr
signific
differ
nasal
microbiota
bc
group
compar
two
group
differ
might
associ
particular
facial
morpholog
andor
breath
pattern
brachycephal
dog
identifi
nasal
microbiota
would
favor
breed
suscept
dolichocephal
dog
nasal
diseas
studi
need
investig
role
nasal
microbiota
variat
trigger
perpetu
factor
nasal
diseas
especi
dog
sinonas
aspergillosi
disclosur
report
aspergillosi
sna
import
caus
chronic
nasal
diseas
dog
character
format
superfici
mucos
fungal
plaqu
within
nasal
caviti
andor
frontal
sinu
system
healthi
dog
aspergillu
fumigatu
classic
recogn
import
etiolog
agent
notabl
speci
consid
group
fumigati
group
includ
sever
speci
distinguish
via
molecular
exam
date
studi
analyz
fungal
isol
involv
canin
sna
case
genet
level
show
fumigatu
sensu
stricto
main
causal
speci
opposit
speci
fumigati
group
call
criptic
speci
viridinutan
complex
found
associ
sna
cat
cat
sna
invas
poor
prognosi
due
involv
space
aim
studi
describ
clinic
mycolog
featur
seri
case
canin
sna
itali
case
recruit
veterinarian
belong
endovet
group
special
endoscopi
diagnosi
achiev
combin
exam
endoscop
visual
fungal
plaqu
andor
visual
fungal
element
cytologyhistolog
nasal
biopsi
fungi
isol
biopsi
identifi
morpholog
key
molecular
analys
sequenc
gene
twenti
isol
chosen
randomli
test
vitro
antifung
agent
commonli
use
dog
sna
itraconazol
clotrimazol
enilconazol
agent
use
human
patient
voriconazol
posaconazol
afumigatu
sensu
stricto
identifi
case
remain
case
due
flavu
fusarium
spp
paecilomyc
spp
one
case
definit
identif
achiev
vitro
mic
minimum
inhibitori
concentr
valu
within
expect
limit
therefor
resist
detect
breed
predisposit
note
contrari
agreement
past
studi
sex
predisposit
could
note
sinc
male
account
sampl
clinic
sign
frequent
observ
alreadi
report
literatur
eg
nasal
discharg
present
case
monolater
frontal
sinu
involv
confirm
case
although
data
follow
visit
incomplet
effect
treatment
seem
repres
mechan
debrid
fungal
plaqu
plu
local
treatment
use
clotrimazol
cream
enilconazol
solut
procedur
conduct
endoscopi
disclosur
report
studi
aim
evalu
compar
natur
canin
urolith
studi
involv
dog
predominantli
central
europ
ce
dog
china
cn
year
analys
perform
use
infrar
spectroscopi
global
statist
urolith
ce
cn
dog
male
femal
neuter
spay
dog
popul
ce
cn
dog
consist
mongrel
breed
urolith
compris
struvit
ce
cn
calcium
oxal
cystin
ammonium
urat
other
ce
cn
dog
median
age
year
struvit
calcium
oxal
cystin
struvit
urolith
ce
cn
dog
account
femal
spay
male
neuter
dog
calcium
oxal
urolith
ce
cn
dog
male
neuter
femal
spay
dog
cystin
urolith
ce
cn
dog
account
male
neuter
femal
spay
dog
ce
cohort
cystin
urolith
present
irish
terrier
breed
report
genet
predisposit
cystin
calculi
cystin
urolith
also
found
american
staffordshir
terrier
bulldog
french
bullterri
huski
chihuahua
cn
cohort
irish
terrier
popul
cystin
urolith
primarili
found
bulldog
french
bullterri
studi
reveal
ce
cn
cohort
urolith
common
order
struvit
calcium
oxal
cystin
ammonium
urat
among
ce
breed
yorkshir
terrier
parson
russel
terrier
subject
calcium
oxal
pug
struvit
format
among
cn
breed
miniatur
schnauzer
bichon
poodl
subject
struvit
urolith
struvit
urolith
ce
cn
dog
occur
equal
femal
rate
substanti
higher
male
within
male
cn
dog
time
suscept
ce
counterpart
consid
role
bacteria
genesi
struvit
urolith
data
suggest
influenc
gender
well
habitat
calcium
oxal
urolith
time
preval
male
dog
femal
ce
cn
cohort
cystin
urolith
substanti
preval
male
femal
dog
ce
cn
cohort
notabl
male
ce
dog
time
suscept
cn
counterpart
overal
data
suggest
canin
urolith
format
wide
depend
breed
gender
environment
factor
like
diet
region
care
practic
disclosur
report
author
breu
wenk
employ
laboklin
gmbh
co
kg
bad
kissingen
laboklin
gmbh
co
kg
basel
e
ownermanag
laboklin
gmbh
co
kg
germani
urinari
proteincreatinin
ratio
upc
ratio
current
frequent
method
proteinuria
quantif
proteinuria
classifi
physiolog
versu
patholog
renal
although
chronic
kidney
diseas
ckd
assum
common
caus
proteinuria
cat
studi
conduct
assess
aetiolog
aim
studi
determin
main
caus
proteinuria
cat
region
lisbon
portug
cat
present
veterinari
hospit
identifi
signific
proteinuria
upc
ratio
includ
caus
proteinuria
intern
renal
interest
societi
iri
stage
systol
blood
pressur
sbp
obtain
medic
record
cat
select
includ
femal
spay
intact
male
neuter
intact
averag
year
old
cat
physiolog
proteinuria
present
renal
proteinuria
proteinuria
suspect
mix
origin
renal
detail
caus
renal
proteinuria
ckd
ckd
complic
acut
kidney
injuri
aki
diseas
capabl
decreas
renal
permselect
proteinuria
due
urinari
tract
infect
uti
cystiti
attribut
ckd
cystiti
ckd
uti
complet
iri
stage
obtain
cat
ckd
two
cat
stage
hypertens
cat
stage
ii
hypertens
cat
stage
iii
hypertens
case
stage
iv
hypertens
regard
sbp
data
avail
case
sever
hypertens
hypertens
one
cat
normotens
studi
strengthen
proteinuria
rare
cat
ckd
frequent
caus
signific
proteinuria
speci
sever
hypertens
common
find
highlight
relev
sbp
measur
cat
fact
iri
stage
possibl
cat
still
reflect
poor
awar
veterinarian
classificationmor
contribut
better
knowledg
caus
proteinuria
studi
suggest
physiolog
caus
induc
signific
proteinuria
cat
disclosur
report
canin
diseas
cvbd
highli
preval
southern
europ
caus
glomerular
diseas
dog
commonli
associ
signific
proteinuria
howev
studi
evalu
role
cvbd
aetiolog
proteinuria
endem
countri
accord
origin
proteinuria
classifi
renal
current
quantifi
urinari
proteincreatinin
ratio
upc
aim
studi
assess
main
caus
proteinuria
dog
region
lisbon
order
estim
role
cvbd
dog
present
lisbon
veterinari
hospit
januari
decemb
identifi
signific
proteinuria
upc
ratio
establish
primari
diagnosi
select
base
medic
record
case
classifi
accord
proteinuria
origin
dog
select
femal
male
averag
year
old
rang
year
old
none
proteinuria
renal
proteinuria
proteinuria
suspect
mix
origin
detail
renal
proteinuria
presumpt
diagnosi
glomerulonephr
secondari
cvbd
show
chronic
kidney
diseas
system
diseas
possibl
induc
impair
glomerular
permselect
bronchopneumonia
enteropathi
liver
diseas
hyperadrenocortic
diabet
mellitu
neoplasia
acut
kidney
injuri
aki
proteinuria
includ
dog
pyometra
urinari
tract
infect
uti
mix
proteinuria
consid
dog
system
diseas
cvbd
ckd
aki
hyperadrenocortic
concurr
uti
andor
cystiti
consid
dog
diagnos
cvbd
posit
serolog
posit
one
agent
detail
serolog
result
dog
posit
leishmania
infantum
rickettsia
spp
heartworm
diseas
borrelia
burgdorferi
ehrlichia
spp
babesia
cani
anaplasma
spp
whilst
signific
proteinuria
uncommon
cvbd
main
caus
renal
proteinuria
dog
leishmaniosi
frequent
cvbd
identifi
serolog
despit
increas
prevent
measur
expect
result
sinc
cvbd
highli
preval
portug
studi
suggest
cvbd
common
differenti
diagnosi
renal
proteinuria
dog
lisbon
result
might
extrapol
endem
southern
european
countri
studi
need
confirm
disclosur
report
renal
protein
loss
mainli
caus
either
tubular
glomerular
dysfunct
differenti
two
type
hold
high
diagnost
therapeut
signific
tubular
proteinuria
defin
loss
low
molecular
weight
protein
wherea
glomerulopathi
albuminuria
pronounc
hypothes
assess
urin
protein
ratio
uapr
abl
identifi
sourc
proteinuria
whether
sole
tubular
origin
glomerular
damag
present
well
proteinur
canin
urin
sampl
use
studi
sampl
belong
laboratori
beagl
clinic
patient
addit
urinari
protein
creatinin
concentr
determin
albumin
measur
immunoturbidimetr
method
urinari
ratio
uac
urinari
ratio
upc
ratio
uac
upc
uapr
calcul
find
compar
sodium
dodecyl
sulfat
polyacrylamid
gel
electrophoresi
sole
tubular
proteinuria
consid
tubular
mix
tubular
glomerular
glomerular
proteinuria
consid
median
lower
upper
quartil
upc
uac
uapr
urin
specimen
receiv
oper
characterist
roc
curv
analysi
ideal
valu
determin
tubular
proteinuria
could
identifi
high
confid
sensit
specif
posit
predict
valu
neg
predict
valu
use
valu
tubular
proteinuria
diagnos
dog
proteinuria
anim
uapr
result
show
high
correl
electrophoresi
outcom
one
dog
fals
neg
result
tubular
uapr
electrophoresi
dog
fals
posit
result
uapr
normal
protein
excret
pattern
electrophoresi
base
find
suggest
uapr
could
simpl
afford
method
identifi
sourc
proteinuria
thu
determin
uapr
may
help
diagnost
therapeut
proteinur
dog
gold
standard
differenti
tubular
glomerular
damag
histopatholog
thu
futur
plan
compar
uapr
histopatholog
diagnosi
disclosur
report
felin
lower
urinari
tract
diseas
flutd
recurr
chronic
diseas
commonli
found
current
practic
male
cat
neuter
sedentari
overweight
present
highest
risk
develop
flutd
aim
studi
evalu
activ
nag
index
earli
tubular
damag
marker
neuter
male
cat
obstruct
flutd
male
cat
differ
breed
age
diagnos
obstruct
lower
urinari
tract
diseas
includ
studi
diagnosi
base
physic
examin
haematolog
biochem
radiolog
ultrasound
exam
urin
specimen
collect
via
cystocentesi
subject
complet
urinari
analysi
urinari
biochemistri
urinari
sediment
cultur
sensit
test
complementari
urinari
nag
index
activ
evalu
sampl
higher
valu
urinari
nag
index
found
male
cat
obstruct
flutd
bacteri
implic
median
valu
ug
compar
asept
obstruct
flutd
median
nag
index
valu
found
ug
prolong
anuria
consecut
uretr
obstruct
well
repeat
obstruct
episod
induc
kidney
tubular
lesion
use
marker
current
medic
practic
allow
earli
diagnosi
patient
tubular
damag
consecut
urethr
obstruct
urinari
reflux
obstruct
male
cat
uti
greater
risk
develop
tubular
lesion
especi
septic
cystiti
disclosur
report
reflux
nephropathi
consid
possibl
caus
kidney
diseas
young
boxer
dog
furthermor
vesicoureter
reflux
found
associ
urinari
tract
infect
aim
studi
evalu
preval
bacteriuria
young
boxer
dog
describ
chang
urin
composit
dog
clinic
healthi
boxer
puppi
urin
collect
cystocentesi
urinalysi
includ
urin
cultur
perform
dog
examin
age
day
median
day
male
femal
dog
cultur
posit
femal
dog
femal
dog
none
male
dog
posit
cultur
cultur
bacteria
e
coli
pyuria
seen
cultur
posit
dog
cultur
neg
dog
bacteria
sediment
seen
cultur
posit
dog
cultur
neg
dog
combin
pyuria
bacteria
sediment
seen
cultur
posit
dog
cultur
neg
dog
urin
specif
graviti
rang
median
significantli
lower
cultur
posit
dog
compar
cultur
neg
dog
median
vs
bacteri
colon
urin
common
young
femal
boxer
dog
signific
find
specif
concern
possibl
associ
develop
kidney
diseas
determin
disclosur
report
studi
support
schweizerisch
b
gerber
speaker
boering
ingelheim
symmetr
dimethylarginin
sdma
sensit
renal
biomark
whose
concentr
increas
earlier
creatinin
glomerular
filtrat
rate
decreas
far
human
sdma
consid
import
earli
biomark
kidney
dysfunct
aim
studi
evalu
sdma
dog
acut
pancreat
ap
associ
kidney
injuri
sever
diseas
dog
ap
present
veterinari
teach
hospit
univers
pisa
prospect
enrol
ap
diagnosi
base
compat
clinic
laboratori
paramet
abnorm
snap
cpl
test
idexx
laboratori
posit
abdomin
ultrasound
within
h
admiss
dog
histori
renal
diseas
clinic
recordshistori
bloodwork
diagnost
imag
urinari
tract
infect
andor
hemodialysi
treatment
exclud
along
dog
receiv
known
nephrotox
drug
eg
drug
aminoglycosid
dog
data
urea
creatinin
urinari
output
uo
record
acut
kidney
injuri
aki
grade
made
base
current
iri
consensu
canin
acut
pancreat
sever
cap
calcul
dog
present
previous
describ
use
divid
dog
two
group
cap
sdma
measur
use
high
perform
liquid
chromatographi
hplc
sdma
compar
uo
group
presenc
aki
cap
score
group
use
welch
base
normal
distribut
sdma
correl
urea
creatinin
level
use
spearman
correl
test
dog
diagnosi
ap
enrol
owner
inform
consent
sixteen
dog
show
aki
overal
median
sdma
mgdl
rang
mgdl
dog
group
sdma
refer
rang
mgdl
median
sdma
significantli
higher
aki
dog
vs
mgdl
p
urea
creatinin
concentr
show
posit
correl
sdma
level
aki
dog
p
r
p
r
respect
correl
signific
group
associ
sdma
uo
found
final
dog
cap
higher
sdma
compar
dog
cap
mgdl
vs
mgdl
p
base
result
sdma
seem
associ
diseas
sever
cap
sdma
correl
well
kidney
disfunct
paramet
urea
creatinin
result
higher
aki
dog
interestingli
dog
present
abnorm
sdma
relat
subclin
kidney
impair
disclosur
report
need
afford
poc
test
accur
detect
signific
bacteriuria
dog
cat
test
may
help
practition
limit
unnecessari
empir
antimicrobi
treatment
improv
patient
outcom
aim
studi
compar
later
flow
immunoassay
poc
detect
bacteriuria
standard
aerob
quantit
bacteri
cultur
qbc
refer
laboratori
studi
design
prospect
cohort
studi
urin
sampl
collect
dog
cat
present
univers
hospit
companion
anim
sampl
subject
parallel
rapidbacvet
qbc
poc
result
interpret
six
investig
blind
gold
standard
result
coeffici
variat
calcul
surplu
urin
sampl
dog
cat
includ
cystocentesi
sampl
yield
coloni
form
unit
cfu
ml
qbc
yield
heavi
growth
cfuml
poc
sensit
specif
posit
neg
predict
valu
respect
eight
fals
neg
sampl
grew
staphylococcu
spp
appli
cfuml
sensit
specif
posit
neg
predict
valu
chang
respect
coeffici
variat
respect
result
suggest
limit
valu
sole
discriminatori
test
urinari
tract
infect
neg
test
result
rule
urinari
tract
infect
may
justifi
withhold
antimicrobi
therapi
pend
urin
cultur
result
disclosur
report
impair
antioxid
enzym
activ
involv
sever
complic
human
patient
manag
intermitt
haemodialysi
hd
differ
factor
concern
uraemia
hd
treatment
promot
oxid
stress
patient
hd
may
gener
oxid
stress
due
sever
factor
reduc
dialyz
biocompat
extens
contact
blood
synthet
surfac
circuit
poor
dialys
steril
aim
present
studi
evalu
antioxid
enzym
activ
haemodialysi
treatment
dog
acut
uraemia
correl
system
inflammatori
respons
syndrom
sir
dissemin
intravascular
coagul
dic
ten
urem
dog
manag
hd
hdg
ten
clinic
healthi
dog
cg
includ
enzymat
activ
catalas
cat
superoxid
dismutas
sod
glutathion
peroxidas
gpx
assess
blood
hemolys
dog
group
hdg
dog
blood
sampl
taken
immedi
hd
end
hd
second
bypass
standard
blood
flow
mlmin
hdg
dog
classifi
accord
iri
guidelin
aki
presenc
sir
dic
diagnos
basi
ematholog
biochem
coagul
profil
accord
recent
publish
criteria
enzymat
activ
cat
sod
gpx
compar
among
cg
pre
hd
treatment
n
post
hd
treatment
n
use
tukey
multipl
comparison
test
enzymat
activ
cat
sod
gpx
show
signific
differ
valu
although
gpx
significantli
increas
p
hdg
compar
cg
dog
dic
n
show
significantli
lower
cat
p
gpx
p
level
dog
without
dic
n
cat
gpx
activ
patient
sir
n
appear
significantli
lower
patient
without
sir
n
cohort
dog
intermitt
hd
seem
significantli
affect
antioxid
enzym
activ
howev
reduc
enzymat
activ
urem
dog
dic
sir
worthi
investig
disclosur
report
leptospirosi
zoonot
diseas
due
risk
human
transmiss
leptospirosi
need
monitor
urin
output
dog
acut
kidney
injuri
highli
recommend
place
indwel
urinari
cathet
hospit
urinari
catheter
predispos
urinari
tract
infect
uti
aim
retrospect
cohort
studi
evalu
type
frequenc
uti
dog
leptospirosi
identifi
risk
factor
associ
uti
leptospirot
dogsth
electron
san
marco
veterinari
clinic
poa
search
dog
diagnosi
leptospirosi
n
diagnosi
leptospirosi
consist
clinicopatholog
sign
posit
microscop
agglutin
test
titer
vaccin
dog
titer
dog
increas
convalesc
titer
andor
posit
pcr
urin
andor
blood
dog
leptospirosi
includ
studi
need
met
follow
criteria
neg
urin
sediment
urin
cultur
arriv
day
hospit
urin
sampl
cytolog
examin
bacteri
cultur
hospit
dog
meet
inclus
criteria
divid
group
catheter
dog
group
dog
group
differ
uti
frequenc
group
evalu
fisher
exact
test
associ
durat
catheter
risk
develop
uti
analys
test
age
sex
diarrhoea
anteced
antibacteri
andor
immunosuppress
treatment
evalu
associ
uti
test
signific
level
statist
test
set
total
dog
met
inclus
criteria
group
group
overal
group
dog
develop
uti
identifi
bacteria
escherichia
coli
dog
pseudomona
aeruginosa
dog
klebsiella
pneumonia
dog
uti
defin
frequenc
uti
significantli
higher
group
compar
group
ci
infect
dog
significantli
longer
catheter
time
median
day
iqr
compar
dog
median
day
iqr
p
age
sex
diarrhoea
anteced
antibacteri
andor
immunosuppress
treatment
significantli
associ
uti
urinari
catheter
durat
urinari
catheter
repres
import
risk
factor
develop
uti
dog
leptospirosi
disclosur
report
graviti
usg
use
proxi
urin
concentr
osmol
usual
determin
use
refractomet
long
held
belief
felin
urin
higher
specif
refract
human
canin
urin
thu
human
refractomet
scale
may
result
fals
high
read
felin
sampl
commerci
avail
veterinari
refractomet
calibr
differ
scale
cat
convers
formula
also
recommend
refractomet
human
scale
use
order
avoid
overestim
usg
cat
two
recent
studi
question
whether
separ
scale
necessari
correct
interpret
refractomet
read
felin
urin
aim
studi
compar
canin
felin
usg
read
obtain
commerci
human
refractomet
weightvolum
measur
usg
data
second
aim
studi
test
whether
centrifug
urin
sampl
may
effect
accuraci
refractometr
usg
determin
usg
thirteen
canin
fifteen
felin
urin
left
specimen
compar
use
refractometri
precis
weightvolum
measur
urin
sampl
clear
pale
dark
yellow
color
bia
two
method
determin
analysi
measur
perform
uncentrifug
centrifug
sampl
effect
centrifug
evalu
pair
test
median
quartil
usg
canin
sampl
mean
usg
felin
sampl
signific
differ
refractometr
usg
valu
canin
felin
urin
sampl
centrifug
mean
bia
refractometr
weightvolum
determin
usg
valu
felin
sampl
use
gener
accept
felin
correct
formula
chang
mean
bia
comparison
mean
bia
canin
sampl
base
result
conclud
unnecessari
use
differ
scale
correct
formula
refractometr
usg
determin
canin
felin
urin
sampl
use
felin
correct
formula
may
result
clinic
import
underestim
usg
usg
measur
perform
nativ
centrifug
urin
sampl
urin
clear
inaccuraci
refractomet
irrespect
speci
taken
consider
clinic
decis
make
disclosur
report
renal
damag
associ
canin
leishmaniasi
induc
nephriti
glomerulonephr
alway
detect
use
classic
laboratori
biomark
creatinin
urea
proteincreatinin
ratio
urin
specif
graviti
nag
glutamyl
http
wwwsciencedirectcomtopicsagriculturalandbiologicalsciencestransferas
ggt
hydrolyt
enzym
found
epitheli
cell
proxim
tubul
kidney
presenc
urin
associ
tubular
damag
henc
aim
evalu
diagnost
power
urinari
nag
ggt
earli
marker
renal
diseas
dog
affect
leishmaniasi
use
modifi
iri
chronic
kidney
diseas
stage
prospect
studi
conduct
group
healthi
dog
c
dog
urinari
proteincreatinin
ratio
upc
plasma
creatinin
cr
mgdl
dog
upc
cr
mgdl
dog
upc
cr
mgdl
dog
upc
mgdl
dog
present
univers
extremadura
small
anim
hospit
varieti
clinic
sign
diagnos
viscer
leishmaniasi
includ
studi
dog
haematolog
biochemistri
blood
protein
electrophoresi
leishmania
elisa
quantitit
abdomin
ultrasonographi
full
urin
analysi
cultur
includ
upc
nag
ggt
carri
nag
determin
use
commerci
kit
germani
ggt
specif
kit
spain
result
normal
respect
urinari
creatinin
express
ratio
unagcr
uggtcr
group
normal
distribut
test
use
compar
among
group
p
consid
statist
signific
urinari
unagcr
iug
mean
sd
group
c
uggtcr
iug
mean
sd
valu
obtain
group
c
unagcr
differ
statist
group
compar
control
differ
signific
differ
uggtcr
found
c
studi
show
unagccr
appear
good
biomark
earli
detect
renal
tubular
damag
earli
stage
canin
leishmaniasi
prior
presenc
azotaemia
proteinuria
contrari
uggtcr
appear
less
use
purpos
consist
elev
advanc
stage
chronic
kidney
diseas
disclosur
report
canin
leishmaniasi
highli
preval
zoonot
diseas
spain
dog
affect
present
structur
andor
function
abnorm
kidney
rang
clinic
present
asymptomat
sever
diseas
individu
clinic
sign
creatin
proteinuria
use
assess
evolut
condit
evalu
marker
earli
renal
damag
could
use
redefin
diseas
classif
prognost
andor
therapeut
guidanc
purpos
moreov
dog
leishmaniasi
optim
natur
model
studi
tubular
damag
biomark
ngal
cysc
canin
chronic
kidney
diseas
aim
evalu
diagnost
power
urinari
ngal
cysc
earli
marker
renal
diseas
dog
diagnos
l
infantum
use
modifi
iri
chronic
kidney
diseas
stage
dog
present
univers
extremadura
veterinari
hospit
varieti
clinic
sign
diagnos
viscer
leishmaniasi
includ
studi
group
stablish
healthi
dog
c
dog
urinari
proteincreatinin
ratio
upc
plasma
creatinin
cr
mgdl
dog
present
upc
cr
mgdl
dog
upc
cr
mgdl
dog
upc
mgdl
dog
also
test
includ
thorac
radiograph
echocardiographi
leishmania
pcr
varieti
tissu
ngal
determin
use
canin
ngal
elisa
kit
abcam
usa
result
express
ngalcreatinin
ratio
ungalcr
cystatin
c
measur
use
turbidimetr
latex
assay
spinreact
spain
express
cysccreatinin
ratio
ucysccr
test
use
run
comparison
due
distribut
data
p
consid
statist
signific
urinari
ungalcr
mean
sd
group
c
ucysccr
mean
sd
valu
obtain
c
biomark
statist
signific
differ
found
control
group
rest
significantli
differ
compar
ngal
cysc
addit
cysc
valu
differ
significantli
result
demonstr
urinari
ucysccr
ungalcr
highli
sensit
biomark
detect
tubular
damag
dog
affect
canin
leishmaniasi
disclosur
report
complic
urinari
tract
infect
cuti
occur
set
urinari
tract
underli
metabol
function
structur
abnorm
typic
requir
longer
antibiot
cours
carri
higher
risk
treatment
failur
uti
major
reason
antibiot
prescript
dog
respons
bacteri
popul
develop
increas
resist
aim
retrospect
studi
investig
preval
pathogen
suscept
pattern
comorbid
urinari
site
involv
detect
ultrasonographi
popul
dog
affect
cuti
four
hundr
thirti
one
urin
sampl
collect
cystocentesi
dog
underw
urin
cultur
diagnost
purpos
antimicrobi
sensit
test
obtain
method
comorbid
deduc
analysi
patient
clinic
ultrasound
report
control
group
dog
dog
affect
random
among
whole
canin
popul
examin
period
time
wilcoxon
test
use
statist
analysi
one
hundr
forti
one
urin
sampl
dog
posit
cultur
crossbre
spay
femal
preval
mean
age
year
signific
higher
preval
among
observ
labrador
retriev
english
bulldog
golden
retriev
beagl
cocker
spaniel
spay
femal
dog
year
old
escherichia
coli
predomin
pathogen
follow
staphylococcu
pseudintermediu
staphylococcu
aureu
streptococcu
faecali
klebsiella
pneumonia
pseudomona
aeruginosa
speci
predomin
singl
isol
compar
polymicrobi
infect
observ
marbofloxacin
overal
effect
molecul
sensit
follow
cefovecin
ceftriaxon
enrofloxacin
pradofloxacin
escherichia
coli
show
highest
sensibl
versu
cefovecin
marbofloxacin
trimetoprimsulphamid
ceftriaxon
pradofloxacin
enrofloxacin
repres
identifi
comorbid
urolithiasi
ckd
hyperadrenocortic
neoplasm
eight
dog
includ
recurr
infect
dog
underw
abdomin
ultrasound
show
ultrasonograph
abnorm
involv
urinari
system
upper
tract
lower
tract
high
rate
antimicrobi
resist
detect
could
lead
treatment
failur
poor
prognosi
addit
guidelin
need
public
health
concern
determin
zoonot
potenti
isol
bacteria
disclosur
report
chronic
kidney
diseas
ckd
among
major
caus
morbid
mortal
cat
signific
preval
year
old
aim
retrospect
observ
studi
evalu
preval
death
surviv
time
risk
factor
popul
cat
risk
affect
ckd
one
hundr
thirti
three
cat
start
popul
year
includ
studi
one
follow
criteria
observ
first
clinic
examin
age
year
serum
creatinin
scr
mgdl
borderlin
patholog
urinari
proteincreatinin
ratio
upc
urin
specif
graviti
usg
furthermor
data
obtain
onlin
questionnair
fill
owner
begin
nephropath
cat
stage
accord
iri
guidelin
nephropath
cat
includ
stage
wilcoxon
test
kaplan
meyer
surviv
curv
analysi
perform
median
age
popul
year
male
vs
domest
shorthair
predomin
breed
forti
nine
cat
includ
stage
stage
stage
stage
stage
mean
scr
valu
mgdl
sixti
cat
natur
dead
euthan
time
survey
due
ckd
paramet
significantli
differ
two
group
dead
ckd
dead
diseas
serum
creatinin
higher
usg
red
blood
cell
rbc
white
blood
cell
wbc
hematocrit
ht
significantli
lower
dead
ckd
cat
surviv
time
nephropath
cat
relat
age
iri
stage
serum
phosphoru
rbc
wbc
ht
cat
stage
surviv
longer
cat
stage
comorbid
reason
consult
cat
lower
surviv
time
observ
cat
bodi
condit
score
differ
normal
higher
lower
lower
surviv
observ
hypertens
condit
whole
popul
cat
consid
ckd
one
scr
result
cbc
usg
keep
consider
prognost
evalu
cat
risk
affect
ckd
age
consid
risk
prognost
factor
disclosur
report
tumor
nasal
caviti
repres
canin
neoplasm
frequent
elderli
anim
epitheli
origin
local
invas
low
metastat
incid
subject
includ
multicent
prospect
studi
examin
june
decemb
rhinoscopi
reveal
new
tissu
format
nasal
caviti
nasopharynx
case
histori
includ
clinic
exam
laboratori
exam
endoscopi
tomographi
histolog
therapeut
choic
subject
collect
analys
dog
princip
dolichocephal
breed
male
femal
averag
age
averag
bc
subject
underw
symptomat
treatment
diagnosi
symptom
present
month
common
clinic
symptom
nasal
discharg
unilater
serosanguin
discharg
andor
epistaxi
present
case
stertor
facial
swell
deform
nasal
planum
andor
exophthalmo
endoscop
examin
found
neoform
unilater
case
nasal
nasopharyng
histolog
type
neoplasm
classifi
malign
epitheli
malign
mesenchym
benign
round
cell
tumor
subject
evalu
underw
endoscop
debulk
diod
laser
associ
grasp
forcep
metronom
therapi
debulk
metronom
therapi
radiat
treatment
radiat
metronom
radiotherapi
chemotherapi
surgeri
debulk
radiotherapi
specif
therapi
deceas
patient
averag
surviv
time
day
malign
epitheli
tumor
day
malign
mesenchym
tumor
patient
underw
debulk
metronom
therapi
averag
surviv
time
day
treat
debulk
alon
day
metronom
therapi
alon
day
therapi
day
date
subject
benign
neoplasia
aliv
conclus
studi
show
nasal
tumor
often
diagnos
late
nasopharynx
alreadi
affect
common
histolog
type
adenocarcinoma
benign
neoplasia
rare
describ
literatur
also
frequent
good
respons
nasal
debulk
combin
metronom
therapi
make
multimod
approach
worthi
evalu
reduc
cost
high
qualiti
life
patient
disclosur
report
hyperthermia
combin
radiotherapi
thermoradiotherapi
use
clinic
particular
case
human
canin
cancer
hyperthermia
provok
chang
differ
level
tumor
microenviron
increas
perfus
oxygen
induc
immun
respons
tumor
cell
induct
cell
death
inhibit
dna
repair
mechan
chang
increas
efficaci
radiat
treatment
toward
better
tumor
respons
howev
molecular
mechan
cellular
sensit
fulli
elucid
aim
studi
firstli
screen
human
canin
cancer
cell
line
sensit
toward
treatment
investig
role
protein
dna
repair
protein
radiosensit
mechan
surviv
curv
treatment
determin
panel
human
canin
cancer
cell
line
use
clonogen
surviv
assay
analyz
effect
cell
prolifer
apoptosi
test
influenc
time
gap
differ
temperatur
order
treatment
use
cell
sensit
hyperthermia
posit
control
level
dna
repair
protein
analyz
cell
line
knockdown
perform
cell
use
sirna
addit
evalu
mrna
level
ex
vivo
canin
tumor
model
soft
tissu
sarcoma
carcinoma
mast
cell
tumor
whether
affect
hyperthermia
eight
cell
line
test
abram
cell
show
signific
decreas
clonogen
cell
surviv
hyperthermia
show
high
baselin
level
induc
upon
treatment
cell
line
low
baselin
express
level
show
strong
induct
upon
treatment
level
affect
addit
knockdown
affect
clonogen
howev
mrna
level
lower
heat
notabl
ex
vivo
treat
canin
soft
tissu
sarcoma
result
show
major
cell
line
radiosensit
vitro
indic
tumor
microenviron
respons
major
effect
hyperthermia
interestingli
discov
suppress
transcript
potenti
inhibit
homolog
recombin
repair
pathway
promis
light
futur
combin
hyperthermia
parp
inhibitor
disclosur
report
canin
nodal
dlbcl
one
import
step
diagnosi
determin
presenc
hepat
infiltr
correspond
stage
iv
base
world
health
organ
stage
lymphoma
assess
liver
involv
classic
made
ultrasonographi
confirm
cytolog
remain
usual
procedur
efficaci
determin
hepat
infiltr
base
abnorm
imag
evalu
respect
sensit
specif
posit
prognost
valu
ppv
neg
prognost
valu
npv
crabtre
aim
work
evalu
associ
abdomin
ultrasound
alt
measur
help
determin
hepat
infiltr
complet
clinic
stage
prospect
perform
dog
examin
oncolog
referr
center
confirm
diagnosi
nodal
dlbcl
liver
ultrasound
cytolog
plasma
alt
measur
perform
dog
ultrasonograph
pattern
characterist
canin
lymphoma
liver
includ
coars
parenchyma
hypoecho
area
hypoecho
nodul
diffus
hypoechogen
diffus
hyperechogen
without
hepatomegali
nyland
crabtre
alt
analysi
perform
result
interpret
refer
rang
classifi
normal
vs
elev
ethic
approv
grant
royal
canin
ethic
committe
hepat
infiltr
confirm
cytolog
found
case
evalu
interest
associ
liver
ultrasound
alt
determin
infiltr
dog
classifi
posit
alt
outsid
laboratori
rang
combin
abnorm
ultrasound
imag
dog
find
consid
neg
sensit
specif
ppv
npv
respect
result
suggest
simultan
find
elev
alt
abnorm
ultrasonographi
allow
identifi
dog
hepat
infiltr
case
nodal
canin
dlbcl
confirm
find
research
need
disclosur
report
work
financi
support
royal
canin
sa
mar
petcar
f
mellet
moniot
jlaxald
j
bayl
employe
royal
canin
pet
owner
burden
recent
explor
studi
veterinari
medicin
take
human
model
veterinari
studi
identifi
phenomena
pet
owner
companion
anim
affect
chronic
termin
ill
furthermor
client
burden
may
exacerb
occup
stressor
veterinarian
studi
aim
understand
pet
owner
interest
psycholog
support
provid
directli
veterinari
hospit
survey
given
wait
room
singl
italian
veterinari
hospit
dog
cat
pet
owner
come
visit
sever
medic
reason
march
survey
includ
question
data
emot
experi
owner
diseas
care
pet
opinion
psychologist
support
total
survei
administr
return
adher
studi
twelv
discard
incomplet
sampl
compos
femal
male
repres
age
group
year
dog
instead
cat
pet
present
depart
intern
medicin
follow
oncolog
emerg
sampl
declar
anxieti
concern
demor
health
anim
subject
report
would
appreci
receiv
help
someon
compet
contrast
declar
support
report
motiv
decis
desir
live
emot
alon
sampl
would
use
servic
andor
suggest
famili
member
case
difficult
decis
poor
prognosi
emot
manag
particularli
claim
normal
feel
anxieti
concern
health
anim
among
would
like
use
servic
final
declar
probabl
beneficiari
servic
psycholog
support
consid
case
hilli
mourn
pet
compar
term
distress
ill
loss
love
one
survey
show
larg
percentag
owner
express
desir
follow
profession
figur
field
psycholog
support
treatment
pet
knowledg
aspect
never
investig
italian
veterinari
hospit
disclosur
report
lymphoma
common
haematopoet
neoplasm
canin
popul
chemotherapi
protocol
cop
chop
lopp
use
treat
lymphoma
due
chemosensit
natur
protocol
routin
involv
vincristin
current
literatur
report
common
vincristin
induc
toxic
gastrointestin
effect
also
suggest
degre
myelosupress
especi
combin
protocol
littl
research
focus
myelosupress
effect
vincristin
alon
singl
dose
neutropenia
lead
treatment
delay
dose
reduct
associ
longer
remiss
time
aim
studi
investig
myelosupress
effect
vincristin
dog
singl
administr
record
dog
previous
untreat
confirm
lymphoma
receiv
vincristin
juli
march
analys
patient
includ
haematolog
perform
prior
receiv
vincristin
repeat
within
day
prior
receiv
second
dose
chemotherapi
patient
exclud
receiv
chemotherapeut
medic
time
oral
prednisolon
therapi
permit
dog
treat
intraven
vincristin
includ
studi
dog
lymphoma
boxer
labrador
spaniel
studi
popul
mean
age
year
rang
year
mean
bodi
weight
kg
rang
four
dog
experienc
neutropenia
neutrophil
count
x
follow
singl
administr
vincristin
two
borderlin
neutropen
start
two
dog
develop
vcog
grade
neutropenia
one
dog
grade
one
grade
studi
popul
mean
neutrophil
count
x
rang
x
prior
vincristin
administr
mean
x
rang
x
one
week
post
vincristin
case
decreas
neutrophil
count
second
sampl
neither
weight
age
influenc
likelihood
develop
neutropenia
fifteen
case
thrombocytopen
x
l
prior
vincristin
compar
two
post
vincristin
mean
respect
case
show
increas
platelet
count
follow
singl
administr
vincristin
studi
show
small
proport
dog
receiv
vincristin
initi
sole
agent
part
chemotherapi
protocol
lymphoma
develop
signific
neutropenia
within
one
week
vincristin
administr
disclosur
report
dog
main
domest
reservoir
l
infantum
leishmania
infect
dog
unabl
control
infect
larg
uncontrol
humor
immun
respons
elicit
ineffici
parasit
high
concentr
antibodi
circul
antigen
canin
leishmaniosi
result
format
circul
immun
complex
cic
deposit
tissu
associ
tissu
damag
especi
glomerulonephr
renal
failur
howev
littl
known
relationship
presenc
cic
progress
diseas
object
evalu
level
cic
correl
sever
diseas
serum
sampl
healthi
infect
anim
total
dog
classifi
accord
leishvet
criteria
healthi
n
infect
asymptomat
n
infect
symptomat
n
ii
n
iii
n
iv
n
includ
studi
cic
isol
serum
sampl
use
slightli
modifi
method
level
measur
elisa
protein
content
estim
bicinchonin
acid
bca
protein
assay
nanoparticl
track
analysi
nta
cic
done
order
investig
relationship
cic
molecular
size
distribut
progress
diseas
result
show
statist
signific
correl
cic
level
stage
patholog
infect
dog
expect
healthi
infect
asymptomat
anim
show
cic
relat
infect
direct
relationship
level
cic
total
protein
concentr
progress
diseas
also
confirm
correl
ifat
titer
cic
level
addit
data
show
dog
sever
clinic
sign
present
larg
size
protein
aggreg
wherea
higher
concentr
smaller
size
aggreg
observ
non
infect
asymptomat
dog
fact
demonstr
clear
posit
correl
clinic
stage
size
first
studi
correl
cic
level
progress
diseas
canin
leishmaniosi
measur
cic
probabl
repres
valuabl
tool
diagnos
also
predict
diseas
progress
activ
asymptomat
seroposit
dog
even
follow
efficaci
treatment
even
measur
cic
biomark
progress
diseas
could
provid
interest
inform
vaccin
immunotherapi
treatment
confirm
control
diseas
disclosur
report
employe
laboratorio
leti
canin
leishmaniosi
canl
diseas
caus
leishmania
infantumth
type
predomin
individu
immun
respons
crucial
present
diseas
determin
clinic
sign
clinicopatholog
abnorm
dog
age
sex
breed
seem
determin
type
clinic
manifest
dog
develop
well
outcom
infect
object
studi
defin
clinicopatholog
find
canl
associ
signal
total
dog
diagnosi
leishmaniosi
retrospect
includ
inform
obtain
clinic
histori
physic
examin
laboratori
test
dog
use
fill
databas
includ
signal
clinic
sign
laboratori
abnorm
clinic
stage
diseas
dog
studi
classifi
moder
clinic
stage
canin
leishmaniosi
young
dog
less
tendenc
develop
system
sign
p
renal
p
hematolog
p
abnorm
dermatolog
sign
appear
common
young
dog
compar
old
one
p
young
dog
show
proteinuria
less
often
older
dog
p
dog
younger
year
present
renal
azotemia
older
dog
show
occasion
renal
azotemia
p
younger
dog
mainli
classifi
stage
diseas
rare
stage
iii
sever
sever
diseas
compar
dog
older
year
old
p
pure
breed
dog
seem
significantli
tendenc
develop
ulcer
dermat
compar
mix
breed
dog
p
studi
describ
first
time
age
appear
associ
differ
clinicopatholog
find
canl
young
dog
appear
present
less
sever
manifest
diseas
prone
develop
dermatolog
sign
dog
moder
clinic
stage
commonli
found
canl
disclosur
report
babesia
gibsoni
babesia
voge
identifi
canin
babesiosi
taiwan
inform
epidemiolog
diseas
limit
although
direct
transmiss
b
gibsoni
fight
dog
report
usa
korea
romania
mode
transmiss
occur
taiwan
object
studi
correl
distribut
babesia
distribut
tick
infest
dog
taiwan
total
surplu
blood
sampl
tick
collect
roam
free
rang
own
dog
neuter
procedur
variou
residenti
site
taiwan
januari
decemb
preval
b
gibsoni
b
voge
determin
pcr
wherea
tick
identifi
stereomicroscop
use
variou
morpholog
key
averag
tick
collect
dog
north
taiwan
dog
middl
dog
south
taiwan
five
differ
speci
tick
found
rhipicephalu
sanguineu
throughout
taiwan
rhipicephalu
haemaphysaloid
north
haemaphysali
hystrici
north
middl
taiwan
amblyomma
testidunarium
ixod
ovatu
north
preval
b
gibsoni
b
voge
infect
respect
posit
b
gibsoni
dog
found
northern
part
countri
wherea
found
middl
part
babesia
voge
infect
distribut
follow
north
middl
south
countri
none
dog
south
infect
b
gibsoni
correl
absenc
h
hystrici
tick
recent
identifi
local
vector
b
gibsoni
babesia
voge
equal
distribut
coincid
occurr
rsanguineu
tick
present
throughout
taiwan
find
discuss
relat
local
clinic
relev
treatment
canin
babesiosi
taiwan
disclosur
report
babesia
gibsoni
b
gibsoni
increasingli
recogn
anem
caus
canin
diseas
worldwid
taiwan
epidem
area
asia
purpos
studi
investig
risk
factor
associ
b
gibsoni
infect
total
dog
compat
clinic
sign
suggest
b
gibsoni
infect
eg
pale
mucou
membran
apathi
anorexia
fever
abnorm
urin
color
rule
larg
piroplasma
infect
ie
b
cani
b
voge
collect
nation
taiwan
univers
veterinari
hospit
januari
decemb
polymeras
chain
reaction
pcr
test
bgibsoni
perform
firstli
divid
dog
posit
dog
neg
dog
group
factor
includ
environ
season
breed
gender
intact
neuter
statu
live
lifestyl
extern
parasit
prevent
urin
color
mucou
membran
color
histori
babesiosi
analyz
use
test
initi
variabl
analyz
stepwis
multivari
logist
regress
analysi
differ
consid
statist
signific
associ
odd
ratio
irregularli
extern
parasit
prevent
p
present
dark
brown
urin
p
respect
therefor
factor
like
associ
infect
result
reveal
regular
prevent
extern
parasit
observ
urin
color
import
babesiosi
epidem
area
disclosur
report
acantocheilonema
reconditum
parasit
transmit
flea
lice
tick
includ
among
filaroid
speci
infect
dog
contrari
dirofilaria
immiti
dirofilaria
repen
reconditum
believ
less
pathogen
adult
worm
local
subcutan
tissu
periren
fat
although
previou
studi
report
absenc
clinic
symptom
infect
dog
data
regard
haematolog
biochem
chang
could
potenti
caus
parasit
hunt
dog
frequent
expos
pathogen
aim
present
studi
assess
preval
risk
factor
potenti
hematobiochem
abnorm
associ
reconditum
infect
specif
canin
popul
blood
sampl
collect
hunt
dog
live
campania
region
test
modifi
knott
techniqu
count
identifi
microfilaria
dog
test
posit
reconditum
overal
preval
ci
number
microfilariaeml
rang
exclud
dog
differ
filari
worm
speci
andor
pathogen
common
southern
itali
n
dog
show
reconditum
singl
infect
main
clinic
featur
observ
dehydr
n
fever
n
congest
mucou
membran
n
exercis
intoler
n
complet
blood
cell
count
result
reveal
leukocytosi
n
anaemia
n
thrombocytopenia
n
eosinophilia
n
biochem
data
show
increas
serum
valu
total
globulin
n
albumin
n
gamma
glutamyl
transferas
n
alkalin
phosphat
n
hypoalbuminemia
observ
one
dog
dog
pathogen
includ
statist
analysi
live
area
p
type
hunt
speci
p
ectoparasit
infest
p
variabl
significantli
associ
reconditum
infect
live
caserta
provinc
ci
napoli
provinc
ci
hunt
wild
mammal
ci
ectoparasit
infest
ci
repres
risk
factor
concern
haematochem
paramet
infect
dog
signific
neg
correl
microfilaraem
load
serum
albumin
level
found
pearson
correl
coeffici
p
obtain
data
confirm
circul
reconditum
within
hunt
dog
popul
southern
itali
provid
inform
pathogen
potenti
filari
worm
disclosur
report
idexx
grant
scholarship
collabor
research
activ
laura
pacifico
felin
immunodefici
viru
fiv
one
common
infecti
agent
cat
fiv
lentiviru
share
mani
properti
human
immunodefici
viru
hiv
caus
acquir
immun
defici
syndrom
aid
due
gradual
loss
helper
cell
number
function
character
increas
suscept
secondari
pathogen
virus
preferenti
infect
lymphocyt
lead
invers
lymphocyt
ratio
tenofovir
nucleotid
analogu
revers
transcriptas
inhibitor
effect
fiv
vitro
evid
tenovovir
might
greater
efficaci
less
cytotox
antiretrovir
compound
present
studi
therapeut
efficaci
human
antiretrovir
compound
use
acquir
immun
defici
syndrom
investig
treatment
cat
natur
infect
felin
immunodefici
viru
fiv
cat
present
symptom
recurr
infect
sinus
stomat
test
fiv
felv
statu
idexx
snap
fivfelv
combo
test
cat
includ
studi
test
posit
fiv
present
chronic
oral
nasal
inflamm
nine
cat
met
mention
inclus
criteria
tenofovir
virofob
alvogen
administ
oral
daili
dose
mgcat
day
alongsid
specif
treatment
experiment
group
day
day
measur
includ
complet
blood
count
ratio
bun
creatinin
one
nine
cat
toler
tenofovir
administr
exclud
studi
five
day
due
sever
hypersaliv
tenofovir
benef
effect
sever
oral
nasal
inflamm
induc
improv
gener
condit
fiv
infect
cat
cat
show
increas
lymphocyt
ratio
treatment
without
sign
nephrotox
myelotox
studi
suggest
tenofovir
human
antiretrovir
compound
effect
treatment
cat
natur
infect
felin
immunodefici
viru
fiv
side
effect
bone
marrow
activ
kidney
function
administr
disclosur
report
canin
lyme
borreliosi
lb
diseas
common
northeastern
midwestern
part
usa
europ
clinic
present
exist
diseas
controversi
discuss
fever
arthriti
clinic
manifest
often
associ
lb
present
renal
cardiac
neurolog
muscular
disord
suspect
sequela
borrelia
burgdorferi
bb
infect
reproduc
experiment
aim
studi
document
variou
present
canin
lb
north
america
europ
dog
includ
retrospect
studi
base
clinic
sign
consist
lb
least
posit
antibodi
detect
nineteen
dog
live
endem
area
usa
dog
resid
europ
medic
record
avail
case
phone
contact
owner
attend
veterinarian
establish
case
lb
discov
accident
three
case
present
veterinarian
well
exam
vaccin
clinic
sign
appar
examin
veterinarian
owner
orthoped
disord
report
case
four
dog
show
gener
sign
diseas
kidney
failur
occur
four
case
one
dog
die
dilat
cardiomyopathi
one
suspici
dog
present
bark
troubl
respond
well
doxycyclin
specif
antibodi
level
bb
correl
clinic
sign
sever
diseas
use
check
furthermor
concurr
specif
antibodi
bb
anaplasma
phagocytophilum
detect
case
borreli
dna
found
synovi
fluid
four
dog
orthoped
disord
one
heart
sampl
recoveri
antibiot
treatment
observ
dog
orthoped
gener
disord
dog
renal
cardiac
manifest
show
poor
prognosi
dog
cardiac
present
case
kidney
failur
die
applic
parasiticid
alway
record
dog
receiv
regular
treatment
treat
regularli
isoxazolin
system
product
collar
one
one
unrecord
brand
studi
suggest
canin
lb
may
present
variou
clinic
form
consid
case
musculoskelet
problem
impair
gener
condit
also
case
renal
cardiac
disord
research
requir
investig
diseas
dog
disclosur
report
marina
gatellet
mari
varloud
employe
ceva
animal
consent
form
sign
veterinari
clinic
owner
prior
enrol
mycoplasma
haemocani
mhc
candidatu
mycoplasma
haematoparvum
cmhp
two
speci
canin
hemoplasma
may
caus
hemolyt
anemia
chronic
diseas
canin
speci
understand
limit
blood
transfus
bloodsuck
arthropod
bite
fight
suspect
rout
hemoplasma
transmiss
dog
aim
present
survey
determin
preval
hemotrop
mycoplasma
infect
hunt
dog
southern
itali
assess
relat
risk
factor
blood
sampl
collect
hunt
dog
napoli
avellino
salerno
provinc
campania
region
southern
itali
test
real
time
polymeras
chain
reaction
assay
amplif
mhc
cmhp
dna
dog
clinic
sign
time
sampl
overal
pcr
posit
rate
mhc
cmhp
coinfect
hemoplasma
speci
found
anim
statist
analysi
reveal
live
salerno
provinc
mhc
ci
cmhp
ci
hound
breed
mhc
ci
cmhp
ci
pack
size
anim
mhc
ci
cmhp
ci
wild
mammal
hunt
mhc
ci
cmhp
ci
associ
risk
factor
canin
hemoplasma
infect
adult
age
variabl
significantli
associ
infect
cmhp
ci
author
knowledg
first
molecular
survey
mhc
cmhp
infect
dog
live
southern
itali
obtain
data
confirm
circul
two
speci
canin
hemoplasma
within
hunt
dog
popul
southern
itali
although
pathogen
potenti
possibl
epidemiolog
relationship
hunt
dog
sympatr
wild
anim
popul
still
unclear
disclosur
report
grant
support
idexx
inc
though
role
cat
reservoir
b
hensela
long
establish
preval
infect
exposur
cat
bartonella
speci
diseas
remain
unreport
use
serolog
polymeras
chain
reaction
pcr
preval
exposur
bacteremia
infect
anaplasmaspp
babesiaspp
cytauxzoonspp
ehrlichiaspp
rickettsiaspp
piroplasma
mycoplasmaspp
bartonellaspp
assess
popul
cat
rural
area
midwestern
unit
state
serum
edta
blood
sampl
collect
cat
captur
part
commun
spay
neuter
program
test
pcr
reveal
cat
posit
bartonella
speci
b
henselaeand
b
clarridgeia
cat
posit
mycoplasma
speci
haemominutim
haemof
serolog
test
reveal
cat
posit
antibodi
bartonella
speci
specif
cat
posit
b
koehlera
posit
b
hensela
posit
b
vinsonii
subspeci
berkhoffi
signific
posit
correl
identifi
posit
bartonella
spp
pcr
result
presenc
antibodi
b
vinsonii
berkhoffi
b
hensela
cat
posit
bartonella
pcr
posit
serolog
three
speci
bartonella
test
odd
ratio
analysi
age
sex
weight
reveal
male
cat
increas
risk
exposur
b
vinsonii
berkhoffi
disclosur
report
palerm
consult
infin
medic
llc
pathogen
leptospira
speci
pose
risk
canin
human
health
worldwid
littl
publish
data
posit
case
leptospirosi
seen
veterinari
practic
unit
kingdom
studi
aim
analyz
case
test
leptospirosi
uk
univers
teach
hospit
data
retrospect
collect
univers
databas
dog
screen
leptospirosi
via
urin
pcr
blood
pcr
serum
mat
includ
n
case
vaccin
within
month
mat
titr
addit
test
neg
urin
blood
pcr
exclud
posit
categori
n
remain
case
test
posit
leptospirosi
number
posit
case
among
test
case
test
neg
posit
case
vaccin
leptospir
vaccin
within
month
receiv
antibiot
therapi
prior
referr
common
present
clinicopatholog
abnorm
posit
case
increas
hepat
renal
valu
four
case
present
none
posit
case
present
pulmonari
haemorrhag
dyspnea
primari
leptospirosi
final
diagnosi
posit
case
six
case
unrel
final
diagnosi
neoplasia
n
biliari
mucocel
n
necrot
fasciiti
n
pericardi
effus
n
three
posit
case
final
diagnosi
chronic
renal
insuffici
two
secondari
congenit
dysplasia
three
case
final
diagnosi
chronic
hepatopathi
posit
case
predominantli
medium
larg
breed
dog
labrador
follow
beagl
cross
breed
border
colli
commonli
observ
posit
categori
conclus
prior
vaccin
antibiot
use
preclud
test
leptospirosi
contrast
case
report
mainland
europ
clinic
pulmonari
diseas
appear
featur
case
leptospirosi
appear
detect
incident
case
potenti
signifi
popul
dog
subclin
infect
disclosur
report
dr
gow
speaker
honorarium
companion
anim
magazin
acvim
ecvim
hwalker
msd
may
provid
assist
travel
involv
studi
design
data
collect
result
urinari
tract
infect
uti
common
dog
appropri
use
antimicrobi
drug
necessari
prevent
emerg
multidrug
resist
mdr
bacteria
awar
preval
urinari
tract
infect
caus
agent
resist
pattern
essenti
guid
appropri
therapi
aim
present
studi
describ
preval
bacteri
uti
dog
identifi
commonli
isol
microorgan
analyz
progress
suscept
pattern
studi
period
result
canin
urin
cultur
antimicrobi
suscept
test
perform
januari
decemb
veterinari
teach
hospit
alfonso
x
el
sabio
univers
retriev
laboratori
databas
sampl
collect
cystocentesi
cultur
within
hour
collect
antimicrobi
suscept
determin
use
disc
diffus
method
multidrug
resist
defin
resist
least
one
antimicrobi
agent
three
differ
antimicrobi
categori
total
urin
sampl
identifi
posit
cultur
result
increas
frequenc
posit
bacteri
cultur
studi
period
interv
rel
risk
irr
ci
p
rel
effect
develop
uti
significantli
higher
femal
male
ci
p
commonli
isol
microorgan
escherichia
coli
staphylococcu
spp
enterococcu
spp
pseudomona
spp
streptococcu
spp
overal
preval
resist
within
enterobacteriacea
famili
cefazolin
pradofloxacin
cefuroxim
enrofloxacin
marbofloxacin
amoxycillin
clavulan
cefovecin
fosfomycin
preval
mdr
infect
rang
meant
increas
trend
mdr
bacteria
irr
p
high
frequenc
increas
trend
antibiot
resist
observ
studi
concern
implic
veterinari
public
health
result
emphasis
import
perform
urinari
cultur
antimicrobi
suscept
test
allow
appropri
select
therapi
although
resist
fosfomycin
compar
low
antimicrobi
agent
licens
veterinari
use
europ
given
use
human
mdr
staphilococcu
aureu
infect
use
antibiot
must
reserv
human
medicin
disclosur
report
magnet
reson
imag
mri
use
gadoxet
acid
wide
use
human
medicin
character
hepat
nodular
lesion
veterinari
medicin
report
use
liver
examin
dog
aim
studi
describ
contrast
enhanc
pattern
differ
type
liver
lesion
administr
dog
studi
carri
six
dog
presumpt
diagnosi
focal
liver
lesion
clinic
examin
laboratori
blood
test
abdomin
ultrasound
carri
prior
mri
anim
examin
use
philip
mri
system
imag
protocol
consist
breath
trigger
weight
sequenc
perform
transvers
plane
administ
intraven
mlkg
follow
ml
salin
solut
sequenc
acquir
minut
contrast
administr
sampl
histopatholog
examin
collect
case
surgic
resect
case
biopsi
case
necropsi
case
parenchym
liver
metastasi
found
one
case
lesion
strongli
hypointens
compar
surround
liver
tissu
sequenc
follow
contrast
administr
observ
focal
nodular
hyperplasia
observ
one
case
isointens
compar
surround
liver
tissu
sequenc
show
post
contrast
similar
observ
surround
healthi
tissu
central
scar
observ
within
lesion
hepatocellular
adenoma
diagnos
two
case
lesion
hypointens
hyperintens
imag
compar
surround
liver
tissu
case
contrast
enhanc
mri
lesion
observ
one
case
hepat
carcinoid
found
liver
parenchyma
tumour
weakli
hypointens
sequenc
weakli
hyperintens
strongli
hyperintens
centr
imag
contrast
enhanc
note
hepatocellular
carcinoma
also
diagnos
one
case
lesion
heterogen
sequenc
moder
hypointens
moder
hyperintens
show
contrast
enhanc
remain
strongli
hypointens
compar
surround
tissu
obtain
result
indic
patter
dog
variou
hepat
neoplast
lesion
similar
human
enhanc
pattern
use
human
medicin
assess
hepat
hyperplast
parenchym
lesion
may
use
veterinari
medicin
disclosur
report
